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ABSTRACT
The studies described in this thesis were designed to evaluate the role of 
gastrointestinal hormones in the regulation of deposition and mobilisation of lipids in 
adipose tissue.
The role of gastrointestinal and pancreatic hormones in fatty acid synthesis and 
lipolysis was evaluated in vitro using explants of rat epididymal adipose tissue. With 
the exceptions of insulin, glucagon and secretin, in vitro effects of the hormones 
investigated on direct control of fatty acid synthesis and on lipolysis were small. 
Secretin had a pronounced lipolytic effect in rat adipose tissue, especially when 
administered in combination with insulin. This hormone may regulate hormone- 
sensitive lipase and be important in mobilisation of lipid stores. GLP-2 was shown to 
have a lipogenic effect when administered in conjunction with insulin. This is of 
particular interest since no physiological role for GLP-2 has been established to date.
Two in vivo dietary studies were undertaken in rats. In the first study dietary 
inclusion of fish oil (5%) resulted in elevated rates of basal and insulin-stimulated fatty 
acid synthesis in rat epididymal adipose tissue in vitro. The enhancement of insulin 
sensitivity of this tissue may have arisen from modification of adipocyte plasma 
membrane fluidity due to incorporation of co-3 polyunsaturated fatty acids from fish 
oil. In the second study dietary inclusion of soluble non-starch polysaccharide was 
without effect on basal and insulin-stimulated fatty acid synthesis in vitro.
An in vivo study using human volunteers investigated postprandial hormone 
secretion and lipoprotein lipase activity in lean and obese subjects in response to 
carbohydrate and fat meals. No differences in post-heparin plasma lipoprotein lipase 
activity were observed. There was no difference in circulating concentrations of GIP 
in response to the test meals by obese and lean subjects. However, postprandial 
secretion of GLP-1 (7-36) amide in response to the carbohydrate meal but not the fat 
meal was attenuated in obese subjects. These hormones cannot be responsible for 
causing the hyperinsulinaemia of obesity, but reduced concentrations of GLP-1 (7-36) 
amide may contribute to insulin resistance in obesity. The attenuated postprandial 
secretion profile of GLP-1 (7-36) amide also suggests a role for GLP-1 (7-36) amide 
in satiety in humans.
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ABBREVIATIONS
ADP Adenosine 5’-diphosphate
AMP Adenosine 5’-monophosphate
APUD Amine precursor uptake and decarboxylation
ATP Adenosine 5’-triphosphate
BMI Body mass index
cAMP Cyclic adenosine 5’-monophosphate
CoA Coenzyme A
DES Diffuse endocrine system
GIP Gastric inhibitory polypeptide or
Glucose-dependent insulinotropic-polypeptide 
GLP-1 Glucagon-like polypeptide-1
GLP-2 Glucagon-like polypeptide-2
HDL High density lipoprotein
HMG CoA 3-hydroxy-3-methylglutaryl-CoA 
KIU KaUikrein inhibitory unit
LDL Low density lipoprotein
mRNA messenger Ribonucleic acid
NADH Nicotinamide adenine dinucleotide (reduced)
NADPH Nicotinamide adenine dinucleotide phosphate (reduced)
NIDDM Non-insulin-dependent diabetes mellitus
NPY Neuropeptide Y
NRS Normal rabbit serum
NSD Not significantly different
NSP Non-starch polysaccharide
PYY Peptide YY
S.D. Standard deviation
SBF Sugar beet fibre
VIP Vasoactive intestinal polypeptide
VLDL Very low density lipoprotein
f%r rexd-
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CHAPTER 1
INTRODUCTION
1.1 INTRODUCTION
The main function of adipose tissue is to provide a store of chemical energy 
in the form of energy dense triglycerides. The amount of fat stored depends on the 
relative rates of lipid deposition and lipid mobilisation. Lipid is deposited either by 
the production of triglyceride from non-lipid sources, de novo lipogenesis, or can 
result from the uptake of free fatty acids from intravascular hydrolysis of circulating 
triglycerides obtained from the diet or endogenously produced sources. Lipid 
mobilisation, lipolysis, is release of free fatty acids from triglyceride stores for energy 
utilisation elsewhere by the body.
Other functions of adipose tissue include insulation, in particular the 
subcutaneous depots especially in animals that have to survive in very cold climates. 
Some adipose tissue sites have a protective role, for example in the eye socket and the 
soles of the feet. Adipose tissue associated with the mammary gland is important in 
the production of hormones, in particular controlling the growth of this gland (Vernon, 
1992). Recently Flint and Vernon (1992) have shown evidence that adipose tissue 
may have an important role in the production of some components of the pathway of 
complement formation in the immune response. Adipose deposits in cardiac and 
intramuscular sites may be an important supply of energy in the form of fatty acids 
to these very active muscle fibres.
Currently the western diet provides a high proportion (approximately 40%) of 
total energy intake in the form of fat (Gregory et al., 1990). Much of the population 
currently consume more energy than is required to fuel the body. This excess dietary 
energy in the form of lipid is transported from the gastrointestinal tract, as 
chylomicrons, to the adipose tissue where the intravascular enzyme lipoprotein lipase 
liberates fatty acids which are taken up and re-esterified within the adipocytes where 
they are stored as triglyceride.
Obesity results from a combination of excessive accumulation of fat from 
excess dietary energy accompanied by lack of exercise to expend this energy and this 
condition is now common in Western society. One of the methods used to quantify 
obesity is the Quetelet Index (Keys et ai, 1972). This is calculated using the 
following formula W/H^ where W = body weight in kg and H = height in metres.
This index is also referred to as the Body Mass Index (BMI) and is the basis for the 
construction of tables outlining ideal bodyweight by life assurance companies. It has 
been estimated that 20% of middle-aged males and 40% of similarly aged females are 
classified as obese (Skouge, 1990). The desire to become lean leads to actions such 
as energy-restricted dieting and in extreme cases to more drastic measures such as 
liposuction or stomach stapling.
There is evidence that the body can store the energy derived from dietary fat 
more efficiently than that derived from dietary carbohydrate (Acheson et al., 1984). 
The metabolic cost of dietary fat entering the triglyceride stores was estimated at 3% 
of ingested fat whereas the cost of storing dietary carbohydrate as triglyceride was 
23%. This supports the evidence obtained in the Vermont studies of obesity where 
it was found that naturally lean subjects had great difficulty gaining weight when the 
excess calories were supplied by carbohydrate and fat compared with the relative ease 
that similar subjects gained weight where the excess calories were supplied as fat 
alone (Danforth, 1985).
Obesity has been implicated in causing or exacerbating conditions such as non­
insulin dependent diabetes mellitus (NIDDM), cardiovascular diseases, hypertension, 
strokes and some forms of cancer, particularly endometrial and ovarian cancer 
(Skouge, 1990).
Comparatively, the uptake of fatty acid from the hydrolysis of circulating 
triglycerides by lipoprotein lipase is a more important process in adipose tissue than 
is de novo lipogenesis. In rats approximately 10-15 fold more triglyceride 
accumulates from the action of lipoprotein lipase than from de novo lipogenesis 
(Stansbie et al., 1976; Hartman, 1977; Rothwell, Stock and Trayhurn, 1983). In 
Western Man, since the diet contains as much as 40% of the dietary energy in the 
form of fat, de novo hpogenesis of triglycerides from non-lipid sources is not required 
to replenish triglyceride stores. The high level of fat intake in the Western style diet 
has been implicated as a major factor in the development of obesity (Danforth, 1985).
The pathways involved in adipose tissue metabolism are under hormonal 
control. Insulin has a well established anabolic role in the control of de novo 
lipogenesis, lipoprotein lipase activity and lipolysis. However, insulin is not released 
in response to the ingestion of fat. Some gastrointestinal hormones that are released
in response to ingestion of fat can also augment insulin secretion and may directly 
influence lipid metabolism of adipose tissue. Greater understanding of the role of 
gastrointestinal hormones in fat deposition and mobilisation could possibly lead to 
more effective approaches to preventing and treating obesity.
1.2 LIPID METABOLISM IN ADIPOSE TISSUE
1.2.1 De novo lipogenesis
A simplified pathway for de novo lipogenesis using glucose as a substrate is 
shown in Figure 1.1. Glucose is converted to pyruvate in the cytosol of the adipocyte 
via glycolysis. The regulatory enzymes involved in glycolysis are hexokinase, 
phosphofructokinase and pyruvate kinase, and insulin can stimulate their activities but 
this action is not as important as in the succeeding stages. Pyruvate is then 
transported into the mitochondria by a specific carrier mechanism (Halestrap, 1975) 
where it is converted to acetyl coenzyme A (acetyl CoA) in a reaction catalysed by 
pyruvate dehydrogenase. If acetate is the lipogenic precursor it is converted to acetyl 
CoA in the cytoplasm in a reaction catalysed by acetyl CoA synthetase.
Mitochondrial acetyl CoA is then transferred to the cytoplasm by means of the 
pyruvate malate cycle. Briefly, citrate formed from acetyl CoA and oxaloacetate by 
the action of citrate synthetase before being then transported into the cytoplasm, via 
the citrate carrier, where acetyl CoA and oxaloacetate are reformed by a reaction 
catalysed by adenosine 5’-triphosphate (ATP) citrate lyase. The oxaloacetate is then 
returned to the mitochondria by successive reduction and decarboxylation to pyruvate. 
An alternative pathway for the oxidation of glucose is the pentose phosphate pathway, 
which is an important source of reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) required for fatty acid synthesis.
Once in the cytosol, acetyl CoA is converted to malonyl CoA in a reaction 
catalysed by acetyl CoA carboxylase. This reaction is irreversible and formation of 
malonyl CoA is seen as the ‘committed step’ in the formation of fatty acids. This has 
led to the recognition of acetyl CoA carboxylase as the rate-limiting enzyme in the 
short term control of de novo lipogenesis (Martin and Makula, 1987).
Figure 1.1 Simplified pathway of de novo lipogenesis in the adipocyte
1 = Glucose transport
2 = Glycolysis
3 = Catalysed by pyruvate dehydrogenase
4 = Pyruvate/malate cycle
5 = Catalysed by acetyl CoA carboxylase
6 = Catalysed by fatty acid synthetase
7 = Estérification
8 = Catalysed by acetyl CoA synthetase 
* = Sites of insulin action
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Malonyl CoA is then converted to fatty acids in a reaction catalysed by fatty 
acid synthetase which is a multi-enzyme complex. This is accomplished by successive 
condensations (to build up chain length) and reductions (from carbonyl to methylene 
groups) with the enzyme catalysing all seven reactions involved. The chain is built 
up two carbons from acetate groups at a time until palmitate (16 carbons) is formed 
and released from the complex (Newsholme and Leech, 1983b).
During the conversion of glucose to fatty acids there is a net production of 
ATP. The rate of fatty acid synthesis is limited by the capacity of the cell to utilise 
the ATP produced. Fatty acid synthesis occurs at a higher rate using acetate and 
glucose as substrates together as opposed to the sum of rates of fatty acid synthesis 
of the two substrates on their own. This is because the ATP produced is utilised for 
the synthesis of acetyl CoA from acetate.
To form triglycerides, estérification of glycerol 3-phosphate and fatty ac^L 
CoA occurs. The fatty acjL CoA can be derived from fatty acid synthesis within the 
cells or from fatty acids obtained from circulating chylomicrons and Very Low 
Density Lipoprotein (VLDL) by the action of lipoprotein lipase. The fatty acids are 
converted to fatty ac^ L . CoA by estérification with coenzyme A, catalysed by fatty 
agU CoA synthetase. Glycerol 3-phosphate is obtained from glycolysis since 
adipose tissue, lacking significant glycerol kinase activity, is not capable of producing 
sufficient directly from glycerol (Wieland and Suyter, 1957).
Hormonal control of fattv acid svnthesis
The role of insulin in metabolism has been well established. Insulin is released 
from B cells of the pancreas and the major stimulus for secretion of this hormone is 
elevated blood glucose concentrations. It facilitates the entry of glucose into the liver, 
where it is converted to glycogen or triglycerides; into muscle, where it is utilised or 
converted to glycogen; and into adipose tissue, where it is converted to glycogen and 
triglycerides (Denton, Brownsey and Belsham, 1981). The subsequent reduction in 
blood glucose concentrations reduces the secretion of insulin, demonstrating a closely 
adjusted negative feedback mechanism.
The effect of insulin on fatty acid synthesis is stimulatory whereas the effects
of adrenaline and glucagon are inhibitory. Insulin has short term effects on the 
conversion of glucose to fatty acids in adipocytes and the points of this control are 
shown in Figure 1.1.
Glucose transport is one process stimulated by insulin in adipocytes and in the 
absence of insulin the transport of glucose is rate-limiting for its metabolism. The 
plasma membranes of mammalian cells possess a facilitated diffusion transport system 
which occurs through the action of a family of related transporters. To date, seven 
glucose transporters have been identified and classified as GLUT 1 - GLUT 7 
depending on their characteristics and the tissues in which they are found. The two 
most important types found in adipose tissue are GLUT 1 and GLUT 4. GLUT 1 
(erythrocyte-type glucose transporter) is predominantly found in red blood cells, brain 
and blood-tissue barriers such as blood-brain barrier, placenta and retina. GLUT 4 
(insulin-responsive glucose transporter) only occurs in muscle and adipose tissue. In 
adipocytes this transporter remains localised in the microsomal fraction in the basal 
state (absence of insulin) and exposure to insulin results in recruitment of the 
transporters to the plasma membrane under metabolically appropriate conditions. 
Therefore the action of insulin on glucose transport is to increase the translocation of 
glucose transporters to the plasma membrane resulting in enhanced (20-30 fold in rat 
adipocytes and 2-4 fold in human adipose tissue) transport across the plasma 
membrane (Gould and Holman, 1993). The activation of this mechanism by insulin 
is the main factor controlling the rate of glycolysis in adipose tissue and therefore the 
supply of acetyl CoA for fatty acid synthesis. The action of insulin on increasing 
glucose transport can be decreased by lipolytic hormones such as catecholamines 
(Smith, Kuroda and Simpson, 1984).
Insulin is capable of stimulating lipogenesis in both the liver and adipose tissue 
of rats (Stansbie et al., 1976). Insulin achieves this by activation of pyruvate 
dehydrogenase and acetyl CoA carboxylase (Stansbie et al., 1976). Pyruvate 
dehydrogenase catalyses the conversion of pyruvate to acetyl CoA and insulin 
stimulates fatty acid synthesis by increasing the proportion of this enzyme present in 
the active, dephosphorylated, state (Coore et al., 1971; Denton, Brownsey and 
Belsham, 1981) and this is reversed by adrenaline (Coore et al., 1971). The 
stimulatory effect of insulin on this enzyme is small and pyruvate dehydrogenase is
not thought to be a rate-controlling enzyme for fatty acid synthesis when glucose is 
the substrate. The exact mechanism for the hormonal control of this enzyme in 
adipose tissue is not known.
As already mentioned acetyl CoA carboxylase catalyses the conversion of 
acetyl CoA to malonyl CoA and has been proposed as the rate-limiting enzyme in the 
short term control of de novo lipogenesis (Martin and Makula, 1987). It is therefore 
a crucial point for the hormonal control of fatty acid synthesis. The activity of acetyl 
CoA carboxylase is stimulated by insulin, changes in the activation step of this 
enzyme in adipose tissue in vivo are seen in response to alterations of circulating 
concentrations of insulin (Stansbie et al., 1976). The activation requires the 
polymerisation of inactive monomers and the enzyme is inactivated by disaggregation 
of the polymers in the presence of long-chain fatty acids (Halestrap and Denton,
1974). Thus increased rates of lipolysis which result in the release of free fatty acids 
potentiate the deactivation of acetyl CoA carboxylase leading to a decrease in the rate 
of lipogenesis. Adrenaline (Halestrap and Denton, 1974) and glucagon (Zammit and 
Corstophine, 1982) inhibit the activity of acetyl CoA carboxylase presumably through 
their stimulation of lipolysis.
1.2.2 Lipolysis
Lipolysis results in the release of free fatty acids into the circulation as an 
energy source. The conversion of stored triglycerides to free fatty acids and glycerol 
is a reaction catalysed by the enzyme hormone-sensitive lipase (Hales, Luzio and 
Siddle, 1978). As is the case with pyruvate dehydrogenase and acetyl CoA 
carboxylase the activation of hormone-sensitive lipase is achieved by phosphorylation 
of the enzyme and this occurs via cyclic adenosine monophosphate (cAMP)-dependent 
protein kinase (StrâHors and Belfrage, 1983). Therefore glucagon and adrenaline, 
which are the two most physiologically important hormones known to stimulate 
adenylate cyclase activity in adipocytes, have the effect of stimulating the activity of 
cyclic AMP-dependent protein kinase resulting in an increase in activity of hormone- 
sensitive lipase. Insulin exerts an antilipolytic effect by stimulating the activity of the 
enzyme cyclic AMP phosphodiesterase which catalyses the conversion of cAMP to
8
adenosine 5’-monophosphate (AMP) leading to dephosphorylation and therefore 
deactivation of hormone-sensitive lipase (Denton, Brownsey and Belsham, 1981). 
This process is known to be strongly dependent on glucose concentration in humans 
in contrast to the situation in rats. There is also variation observed in antilipolytic 
response depending on the site from which the adipose tissue is obtained (Amer, 
1988).
1.2.3 Lipoprotein lipase
The key enzyme involved in the uptake of circulating triglycerides derived 
from the diet or produced endogenously is lipoprotein lipase. Lipoprotein lipase is 
synthesised by most tissues including adipose tissue, heart, lung, mammary gland, 
skeletal muscles and kidney. (For reviews see Eckel, 1987; Eckel, 1989; Bensadoun, 
1991).
Its site of action is at the vascular endothelial cell surface where it is anchored 
by heparan sulphate proteoglycans integrated into the luminal aspect of the glycocalyx 
on the endothelial membrane (Eckel, 1989). The mechanism for this transfer to the 
vascular endothelial cell surface is unclear but it has been suggested that following 
release from the adipocyte plasma membrane the enzyme is internalised in the 
endothelial cell and transported in secretory vesicles to the luminal surface (Robinson 
and Speake, 1989).
Once at its site of action, lipoprotein lipase hydrolyses lipoprotein triglycerides 
from chylomicrons and VLDL in the circulation to form free fatty acids which are 
transported into the adipocyte for estérification and storage.
Insulin is known to stimulate the activity (Cryer, et a i, 1976; Sadur and Eckel, 
1982; Eckel, 1987) and the rate of synthesis (Spooner et al., 1979; Vydelingum et al., 
1983; Speake, Parkinson and Robinson, 1985) of lipoprotein lipase. Glucagon and 
catecholamines decrease the activity of hpoprotein lipase (Eckel, 1987). A possible 
mechanism for this inhibitory effect of adrenaline is through stimulation of 
degradation of the enzyme (Ball, Speake and Robinson, 1986).
1.2.4 Fatty acid transport into adipose tissue
In order for the fatty acids released due to the action of lipoprotein lipase in 
the vascular endothelium to be esterified, they must first be transported into the 
adipocyte. A model has been proposed for this whereby the free fatty acids move into 
the endoplasmic reticulum of the adipocyte laterally though continuous cell 
membranes of adjacent cells (Scow and Blanchette-Mackie, 1985). It has been 
demonstrated that lipoprotein lipase can be dissociated from cultured endothelial cells 
by physiological concentrations of fatty acids (Saxena, Witte and Goldberg, 1989). 
This suggests that if free fatty acids released from the hydrolysis of circulating 
lipoprotein triglycerides are not transported into the adipocytes at a sufficient rate then 
accumulation of fatty acids will result in the dissociation of the enzyme from the 
endothelial cell, halting the hydrolysis.
A mechanism for the transport of fatty acids across the adipocyte plasma 
membrane has been described (Abumrad, Park and Park, 1984). Transport is 
stimulated by adrenaline and inhibited by insulin (Abumrad, Perry and Whitesell, 
1986) which suggests a possible further mechanism for the antilipolytic effect of 
insulin.
1.2.5 Re-esterification
Triglycerides are formed within the adipocyte by the estérification of glycerol 
in the form of glycerol 3-phosphate with three fatty acids in the form of long-chain 
fatty acjf CoA.
Briefly, a saturated fatty acjb CoA is esterified at the 1 position of the 
glycerol 3-phosphate, catalysed by glycerophosphate acyltransferase, to form 
monoacylglycerol phosphate. Then a second, unsaturated, fatty acyL CoA is 
esterified at the 2 position, catalysed by monoacylglycerol phosphate acyltransferase, 
after which the phosphate group is removed in a reaction catalysed by phosphatidate 
phosphohydrolase. The final fatty acjU CoA which can be saturated or unsaturated 
is esterified to position 3, catalysed by diacylglycerol acyltransferase.
Glycerol 3-phosphate is either derived by phosphorylation of glycerol, a
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reaction catalysed by glycerol kinase, or from reduction of dihydroxyacetone 
phosphate, catalysed by glycerol 3-phosphate dehydrogenase (Newsholme and Leech, 
1983c). Since glycerol kinase is absent or only present in low amounts in white 
adipose tissue (Wieland and Suyter, 1957; Margolis and Vaughan, 1962) 
glycerol 3-phosphate arises from phosphorylation of glycerol in the liver or reduction 
of dihydroxyacetone phosphate in the adipocyte.
As lipolysis and estérification both occur in adipose tissue some fatty acids 
released during lipolysis are re-esterified. This substrate cycle which regulates the 
release of free fatty acids into the circulation is itself regulated by changes in rates of 
lipolysis and estérification (Newsholme, 1980).
1.2.6 Summary of role of insulin in adipose tissue metabolism
In summary, insulin has an anabolic role in lipid metabolism and this has been 
demonstrated in the pathways of de novo lipogenesis, lipolysis and uptake of fatty 
acids from the hydrolysis of circulating triglycerides.
Insulin stimulates the rate of de novo lipogenesis at several points in the 
pathway. Firstly insulin stimulates the transport of glucose into the adipocyte by 
increasing the number of glucose transporters in the plasma membrane of the 
adipocyte (Gould and Holman, 1993). Secondly insulin activates the enzyme pyruvate 
dehydrogenase which catalyses the conversion of pyruvate to acetyl CoA in the 
mitochondria (Stansbie et al., 1976). Most importantly insulin is capable of activating 
acetyl CoA carboxylase which is the rate-limiting enzyme in this pathway (Stansbie 
et al., 1976).
Insulin has an antilipolytic effect in adipose tissue by decreasing the activity 
of hormone-sensitive lipase by stimulating the activity of the enzyme cyclic AMP 
phosphodiesterase which catalyses the conversion of cAMP to AMP therefore leading 
to dephosphorylation and deactivation of hormone-sensitive lipase (Denton, Brownsey 
and Belsham, 1981) and possibly by inhibiting the outward transport of fatty acids 
across the plasma membrane of the adipocyte (Abumrad, Perry and Whitesell, 1986).
Insulin also stimulates the activity of lipoprotein lipase (Cryer, et al., 1976; 
Sadur and Eckel, 1982; Eckel, 1987) thereby increasing the rate of hydrolysis of
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circulating lipoprotein triglycerides and their subsequent incorporation into adipose 
tissue.
1.3 BIOCHEMISTRY, DIETARY MODIFICATION AND PHYSIOLOGY
OF GASTROINTESTINAL HORMONES
1.3.1 Introduction
The concept of endocrine control of digestion emerged from early observations 
of Bayliss and Starling (1902) in which it was noted that an extract of mucosa of the 
canine small intestine could alter the secretion of pancreatic juice and bile when 
infused intravenously into the dog. This action was found to be independent of the 
nervous system. They named the ‘exciting substance’ secretin. The discovery of 
gastrin followed when it was observed that extracts of the pyloric area of the stomach 
could stimulate the oxyntic cells of the stomach when injected intravenously (Edkins, 
1905).
The structures of gastrointestinal peptides were not elucidated until many years 
later, for example, the amino acid sequence of gastrin was not determined until 1964 
(Gregory et al., 1964).
A wealth of published studies have supported the hypothesis that more than 
one peptide can be involved in the regulation of gastrointestinal function, for example 
gastric and pancreatic secretion, and gastrointestinal motility, acting as stimulants or 
inhibitors. However, more recently researchers have turned their attention to possible 
roles for gastrointestinal hormones outside the gastrointestinal tract.
The amino acid sequences of many peptides have been determined. These 
sequences indicate similarities in the structures of some peptides and they are referred 
to as families. For example gastrin and cholecystokinin have a common sequence for 
five amino acid residues at the C-terminal of the molecule and therefore both belong 
to the cholecystokinin family of hormones (Mutt, 1982).
A given hormone can exist in several different chemical forms (reviewed Mutt, 
1982). These differences may be due to variations in the size of the peptide which 
arise from differential processing of the precursor molecule. Subtle species differences
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in amino acid sequences also arise and result in altered activities of a given peptide 
between species.
Cells producing regulatory peptides are distributed throughout the 
gastrointestinal tract. Because many similarities have been observed between various 
peptide-producing cells some authors have grouped them as the diffuse endocrine 
system (DES) or amine precursor uptake and decarboxylation series (APUD) (Solcia 
et al., 1987). A detailed description of the Lausanne classification of 
gastroenteropancreatic cells is given by Solcia et al. (1977); this classification is used 
in this review.
Gastrointestinal hormones are released in response to the ingestion and 
absorption of nutrients. The studies described in this thesis, of the role of 
gastrointestinal hormones in adipose tissue metabolism, have however been confined 
to those whose secretion is stimulated by fat ingestion; it is those that are discussed 
below.
1.3.2 Gastric inhibitory polypeptide (GIP)
GIP is a 42 amino acid hormone originally discovered by its action of potent 
inhibition of gastric acid secretion (Brown, Mutt and Pederson, 1970). It is localised 
in the duodenum and jejunum (Bloom and Polak, 1980) in cells termed K cells.
Secretion of GIP is stimulated by the ingestion of glucose in man (Cataland 
et al., 1974) and in particular it is necessary for there to be active transport of glucose 
and other monosaccharides for this stimulation to occur (Sykes et al., 1980). The 
other main stimulus for the secretion of GIP in man is ingestion of fat (Falko et al.,
1975) which is a more potent stimulant than glucose in man. Absorption of fat is a 
prerequisite for GIP secretion (Ebert and Creutzfeldt, 1980). Digestion of fat is 
necessary in order to elicit the response as the GIP secretion is proportional to the 
quantity of long-chain fatty acids, which are the end product of triglyceride hydrolysis, 
in the gastrointestinal tract (Ross and Shaffer, 1981). It appears that chylomicron 
formation is a prerequisite for GIP secretion since blocking the formation of 
chylomicrons using a detergent (Tso et al., 1981) results in inhibition of GIP release 
(Creutzfeldt and Ebert, 1988).
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The first documented action of GIP was its ability to inhibit gastric acid 
secretion (Brown, Mutt and Pederson, 1970) but this effect is weak in humans since 
increases in circulating concentrations of GIP caused by feeding were insufficient to 
cause any significant inhibition of acid secretion (Maxwell et al., 1980). However, 
there is considerable evidence that GIP can inhibit the secretion of gastric acid and 
this action may be mediated by locally released somatostatin (Brown et al., 1989).
The major biological activity of GIP is its potent stimulation of the secretion 
of insulin. It was observed that the infusion of GIP in humans together with an 
infusion of glucose resulted in potentiation of insulin release and improvement in 
glucose tolerance (Dupre et al., 1973). This action of GIP is covered more 
extensively in section 1.4.
It has recently become apparent that GIP may have direct effects on lipid 
metabolism (Beck, 1989). This is examined in section 1.5.
1.3.3 Secretin
The amino acid sequence of secretin was first determined in porcine intestinal 
mucosa by Mutt, Jorpes and Magnusson (1970). Secretin was found to be localised 
in specialised cells in the upper small intestine termed S cells (Bloom and Polak, 
1980).
The main stimulant for the secretion of secretin in humans is intraduodenal 
instillation of hydrochloric acid. Glucose, fat, amino acids, ethanol and ingestion of 
a protein rich meal were without effect (Fahrenkrug and Schaffalitzky de Muckadell,
1977). A study investigating the effect of products of fat digestion on secretin 
secretion found that to elicit secretion fat needs to have been hydrolysed by the 
actions of pancreatic enzymes since neutral fat is without effect (Watanabe et al., 
1986).
The stimulation of exocrine pancreatic secretion was the first documented 
action of secretin (Bayliss and Starling, 1902). This has been confirmed by more 
recent studies and in humans (Rhodes, Tai and Chey, 1976; Schaffalitzky de 
Muckadell, et al., 1979).
There have also been reports that physiological doses of secretin can inhibit
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spontaneous pyloric antral motility and gastric emptying in humans (Dinoso et al., 
1969; Valenzuela and Defilippi, 1981).
Some early studies reported that secretin was capable of stimulating the release 
of insulin (Enk, 1976) but more recent studies have shown that this effect is not 
observed using physiological doses of secretin in humans (Fahrenkrug, Schaffalitzky 
de Muckadell and Kuhl, 1978; Brodows and Chey, 1980).
Secretin has been demonstrated to inhibit the secretion of glucagon and 
stimulate the secretion of pancreatic somatostatin in dogs (Hisatomi and Unger, 1983).
Secretin has also been shown to stimulate lipolysis in adipose tissue in vitro 
(Butcher and Carlson, 1970; Rudman and del Rio, 1969).
1.3.4 Glucagon-like polypeptide-1 (GLP-1)
Glucagon and the glucagon-like peptides are encoded in a much larger 
precursor known as proglucagon. Tissue-specific post translational processing leads 
to the production of the many forms of these peptides (Conlon, 1988; Drucker, 1990).
The sequence of human preproglucagon was determined (Bell, Santerre and 
Mullenback, 1983) and found to contain the sequence of glucagon and of two 
glucagon-like peptides referred to as glucagon-like polypeptide-1 (GLP-1) and 
glucagon-like polypeptide-2 (GLP-2). From examination of the gene sequence it was 
predicted that GLP-1 would contain 37 amino acids corresponding to proglucagon (72- 
108). The presence of the glycine residue at the C-terminal suggested that the peptide 
is likely to be amidated by decarboxylation of glycine as is seen in other 
gastrointestinal hormones (Tatemoto and Mutt, 1980). This amidation is often found 
to be necessary for the hormones to be biologically active (Rehfeld et al., 1980). 
Thus two structures of GLP-1 were predicted corresponding to GLP-1 (1-37) and 
GLP-1 (1-36) amide.
It was then demonstrated that GLP-1 undergoes further processing in the 
intestine whereby the 6 N-terminal amino acids are cleaved producing GLP-1 (7-37) 
or GLP-1 (7-36) amide (Mojsov et al., 1986). Once this was discovered GLP-1 (7-36) 
amide was then isolated from the intestine of pigs (Holst et al., 1987), rats (Kreymann 
et al., 1988) and humans (0rskov et al., 1989). The predominant form of GLP-1 in
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the intestine was shown to be the amidated form (0rskov et al., 1989).
GLP-1 has been found to be localised in the distal regions of the intestine, 
most notably the ileum and colon (Kreymann et al., 1988). The endocrine cells in 
which GLP-1 is synthesised and secreted are also responsible for the secretion of 
enteroglucagon, GLP-2, glicentin (0rskov et al., 1986) and peptide YY (PYY) (Ali- 
Rachedi et al., 1984) and are termed L cells. GLP-1 is also localised in the A-cells 
of the pancreas (Uttenthal et al., 1985; Mojsov et al., 1986; 0rskov et al., 1986; 
Vaillant and Lund, 1986).
Glucose has been shown to stimulate the release of GLP-1 (7-36) amide 
(Kreymann et al., 1987; 0rskov et al., 1991). Also a mixed meal results in increased 
secretion of GLP-1 (7-36) amide (Kreymann et al., 1987). A recent study from our 
laboratory has demonstrated increases in circulating concentrations of GLP-1 (7-36) 
amide following the ingestion of glucose, protein, fat or a mixed meal in humans 
(Elliott et al., 1993).
It is interesting to note that the postprandial peak in plasma GLP-1 (7-36) 
amide concentrations occurs within 30 minutes of the ingestion of the meal. Since the 
peptide is released from distal regions of the intestine it is unlikely that the nutrients 
have come into contact with the lumen or are absorbed here; thus the release may be 
stimulated by neural (Roberge and Brubaker, 1991) or hormonal signals from the 
upper gut (Brubaker, 1991). It has been established that GIP is not responsible for the 
stimulation of GLP-1 (7-36) amide secretion since it has been shown not to raise 
GLP-1 (7-36) amide concentrations at physiological concentrations of GIP (Nauck et 
al., 1991).
The most documented action of GLP-1 (7-36) amide is its ability to stimulate 
the release of insulin during hyperglycaemia from the perfused pancreas (Holst et al., 
1987; Mojsov, Weir and Habener, 1987). This action is discussed in greater detail in 
section 1.4.
GLP-1 (7-36) amide has been demonstrated to inhibit pentagastrin-stimulated 
gastric acid secretion in humans (O’Halloran et al., 1990) suggesting a role for this 
peptide as an enterogastrone.
GLP-1 (7-36) amide has been shown to stimulate the release of somatostatin 
from perfused pig pancreas (0rskov, Holst and Nielsen, 1988), perfused rat pancreas
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(Schmid et al., 1990) and perfused rat stomach (Eissele, Koop and Arnold, 1990). 
Receptors for GLP-1 (7-37) have been discovered on a somatostatin secreting cell line 
(Fehmann and Habener, 1991). Receptors for GLP-1 (7-36) amide have also been 
found in the rat brain and lung (Kanse et al., 1988). The presence of binding sites in 
the brain suggest that GLP-1 (7-36) amide may have a role as a neurotransmitter.
To date no physiological role for GLP-2 has been established but this peptide 
has been shown, along with GLP-1 (7-36) amide, to stimulate adenylate cyclase 
activity in hypothalamic and pituitary regions of rat brain (Hoosein and Gurd, 1984).
More recently GLP-1 (7-36) amide has been reported to have effects on lipid 
metabolism. This is discussed in greater detail in section 1.5.
1.3.5 Somatostatin
Somatostatin is a ubiquitous inhibitory peptide found throughout the body; the 
greatest concentrations within the gastrointestinal tract are found in the antrum, 
duodenum and pancreas but it is present throughout the mucosa (Bloom and Polak, 
1980). In the mucosa the peptide is found stored in the endocrine cells referred to as 
D cells (Polak et al., 1975). These cells have characteristic cytoplasmic processes 
which connect them with other endocrine cells such as antral G cells. This feature 
suggests a local or paracrine role for somatostatin (Larsson et al., 1979).
An N-terminally extended form of somatostatin, somatostatin-28, has also been 
isolated and sequenced (Pradayrol et a l, 1980).
In humans the ingestion of a mixed meal leads to a significant stimulation of 
somatostatin release from the stomach and pancreas. Fat and protein were shown to 
elicit a greater response than glucose (Wass et al, 1980; Penman et al., 1981). The 
ingestion of fat by humans has been shown to stimulate the release of somatostatin-28 
(D’Alessio et al., 1989).
Since the discovery of the role of somatostatin in the inhibition of pituitary 
growth hormone secretion (Brazeau et al., 1973) it has been found to be a peptide 
associated with inhibitory actions on many physiological functions, including the 
release of insulin from the endocrine pancreas (Koerker et al., 1974). Somatostatin 
also inhibits the release and action of gastric inhibitory polypeptide (Pederson,
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Dryburgh and Brown, 1975) and secretin (Boden et al., 1974).
Somatostatin has a widespread action on digestive processes of the 
gastrointestinal tract and is thought to have a role in the regulation of nutrient entry 
(Schusdziarra, 1980). This was first demonstrated by Schusdziarra et al. (1979) by 
intraportal infusion of somatostatin into conscious dogs leading to a decrease in the 
rise of absorbed nutrients appearing in the plasma. This may be partly explained by 
the inhibition of gastric emptying (Bloom et al., 1975) or other inhibitory actions of 
somatostatin.
Somatostatin-28 has been shown to reduce the stimulation of insulin secretion 
by intravenous administration of glucose, arginine or secretin and it was concluded 
that the postprandial concentrations of somatostatin-28 are sufficient to attenuate B- 
cell secretion and that this hormone may physiologically modulate nutrient-stimulated 
insulin release (D’Alessio et al., 1989).
These actions of somatostatin suggested a possible therapeutic use in treating 
a variety of endocrine conditions but the short half life of somatostatin precluded its 
use in clinical trials. The development of a long-acting synthetic analogues enabled 
the treatment of endocrine conditions and one of these analogues is octreotide. 
Octreotide has been demonstrated to possess the inhibitory properties of somatostatin 
on the endocrine pancreas (Creutzfeldt et al., 1987).
1.3.6 Pancreatic polypeptide
Pancreatic polypeptide is localised in the pancreas in endocrine cells termed 
PP cells (Taylor, 1989) which are distinct from A, B and D cells. It is found between 
acinar cells lining the ducts of the exocrine parenchyma as well as in the edge of the 
islets of Langerhans especially in the head of the pancreas (Adrian et al., 1976).
Pancreatic polypeptide is released in response to the ingestion of fat and 
protein (Adrian et al., 1976; Schwartz et al., 1976). Decreased circulating 
concentrations of pancreatic polypeptide have been reported in obese subjects 
(Lassman et al., 1980). However, it was later shown that circulating concentrations 
fluctuate with the patterns of intestinal motility in obese as well as lean subjects and 
that the levels were in fact similar (Pieramico et al., 1990) and the differences
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observed in the earlier study may have been due to the interdigestive fluctuations in 
concentration of the hormone.
Infusion of doses of pancreatic polypeptide within the physiological range have 
been shown to inhibit exocrine pancreatic secretion (Adrian et al., 1978; Greenberg 
et al., 1978).
Infusion of pancreatic polypeptide has been shown to raise the basal 
concentrations of insulin in humans but was without effect on glucose- or arginine- 
stimulated insulin or glucagon secretion (Adrian et al., 1980). In contrast chronic 
administration of pancreatic polypeptide in obese rats led to a reduction in circulating 
insuhn concentrations and improved peripheral sensitivity to insulin (Gettys et al., 
1991).
1.3.7 Peptide YY (PYY)
The amino acid sequence of PYY was determined by Tatemoto (1982). In 
humans PYY is located mainly in the ileum and colon with significant amounts also 
found in the pancreas (El-Salhy et al., 1983).
In humans, the presence of fat in the intestinal lumen is the strongest stimulus 
for the release of PYY with the responses to isocaloric loads of protein or glucose 
being significantly smaller (Adrian et al., 1985a). The fact that cells containing PYY 
are only found in the ileum and colon suggest that the release may be modified by 
neural or hormonal factors since the peak response to the meal occurs after only 30 
minutes, before the meal has reached that region of the gastrointestinal tract (Hill et 
a l, 1991).
PYY has been demonstrated to inhibit gastric acid secretion in humans (Adrian 
et a i, 1985b) and pancreatic exocrine secretion in dogs (Hill et al., 1991). It also 
causes inhibition of gastric emptying in humans (Allen et al., 1984) and this was 
accompanied by decreased glucose and insulin concentrations resulting firom the 
delayed appearance of the glucose meal in the duodenum. Its effect on gastrointestinal 
motility extends to the inhibition of intestinal transit in humans resulting in greater 
mouth to caecum transit times (Savage et al., 1987). PYY has been proposed as an 
‘ileal brake’ - a gut factor which coordinates the slowing of gastric and pancreatic
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exocrine secretion and gastrointestinal motility (MacFarlane et aL, 1983). It fulfils the 
criteria since it has been shown to inhibit gastrointestinal motility and secretions from 
the stomach and pancreas (Hill et al., 1991).
1.3.8 Neurotensin
The amino acid sequence of bovine neurotensin was determined by Carraway 
and Leeman (1975). Apart from its abundance in nerves neurotensin is found in the 
ileal mucosa of man in cells termed NT cells (Bloom and Polak, 1980).
Fat has been found to be the most effective nutrient at stimulating the release 
of neurotensin (Rosell and Rokaeus, 1979) and this increase is sufficient to inhibit 
postprandial gastric motility and secretion observed in humans. This ability of fat to 
stimulate neurotensin release whilst glucose was without effect was corroborated by 
Go et al., (1980).
Neurotensin has a pronounced stimulatory effect on smooth muscle activity 
along the gastrointestinal tract in various animals including humans. It has been 
shown to cause a delay in gastrointestinal transit in the stomach and small intestine 
which may lead to enhancement of the absorption of nutrients across the luminal 
epithelium (Ferris, 1989). Neurotensin has been shown to inhibit gastric acid secretion 
in humans (Kihl et al., 1981).
Neurotensin has been shown to affect the blood flow to adipose tissue. In dogs 
intravenous infusion of neurotensin leads to a decrease in blood flow to the adipose 
tissue suggesting that neurotensin may have an indirect role in vascular resistance in 
adipose tissue (Rosell et al., 1976). In humans infusion of neurotensin reduces the 
blood flow to the abdominal adipose tissue but is without effect on the subcutaneous 
adipose tissue of the thigh and it is proposed that neurotensin may have a role in the 
postprandial regional deposition of lipids (Linde, Rosell and Rokaeus, 1982).
The other main action of neurotensin is its effect on pancreatic function, most 
importantly the endocrine secretion. Intravenous infusions of neurotensin have been 
shown to increase the circulating levels of insulin and glucagon in dogs (Kaneto et al.,
1978). The intravenous infusion of neurotensin in humans has been demonstrated to
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result in an 8-fold increase in circulating pancreatic polypeptide (Blackburn et aL, 
1980),
1.4 ROLE OF GASTROINTESTINAL HORMONES IN THE
REGULATION OF INSULIN SECRETION
1.4.1 Incretin effect
The idea of regulation of the endocrine pancreas by signals from the 
gastrointestinal tract was proposed in 1929 by Zunz and La Barre. They termed this 
regulator an ‘incretin’. Further support for this theory came with the observation by 
two independent groups in 1964 that glucose given orally led to a much greater 
increase in insulin than when an equivalent amount of glucose was given intravenously 
(Ehick et aL, 1964; McIntyre, Holdsworth and Turner, 1964). The explanation for 
this effect was that insulinotropic factors, termed incretins, were released from the 
gastrointestinal tract in response to nutrient (most notably glucose) absorption. A 
comparable experiment revealed that oral as opposed to intravenous amino acid loads 
caused a similar effect (Dupre et al., 1968).
In order to be considered as incretin candidates, peptides need to fulfil certain 
criteria : they must be released in response to ingestion of nutrients, especially 
glucose, and should reach postprandial concentrations in vivo that are of a sufficient 
magnitude to elicit an insulinotropic response at elevated glucose concentrations 
(Creutzfeldt, 1979).
1.4.2 Enteroinsular axis
The term ‘enteroinsular axis’ was suggested by Unger and Eisentraut (1969) 
to describe the regulation of endocrine secretion from the pancreas. This included 
regulation by hormones, neural factors and substrate stimulation originating from the 
gastrointestinal tract in response to the ingestion and digestion of nutrients that may 
alter the secretion of insulin from pancreatic B cells.
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The pancreas has an abundant supply of autonomic nerve fibres which enter 
the organ with the arteries (Woods and Porte, 1974) suggesting that nervous control 
of pancreatic secretions is important. Cholinergic, adrenergic and peptidergic neurones 
have aU been demonstrated.
The role of cholinergic nerves in control of endocrine secretion from the 
pancreas appears to be in the early (cephalic) insulin response to a meal and not 
associated with the absorption of nutrients. It has also been proposed that cholinergic 
control may be involved in some models of animal obesity and in regulation of basal 
and postprandial insulin secretion (Ahrén, Taborsky and Porte, 1986).
The role of adrenergic neurones in the control of endocrine secretion appears 
to be related to stress states. In this case there is dual control, a-adrenergic activity 
inhibits insulin secretion and p-adrenergic activity leads to stimulation of insulin 
secretion (Ahrén, Taborsky and Porte, 1986). These opposing adrenergic influences 
make the net effect on insulin secretion very difficult to assess.
There are many peptides that have been shown to be present in nerve terminals 
in the pancreas which may be involved in peptidergic regulation of pancreatic 
endocrine secretion. These include vasoactive intestinal peptide (VIP), 
cholecystokinin, gastrin releasing polypeptide, galanin, neuropeptide Y (NPY), 
calcitonin gene-related peptide, substance P and enkephalin.
Observation of a change in the circulating concentrations of insulin is not 
necessarily a result of variation in the rate of its secretion but may occur in response 
to modification of the rate of hepatic extraction of this hormone. Creutzfeldt and 
Ebert (1985) proposed that the alteration in the rate of hepatic extraction of insulin 
plays a major part in the incretin effect. It is possible to estimate the rate of insulin 
secretion by measuring the plasma levels of C-peptide. This peptide is co-secreted 
with insulin in equimolar amounts but unlike insulin is not subject to hepatic 
extraction and so can be used to quantify insulin secretion rates.
Intravenous glucose was found to be associated with higher rates of hepatic 
insulin extraction than oral glucose (Nauck et al., 1986; Shuster et al., 1988) and it 
was suggested that this difference may be due to the action of gastrointestinal 
hormones or neural signals released in response to the absorption of nutrients. The
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nature of the signal remains unresolved as an obvious candidate, GIP, has been shown 
not to affect the hepatic extraction of insulin (Hanks et aL, 1984).
The two peptides most likely to contribute to the incretin effect are GIP and 
GLP-1 (7-36) amide although many other gastrointestinal hormones are considered to 
be candidate incretins also.
1.4.3 Role of GIP in the enteroinsular axis
Soon after the isolation of GIP, its insulinotropic actions were demonstrated 
in humans (Dupre et aL, 1973; Anderson et aL, 1979; Elahi et aL, 1979). When 
human subjects were given intravenous porcine GIP simultaneously with intravenous 
glucose there was a greater insuhn response and improved glucose tolerance compared 
with glucose infusion alone (Dupre et aL, 1973). This effect could be reduced in rats 
by the infusion of anti GIP antisemm (Holst, Lauritsen and Moody, 1980; Ebert and 
Creutzfeldt, 1982).
The potent ability of GIP to stimulate insuhn secretion was demonstrated to 
be glucose-dependent in the perfused rat pancreas (Pederson and Brown, 1978). This 
was confirmed in humans where ingestion of an oral fat load stimulated the release 
of GIP but not insuhn. When the fat load was ingested together with intravenous 
administration of glucose the insuhn response was greater than when the infusion of 
glucose was given alone (Crockett et aL, 1976). This observation confirmed the 
insuhnotropic action of GIP to be glucose-dependent. Also, when the fat load was 
ingested during the infusion of intravenous glucose the GIP response was smaller than 
that observed when the fat meal was ingested alone suggesting feedback inhibition by 
insuhn (Crockett et aL, 1976).
Since the insuhnotropic effect was not totally abolished by the administration 
of anti GIP antiserum in rats it is likely that GIP is not the only incretin (Holst, 
Lauritsen and Moody, 1980; Ebert and Creutzfeldt, 1982).
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1.4.4 Role of GLP-1 (7-36) amide in the enteroinsular axis
GLP-1 (7-36) amide was demonstrated to be a physiological incretin, possibly 
more powerful than GIP (Kreymann et al., 1987).
GLP-1 (7-36) amide was considered to be a gastrointestinal hormone of 
physiological significance following the discovery of specific binding sites for GLP-1 
(7-36) amide on pancreatic B-cells (Goke and Conlon, 1988). It was also confirmed 
that GLP-1 (7-36) amide had potent insulinotropic effects (0rskov, Holst and Nielsen, 
1988; Shima, Hirota and Ohboshi, 1988). The insulinotropic effect of GLP-1 (7-36) 
amide is glucose-dependent as demonstrated from studies using perfused porcine 
pancreas (Holst et al., 1987) and perfused rat pancreas (Mojsov, Weir and Habener, 
1987).
1.4.5 Role of other gastrointestinal hormones in the enteroinsular axis
Cholecystokinin has been shown to stimulate the release of insulin from the 
endocrine pancreas (Unger et al., 1967; Dupre et al., 1969).
Neurotensin (Brown and Vale, 1976) and somatostatin (Pederson, Dryburgh 
and Brown, 1975) inhibit the release of insulin. Somatostatin also inhibits the release 
of glucagon and GIP (Pederson, Dryburgh and Brown, 1975). The circulating levels 
of somatostatin are thought to be important in the control of nutrient entry into the 
bloodstream via neural, hormonal and humoral factors (Schusdziarra, 1988).
1.5 PHYSIOLOGICAL ROLE OF GASTROINTESTINAL HORMONES 
IN THE CONTROL OF ADIPOSE TISSUE METABOLISM
Little is known of any physiological role of gastrointestinal hormones in the 
control of lipid deposition and mobihsation in adipose tissue. However, a limited 
number of investigations have demonstrated that these hormones may have an 
important role in the control of pathways of lipid metabolism. The control may be 
consequent to changes in the secretion of insulin or directly by controlling lipogenesis, 
lipolysis or the activity of lipoprotein lipase. Most of this knowledge comes from in
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vitro studies and the problems associated with tissue viability and pharmacological 
doses of hormones need to be considered in the interpretation of data obtained.
1.5.1 Indirect control via regulation of insulin secretion
Insulin is known to stimulate lipogenesis (Stansbie et aL, 1976), the activity 
of lipoprotein lipase (Cryer, et aL, 1976; Sadur and Eckel, 1982; Eckel, 1987) and to 
have an antilipolytic effect (Denton, Brownsey and Belsham, 1981). Therefore, any 
hormones that affect the secretion of insulin will indirectly affect adipose tissue 
metabolism via these mechanisms. Several gastrointestinal hormones are known to 
stimulate the release of insulin and their role in the enteroinsular axis is established. 
The most important hormones fulfilling this role are GIP (Dupre et aL, 1973; 
Anderson et at., 1979; Elahi et aL, 1979) and GLP-1 (7-36) amide (Kreymann et aL, 
1987). Other hormones that have been demonstrated to stimulate insulin release 
include cholecystokinin (Unger et aL, 1967; Dupre et aL, 1969). Neurotensin (Brown 
and Vale, 1976) and somatostatin (Pederson, Dryburgh and Brown, 1975) have also 
been shown to inhibit the secretion of insulin.
1.5.2 Control of lipogenesis
Recently it has become apparent that GIP may have direct effects on 
metabolism, in particular anabolic effects, and not solely indirectly via its stimulation 
of insulin release (Beck, 1989).
GIP has been found to exert a direct influence on the insulin sensitivity of rat 
adipocytes. The incubation of isolated adipocytes with GIP led to increased insulin 
receptor affinity. An increase in the sensitivity of insulin-stimulated glucose transport 
was also demonstrated (Stanch, Bar and Mazzaferri, 1985) which is the first step in 
the synthesis of triglycerides from this precursor.
It has been reported that GIP is capable of stimulating the transport of glucose 
into isolated rat adipocytes and the incorporation of glucose into extractable lipids 
(Banner et at., 1988).
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Studies from this laboratory measuring the incorporation of acetate into 
saponifiable fat in explants of rat adipose tissue as an estimation of lipogenesis 
showed that insulin, GIP and GLP-1 (7-36) amide at physiological concentrations 
stimulated fatty acid synthesis. Glucagon and GLP-2, another product of the 
proglucagon gene, were without effect on fatty acid synthesis (Oben et aL, 1991b). 
A recent study has shown GIP to stimulate the incorporation of glucose into 
saponifiable fatty acids by explants of rat adipose tissue (McCarthy, 1993) and a weak 
lipogenic effect of GIP has also been demonstrated in ovine adipose tissue using 
acetate as a precursor (Haji Baba and Buttery, 1991; McCarthy, 1993).
GIP has been shown to stimulate fatty acid synthesis in explants of 
subcutaneous adipose tissue obtained from the lean littermates of the genetically obese 
(ob/ob) mouse but without effect in the obese mice. When obese mice were passively 
immunised with anti-GIP antiserum, fatty acid synthesis was stimulated in adipose 
tissue although not as strongly as that observed in the lean littermates (Oben et aL, 
1991a)
Studies carried out using ovine perirenal adipose tissue have demonstrated GIP 
to stimulate fatty acid synthesis but also showed that inclusion of insulin in the 
medium reduced the magnitude of this GIP effect. In the same report somatostatin 
was shown to inhibit insulin-stimulated fatty acid synthesis (Haji Baba and Buttery, 
1991).
1.5.3 Control of lipolysis
The stimulatory effect of glucagon on lipolysis has long been known after first 
being demonstrated in rat adipose tissue (Hagen, 1961; Vaughan, 1961).
Secretin, which is related to glucagon in structure, has also been shown to 
stimulate lipolysis in isolated rat adipocytes (Rudman and Del Rio, 1969). This action 
was confirmed in a similar study where it was shown that secretin also causes an 
increase in cyclic AMP levels in the adipocytes (Butcher and Carlson, 1970).
VIP is related structurally to glucagon and was demonstrated to stimulate 
lipolysis in isolated rat adipocytes. Again, this action was accompanied by raised 
concentrations of cyclic AMP in the adipocytes but was not competitive with glucagon
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(Frandsen and Moody, 1973) implying that VIP exerts its effect through a different 
receptor.
The effect of GIP on lipolysis was investigated in adipocytes isolated from rat 
adipose tissue and was found not to stimulate lipolysis itself but was capable of 
inhibiting the lipolytic action of glucagon. GIP was without effect on the lipolysis 
stimulated by secretin or VIP. The antilipolytic effect appeared to result from 
competition for the glucagon receptor since GIP was able to bind non-
functionally to the glucagon receptor (Dupre et al., 1976).
In a more recent study GIP has been found to have a weak lipolytic effect in 
adipocytes isolated from rat adipose tissue (Hauner et al., 1988). This discrepancy 
with the previous study may arise from the different methods used to estimate 
lipolysis. By measuring the release of free fatty acids, GIP was shown not to 
stimulate lipolysis (Dupre et al., 1976) whereas by measuring glycerol release it was 
found to be weakly lipolytic (Hauner et al., 1988). It is possible that the free fatty 
acids released during lipolysis may become re-esterified in the adipocyte and therefore 
mask a weak lipolytic effect. A study from this laboratory has suggested that in 
brown adipocytes glucagon may increase the re-esterification of liberated fatty acids 
with glycerol 3-phosphate from glucagon-induced glycogenolysis (Howland and Bond, 
1987) and it is possible that a similar mechanism may explain the discrepancy in the 
studies with GIP.
In an investigation into the possible lipolytic effects of different fragments of 
cholecystokinin it was discovered that cholecystokinin 1-21, which is not the fragment 
involved in actions on gallbladder and intestinal motility, was able to stimulate 
lipolysis in human adipose tissue whereas cholecystokinin 25-33 (CCK-8) was without 
effect (Richter and Schwandt, 1989).
An investigation into the lipolytic effects of glucagon and VIP on human 
adipose tissue reported that both hormones were capable of stimulating lipolysis, as 
measured by the release of free fatty acids, in human adipose tissue but that the action 
of VIP may only be of pharmacological importance (Richter, Robl and Schwandt, 
1989).
PYY, along with the related NPY were demonstrated to inhibit lipolysis in 
isolated adipocytes obtained from canine and human adipose tissue by exerting a
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negative effect on adenylate cyclase through specific receptors coupled with the 
adenylate cyclase system (Valet et at., 1990).
Recently it has been reported that GLP-1 (7-36) amide and, to a lesser extent, 
GLP-1 (1-36) amide stimulated lipolysis in isolated rat adipocytes although the effect 
was very weak compared to that of glucagon (Ruiz-Grande et aL, 1992). GLP-2 was 
without effect on lipolysis. GLP-1 (7-36) amide also stimulated cyclic AMP in 
adipocytes whereas GLP-1 (1-36) amide did not.
1.5.4 Control of lipoprotein lipase activity
In addition to its lipogenic effect GIP has also been shown to stimulate the 
release of lipoprotein lipase activity from cultured 3T3-L1 preadipocytes into the 
medium and also the total amount of lipoprotein lipase activity within these cells in 
a dose-dependent manner (Eckel, Fujimoto and Brunzell, 1979). This was followed 
by demonstration that the infusion of GIP in dogs promoted the clearance of 
chylomicron triglycerides which had been administered in the form of chyle collected 
from donor dogs following a triglyceride rich meal (Wasada et aL, 1981). This is 
presumed to occur via the stimulation of lipoprotein lipase activity by GIP, lipoprotein 
lipase being involved in the transfer of circulating lipoprotein triglycerides to adipose 
tissue, although it is possible that this effect results from increased transport of free 
fatty acids into the adipocytes. GIP has been shown to promote the insulin-stimulated 
incorporation of fatty acids into rat adipose tissue; this effect occurs using 
physiological doses of GIP and is dose-dependent. It was suggested that GIP may 
exert its effect by facilitating the passage of fatty acids through the membrane of the 
adipocyte (Beck and Max, 1983).
Using obese Zucker (fa/fa) rats it has been reported that the effect of GIP alone 
or simultaneously with insulin on the fatty acid incorporation into explants of adipose 
tissue is significantly greater in the obese compared to the lean (fa/-) littermates. 
Since the GIP responses to a glucose load are similar in both sets of animals these 
observations lend further weight to the theory that GIP may increase the affinity of 
the insulin receptors (Beck and Max, 1987). GIP may, therefore, improve the
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efficiency of the deposition of nutrients obtained from the diet via this effect on 
lipoprotein lipase activity and passage of fatty acids across adipocyte membranes.
It has been demonstrated in our laboratory that GIP stimulates total cellular 
lipoprotein lipase activity in explants of rat adipose tissue whilst GLP-1 (7-36) amide 
was found to be without effect (Oben et al., 1991c)
1.6 AIMS AND SCOPE OF THE RESEARCH PROJECT
The survey of the literature indicates that gastrointestinal hormones released 
during the digestion and absorption of nutrients directly affect the partitioning of the 
nutrients within the body. In particular gastrointestinal hormones appear to have 
regulatory roles in the complex lipogenic and lipolytic pathways that occur in white 
adipose tissue. Elucidation of the roles of gastrointestinal hormones in fat deposition 
and mobilisation may lead to further understanding of the mechanisms of obesity 
which in turn could indicate more effective approaches to the prevention and treatment 
of obesity.
Thus the aims of this research project were :
1) To investigate the in vivo effect of manipulation of some dietary
components in rats to clarify how changes in circulating hormones may alter 
basal rates of fatty acid synthesis and sensitivity of adipose tissue to insulin.
2) To investigate the influence of gastrointestinal hormones on rates of fatty
acid synthesis, lipolysis and activity of lipoprotein lipase in vitro using rat and 
human adipose tissue.
3) To examine the functional interrelationships in humans between
gastrointestinal hormones and lipoprotein lipase activity in vivo and to compare 
the interactions in normal and obese states in response to meals of different 
composition.
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In pursuing these aims, the following experimental work was carried out.
1) Two in vivo dietary manipulation experiments were carried out in rats, one 
manipulating dietary fatty acid composition and the other manipulating dietary 
non-starch polysaccharide composition.
2) In order to investigate in vitro adipose tissue metabolism it was proposed 
firstly to substantiate earlier work from this laboratory (Oben et al., 1991b) by 
demonstrating stimulation of fatty acid synthesis in explants of rat adipose 
tissue by insulin, GIP and GLP-1 (7-36) amide, then to validate and optimise 
the technique in order to investigate the possible effects of other 
gastrointestinal hormones, the circulating levels of which are known to be 
affected by the ingestion of fat. Parallel measurements of lipolysis were 
additionally incorporated in order to assess the contribution of fatty acid 
synthesis and lipolysis to the observed net changes in lipid deposition and 
mobilisation. This required the development, optimisation and validation of 
a method for the estimation of lipolysis for use with small amounts of adipose 
tissue when studying explants of adipose tissue. The effects of gastrointestinal 
hormones on adipose tissue lipoprotein lipase activity was investigated in 
explants of both rat and human adipose tissue.
3) In order to investigate the in vivo functional relationships between 
gastrointestinal hormone secretion and lipoprotein lipase activity in humans, 
the effect of oral fat and carbohydrate loads on post-heparin plasma lipoprotein 
lipase activity was investigated in obese and lean subjects, and postprandial 
gastrointestinal hormone and insuhn secretion was manipulated by infusion of 
octreotide. This was in order to assess the importance of hormones such as 
GIP and GLP-1 (7-36) amide in postprandial insulin secretion and lipoprotein 
lipase activation and their possible role in the onset and maintenance of 
obesity. There are conflicting reports as to the importance of GIP in obesity 
in humans and the contribution of GLP-1 (7-36) amide has not been 
investigated previously. Both these hormones have been demonstrated to
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contribute to the incretin effect and their possible contribution to the 
hyperinsulinaemia of obesity and any consequent effect on postprandial 
lipoprotein lipase activity was therefore investigated.
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CHAPTER 2
MATERIALS AND METHODS
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2.1 INTRODUCTION
This chapter describes the various methods used during the studies. Specific 
study designs and any necessary modifications to the techniques are described in the 
relevant experimental chapters. A comparison is made of adipocytes and explants of 
adipose tissue for investigation of rates of fatty acid synthesis. The optimisation of 
conditions for determination of fatty acid synthesis and lipolysis in explants of rat 
adipose tissue is also described with a description of the basic methods adopted.
2.2 MATERIALS
All chemicals are AR grade unless otherwise stated.
Adenosine deaminase - Type IX from calf spleen (Sigma, Poole).
Adenosine-5’-triphosphate (ATP) - 98% (Boehringer Mannheim, Lewes).
Aprotinin - (Sigma, Poole).
Bacitracin - (Sigma, Poole).
Bovine serum albumin for use in radioimmunoassay - fraction V (Sigma, Poole). 
Bovine serum albumin for use in explant incubations - essentially fatty acid free 
(Sigma, Poole).
Centrifuge tubes - 15ml, disposable (Sarstedt, Leicester).
Charcoal - Norit OL (Aldrich Chemical Company, Poole).
Charcoal - Activated (BDH, Poole).
CoUagenase (crude) - (Sigma, Poole).
C-peptide radioimmunoassay kit - (Guildhay, Guildford).
Cuvettes - small volume, UV grade (Fisons Scientific Equipment, Loughborough). 
Dextran - T-70 (Pharmacia, Uppsala, Sweden).
Diethyl ether - (Fisons Scientific Equipment, Loughborough).
Donkey anti-rabbit IgG - (Guildhay, Guildford).
Fluoride oxalate tubes - (Laboratory Sales Ltd, Cambridge).
GIP (human synthetic) for radioimmunoassay - Catalogue no. 7154 (Peninsula 
Laboratories, St Helens).
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GIP (human synthetic) for incubation with explants - Catalogue no. G2269 (Sigma, 
Poole).
GIP (natural porcine) - Gift from Professor J.C. Brown (University of British 
Columbia, Vancouver).
GIP (synthetic porcine) for incubation with explants - Catalogue no. G5512 (Sigma, 
Poole).
Glucagon - (Calbiochem, Nottingham)
GLP-1 (1-37) - Catalogue no. 7169 (Sigma, Poole).
GLP-1 (7-36) amide (synthetic) - Catalogue no. 7168 (Peninsula Laboratories, St 
Helens).
GLP-1 (7-37) - Catalogue no. 7123 (Peninsula Laboratories, St Helens).
GLP-2 - Catalogue no. 7167 (Peninsula Laboratories, St Helens).
yfxxdJuo
D-[U-^ "^ C] Glucose - Specific^ctivity 8.5-13.7 GBq/mmol (Amersham International, 
Aylesbury).
Glycerokinase - (Boehringer Mannheim, Lewes). S5fe.0U'
Glycerol - (BDH, Poole).
Glycerol 3-phosphate dehydrogenase (GDH) - (Boehringer Mannheim, Lewes). GOO 
Glycine - molecular biology grade (BDH, Poole).
Heparin - (Sigma, Poole).
Human serum albumin for use in radioimmunoassay - fraction V (Sigma, Poole). 
Hydrazine hydrate - (BDH, Poole).
Hydrochloric acid - (Fisons Scientific Equipment, Loughborough).
Insulin (natural porcine) - catalogue no. 13505 (Sigma, Poole).
Insulin radioimmunoassay kit - (Guildhay, Guildford).
Iris scissors - straight with tungsten carbide insert (Downs Surgical Ltd, Sheffield). 
Isoproterenol - (Sigma, Poole).
LP3 tubes - polystyrene tubes 3ml volume (Luckham Ltd, Burgess Hill).
LP4 tubes - polystyrene tubes 4ml volume (Luckham Ltd, Burgess Hill).
Magnesium Chloride - (BDH, Poole).
Medium 199 - containing Earle’s salts, 25mM HEPES, L-glutamine and sodium 
bicarbonate (Gibco BRL, Uxbridge).
Methanol - (Fisons Scientific Equipment, Loughborough).
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Microcentrifuge tubes - 1.5ml (Scotlab, Coatbridge).
Minisorp tubes - plastic 3ml and 10ml (Life Technologies, Uxbridge).
Multiwell culture dishes - 24 wells (Gibco BRL, Uxbridge).
[Gin"*]-Neurotensin - Catalogue no. N9885 (Sigma, Poole).
P-Nicotinamide-adenine dinucleotide (NAD) crystallized, 100% - (Boehringer 
Mannheim, Lewes).
Normal rabbit serum - (Guildhay, Guildford).
Octreotide (Sandostatin) - Gift from Sandoz (Basle).
Optiphase ‘Safe’ - (FSA Lab supplies, Loughborough).
Oxyntomodulin - Catalogue no. 7170 (Peninsula Laboratories, St Helens).
Pancreatic polypeptide (rat, synthetic) - Catalogue no. P6410 (Sigma, Poole). 
Pentane - 98% (Aldrich Chemical Co. Ltd, Gillingham, Dorset).
Peptide YY (human) - Catalogue no. 7650 (Peninsula Laboratories, St Helens). 
Perchloric acid - (Fisons Scientific Equipment, Loughborough).
Phosphatidyl choline - (Sigma, Poole).
Potassium hydroxide - (BDH, Poole).
Secretin (rat) - Catalogue no. 7319 (Peninsula Laboratories, St Helens).
Seitz filters - Fütrox (W-steril) filters (H. Erben Ltd., Ipswich).
Sodium acetate, anhydrous - (BDH, Poole).
Sodium [l-^ ^^ C] acetate - Specific^activity 1.85-2.29 GBq/mmol (Amersham 
International, Aylesbury).
^^ I^ Sodium iodide (carrier fi'ee) - (ICN Biomedicals Ltd, High Wycombe). 
Somatostatin-14 - Catalogue no. S9129 (Sigma, Poole).
Somatostatin-28 - Catalogue no. S6135 (Sigma, Poole).
Soybean trypsin inhibitor. Type nS - (Sigma, Poole), lo o o o  per ctq
Triolein - (Sigma, Poole). .
/mcUB
^H Triolein, [Glycerol tri[9,10(n)^H] oleate - Specific/activity 185-740 GBq/mmol 
(Amersham International, Aylesbury).
Trypan blue (0.4% saline solution) - (Sigma, Poole).
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2.3 PREPARATION AND INCUBATION OF EXPLANTS OF ADIPOSE 
TISSUE
Adipose tissue from rats or humans was excised from an appropriate site and 
placed in a vial containing Medium 199 which had been prewarmed to 37°C for 
transport to the laboratory in a vacuum flask.
Explants (0.2-0.5mg) of adipose tissue were prepared under a dissecting 
microscope using eye surgeon’s iris scissors and fine forceps as described by Oils and 
Forsyth (1981). Any blood vessels were carefully dissected away from the adipose 
tissue and explants of approximately l-2mm^ were prepared.
After the requisite number of explants for the particular investigation had been 
cut they were then transferred to multiwell (24 well) culture dishes containing 1ml of 
Medium 199 per well and incubated at 37°C in air for 90 minutes in order that the 
cells could recover. This stage was included since the transport and cutting of the 
adipose tissue results in some anoxia and so the tissue is rested to allow restoration 
of ATP and AMP levels to normal levels (Vernon, 1992).
After recovery the Medium 199 was removed from the wells and replaced by 
fresh warmed Medium 199 containing the test substances at the appropriate 
concentrations. Contamination from any remaining Medium 199 from the recovery 
phase was minimal.
2.4 MEASUREMENT OF FATTY ACID SYNTHESIS IN EXPLANTS
2.4.1 Incubation
During investigations into the hormonal control of fatty acid synthesis, basal 
rates were always determined and insulin was always included as a positive control 
at a concentration of 2 or 4nM (see section 2.6.1) to ensure that the tissue had retained 
its hormonal responsiveness.
Sodium [1-^ ‘^ C] acetate was used to trace the incorporation of acetate into fatty 
acids by the explants and was added with unlabelled sodium acetate to the test 
medium to give a final concentration of acetate in the wells of lOmM and 7.4kBq/ml.
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The expiants were then incubated at 37°C for 2 hours with and without the hormones 
under investigation. At the end of incubation the medium was removed from the 
explants and replaced with Medium 199 containing lOmM unlabelled sodium acetate 
to prevent further incorporation of [l- '^^C] acetate into fatty acids. In total, explants 
were washed three times with 1ml of this solution. The multiwell culture dishes 
containing the explants were then stored at -20”C prior to the extraction of 
saponifiable fats from the explants in order to estimate the rates of fatty acid 
synthesis.
2.4.2 Extraction and measurement of saponifiable fats from explants
After thawing, explants were blotted dry and weighed (1.6-4mg tissue per well) 
and transferred to 15ml glass test tubes. Fat in the explants was then saponified by 
the addition of 1ml of 5M potassium hydroxide in methanol : water (1:1 v/v) and 
heating to 70°C for 2 hours in a water bath.
Tubes were cooled to room temperature and saponified samples acidified to pH 
< 3 with 0.5ml HCl (11.6M).
Unesterified fatty acids were extracted twice with 1ml pentane : diethyl ether 
(7:3 v/v) and washed in 2ml distilled water. The organic phase was transferred to 
scintillation vials and the solvents allowed to evaporate to dryness. After the addition 
of 4ml scintillant (Optiphase ‘Safe’) the radioactivity was counted using a Wallac 
1410 beta counter programmed to count each vial for 5 minutes on a programme. 
Total acetate incorporation into saponifiable fat was calculated after correcting for 
85% recovery and expressed as nmol/mg wet weight of tissue per 2 hours.
The intra-assay coefficient of variance for basal rate of acetate incorporation 
into saponifiable fat in explants was 8.5%.
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2.5 MEASUREMENT OF FATTY ACID SYNTHESIS IN RAT
ADIPOCYTES
2.5.1 Preparation of adipocytes from rat adipose tissue
Epididymal adipose tissue was excised from male Wistar Albino rats (100- 
200g) and placed in a vial containing Medium 199 which had been prewarmed to 
37°C for transport to the laboratory in a vacuum flask.
Adipocytes were then isolated using the method described by Rodbell (1964) 
with minor modifications. The tissue was transferred to a 50ml plastic vial containing 
10ml Medium 199 supplemented with collagenase (Img/ml), soybean trypsin inhibitor 
(0.5mg/ml), bacitracin (1 mg/ml) and fatty acid free bovine serum albumin (4%w/v) 
and finely minced using a small pair of sharp scissors. The adipocytes were then 
liberated by incubation at 37°C for 1 hour in a shaking water bath at 80 cycles per 
minute.
To remove any undigested tissue the cell suspension was then passed through 
Imm^ nylon mesh into a plastic beaker. Adipocytes were then separated by flotation 
and washed. This was carried out by allowing the mixture to stand for 5 minutes, 
removing the infranatant, adding 10ml of fresh warmed Medium 199, mixing and 
allowing to stand again. This procedure was repeated three times, the resulting cell 
suspension made up to 5 ml in fresh warmed Medium 199 and allowed to rest at 
37°C for 90 minutes.
During this time an aliquot of the cell suspension was counted using a 
haemocytometer. Adipocyte yield was approximately 2.5-3 x 10^  cells per gram of 
adipose tissue. Cell viability of the adipocyte suspension, assessed by trypan blue 
exclusion, was 100%.
2.5.2 Measurement of fatty acid synthesis in adipocytes
For the incubation, adipocytes (lOOpl of adipocyte suspension containing 
approximately 4-5 x 10^  cells) were transferred to multiwell (24 well) culture dishes 
containing Medium 199 supplemented with hormones at the appropriate
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concentrations, fatty acid free bovine serum albumin (4% w/v), bacitracin (1 mg/ml), 
soybean trypsin inhibitor (0.5mg/ml) and sodium acetate (lOmM and 7.4kBq/ml). The 
adipocytes were incubated for 2 hours at 37°C in air. At the end of the incubation the 
infranatant was carefully removed from adipocytes by flotation and replaced with 1ml 
Medium 199 containing sodium acetate (lOmM).
Extraction of saponifiable fatty acids was then performed immediately by 
quantitatively transferring the contents of the wells to labelled 15ml test tubes and 
carrying out the saponification and extraction of fatty acids as described under section 
2.4.2. Total acetate incorporation was calculated from 85% recovery and expressed 
as nmol/10^ cells per 2 hour incubation.
2.5.3 Comparison of adipocyte and explant techniques
A comparison of basal and insulin-stimulated rates of fatty acid synthesis as 
estimated by measuring the incorporation of acetate into saponifiable fatty acids 
is shown in Figures 2.1a and 2.1b.
Following the introduction of a method for isolating adipocytes (Rodbell, 1964) 
this technique has been used extensively for the investigation of various aspects of 
adipose tissue metabohsm.
The main advantages of using isolated adipocytes are that size and number of 
fat cells can be fairly accurately measured allowing studies of cellularity, for example 
comparing between adipose sites or different animal species (Gurr and Kirtland, 1978). 
Since the cells are isolated by flotation they are easily separated from other cell 
populations. Therefore measurement of the metabolic parameter represents that of the 
adipocytes exclusively and not the connective tissue. Also, because the cells are 
isolated there is no restriction resulting from nutrient availability and removal of waste 
products from the cells.
The main disadvantages are that structural integrity is lost so cell interactions 
are effectively removed and that collagenase digestion can result in receptor damage. 
This appears to be particularly important in the measurement of rates of lipolysis in 
adipocytes as collagenase digestion has been shown to result in inhibition of 
phosphodiesterase activity of the cells. This was not prevented by the addition of
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trypsin inhibitor and so resulted in higher observed rates of lipolysis compared with 
determinations made in adipose tissue fragments (Engfeldt, Amer and Ostman, 1980).
The advantages of using adipose tissue fragments are the retention of structural 
integrity and minimal damage to the cell membranes, due to the absence of 
collagenase digestion, which is particularly important in determination of factors 
controlling lipolysis.
The disadvantages are that non-adipose cell populations contribute to metabolic 
measurements and that differences in cellularity limit comparisons of responses 
between adipose sites and between animal species due to variation in cell numbers for 
a given weight of tissue. Variation can also arise from cells in the centre of adipose 
tissue fragments obtaining insufficient nutrients and accumulating waste
products.
In the present study a comparison of estimations of fatty acid synthesis as 
determined by the measurement of incorporation of acetate into saponifiable fat 
showed very large standard deviations when using adipocytes (Figure 2.1b). This is 
likely to have resulted from loss of cells during the washing stage at the end of the 
incubation and from high blank values. Also, responses were not consistent implying 
that cell preparations did not always retain their hormone responsiveness. By 
comparison, determinations using explants resulted in much smaller variation as seen 
by smaller standard deviations (Figure 2.1) and a consistent response to insulin was 
observed suggesting that during the preparation of explants the tissue retained its 
hormone responsiveness more consistently.
From the results obtained in this comparison between techniques, coupled with 
the objective to make simultaneous measurements of lipolysis and fatty acid synthesis, 
and in the light of the reported decrease in phosphodiesterase activity resulting from 
collagenase digestion (Engfeldt, Amer and Ostman, 1980) the explant technique was 
selected. In order to minimise the possibility of the shortage of nutrients or oxygen 
and accumulation of waste products in the cells explant size was small (l-2mm^). The 
problem of differences in cellularity of adipose tissue was minimised by using 
similarly sized animals and always selecting the same adipose tissue site.
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2.6 MEASUREMENT OF FATTY ACID SYNTHESIS IN EXPLANTS OF
RAT ADIPOSE TISSUE : OPTIMISATION OF CONDITIONS
2.6.1 Insulin effects
Explants were prepared from the epididymal pads of adipose tissue of male rats 
(100-200g) and incubated as described in section 2.4.1. Eight explants per well were 
used and the volume of medium used was 1ml per well. The effect of insulin at 
concentrations ranging from 2-16nM was investigated in the explants. It was intended 
to ascertain a concentration to use as a positive control for all fatty acid synthesis 
investigations.
Incubation of explants with insulin was found significantly to stimulate fatty 
acid synthesis in explants of epididymal adipose tissue (Figure 2.2) at all 
concentrations investigated.
The insulin response was obtained with maximal rates of fatty acid synthesis 
being observed within the physiological range of circulating concentrations of insulin 
for rats. From the results it was decided to include insulin as a positive control at a 
concentration of 2nM.
2.6.2 Length of incubation
The optimum length of incubation where fatty acid synthesis had attained a 
rate that was linear, and before the cells in the explants began to die leading to 
reduced rates of fatty acid synthesis when expressed per hour was determined.
Explants were prepared from the epididymal pads of adipose tissue removed 
from male Wistar albino rats (100-200g) and incubated as described in section 2.4.1. 
Eight explants per well were used and the volume of medium used was 1ml per well. 
Rates of both basal and insulin-stimulated (4nM) incorporation of acetate into 
saponifiable fat were determined for incubation lengths ranging from 30 minutes to 
6 hours following a standard 90 minute resting period.
The results are shown in Figure 2.3. Insulin-stimulation of fatty acid synthesis 
was not observed before 1 hour and by 2 hours the rate of fatty acid synthesis was
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Figure 2.2 Effect of insulin on incorporation of acetate into saponifiable fatty 
acids by explants of rat epididymal adipose tissue (values denote mean 
± S.D. (n=4) per 2 hour incubation).
Acetate incorporation (nmol/mg/2h)
0 42 6 8 10 12 14 16
[Insulin] (nM)
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Figure 2.3 Effect of incubation time on basal and insulin-stimulated (4nM) rates 
of incorporation of acetate into saponifiable fatty acids by explants of 
rat epididymal adipose tissue (values denote mean ± S.D. (n=4)).
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linear. The rate was still linear after a 6 hour incubation suggesting that the explants 
were still fuUy viable at this stage.
An incubation length of 2 hours was decided upon as the rate of incorporation 
of acetate into saponifiable fat was linear, of sufficient magnitude to be measured 
accurately, and the tissue was viable.
2.6.3 Effect of concentration of sodium acetate on basal and insulin- 
stimulated fatty acid synthesis
An appropriate concentration of sodium acetate in the incubation was 
determined that was sufficient not to limit the rate of incorporation of acetate into 
saponifiable fat.
Explants were prepared from the epididymal pads of adipose tissue removed 
from 4 male Wistar Albino rats (100-200g) and incubated as described in section 
2.4.1. Eight explants per well were used and the volume of medium used was 1ml 
per well. Rates of both basal and insulin-stimulated (2nM) acetate incorporation into 
saponifiable fat were determined for concentrations of sodium acetate ranging from 
2-.5-20mM retaining the amount of acetate at 7.4kBq/ml.
The results are shown in Figure 2.4. The rates of fatty acid synthesis increased 
with increasing concentration of acetate in both basal and insulin-stimulated situations. 
The basal rate of fatty acid synthesis reached a plateau at lOmM and so this 
concentration was used in all incubations.
2.6.4 Effect of temperature and insulin during recovery incubation on 
subsequent rates of fatty acid synthesis
The effects of altering the temperature of the incubation during the recovery 
and of including insuhn in this incubation on the subsequent rate of acetate 
incorporation into saponifiable fat by the explants were investigated.
Explants were prepared from the epididymal pads of adipose tissue of 2 male 
Wistar Albino rats (100-200g) and incubated as described in section 2.4.1. Eight 
explants per well were used and the volume of medium used was 1ml per well. Basal
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Figure 2.4 Effect of concentration of sodium acetate on basal and insulin- 
stimulated (2nM) rates of incorporation of acetate into saponifiable 
fatty acids by explants of rat epididymal adipose tissue (values denote 
mean ± S.D. (n=4) per 2 hour incubation).
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and insulin-stimulated rates of fatty acid synthesis were determined after a standard 
2 hour incubation following a 90 minute resting period. During the resting period the 
effect of incubating the explants at either room temperature or at 37°C and the effect 
of including insulin in the incubation medium during the resting period were 
investigated. In the studies where insulin was included in the medium during the 
resting period the medium was still replaced with fresh medium containing the same 
concentration of hormone before commencement of the test incubation.
No difference was observed between resting the explants at room temperature 
or 37°C (Figure 2.5) nor was there any difference observed when the explants were 
rested in the presence or absence of insulin at either room temperature or 37°C (Figure 
2.6i).
From these results it was decided not to include the hormone in the medium 
during the resting period since this did not affect the rate of insulin-stimulated 
incorporation of acetate into saponifiable fat. It was decided to keep the temperature 
of the resting incubation period at 37°C so that the temperature did not vary between 
experiments.
2.6.5 Comparison of rates of fatty acid synthesis in fed and fasted rats
The effect of prior feeding of rats on the basal and insuhn-stimulated rates of 
incorporation of acetate into saponifiable fat was investigated in order to ascertain 
whether this affected rates of fatty acid synthesis. From the results it could be 
determined whether the animals were required to be fasted overnight before study 
days.
Fed animals were allowed ad libitum access to diet at all times whereas fasted 
animals had their diet withdrawn at 1600 hours on the afternoon prior to the study.
The results are shown in Figure 2.7. There were no significant differences in 
either basal or insulin (2nM)-stimulated rates of incorporation of acetate into 
saponifiable fat by explants of adipose tissue from fasted or fed rats.
. Therefore, since fasting was without effect on subsequent fatty acid synthesis 
in adipose tissue, the animals were allowed ad libitum access to diet for humane 
reasons.
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Figure 2.5 Effect of temperature during the recovery incubation period on 
subsequent rates of basal and insuhn-stimulated (2nM) incorporation of 
acetate into saponifiable fatty acids by explants of rat epididymal 
adipose tissue (values denote mean ± S.D. (n=4) per 2 hour 
incubation).
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Figure 2.6 Effect of inclusion of insulin during the recovery incubation period on 
subsequent rates of basal and insuhn-stimulated (2nM) incorporation of 
acetate into saponifiable fatty acids by explants of rat epididymal 
adipose tissue (values denote mean ± S.D. (n=4) per 2 hour 
incubation).
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Figure 2.7 Rates of basal and insulin-stimulated (2nM) incorporation of acetate 
into saponifiable fatty acids by explants of epididymal adipose tissue. 
Comparison in tissue obtained from 16 hour fasted or fed rats (values 
denote mean ± S.D. (n=4) per 2 hour incubation).
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2.6.6 Effect of fatty acid free bovine serum albumin on basal and insulin- 
stimulated fatty acid synthesis
The effect of including fatty acid free bovine serum albumin in the incubation 
medium on the rate of incorporation of acetate into saponifiable fat was investigated 
since it was necessary to include it in some studies. In studies investigating lipolysis 
fatty acid free bovine serum albumin is used as a fatty acid acceptor since 
accumulation of fatty acids in the medium inhibits lipolysis (Di Girolamo and Fried, 
1^ 7).
Explants were prepared from the epididymal pads of adipose tissue of male 
Wistar Albino rats (100-200g) and incubated as described in section 2.4.1. Eight 
explants per well were used and the volume of medium used was 1ml per well. Basal 
and insulin-stimulated rates of incorporation of acetate into saponifiable fat were 
determined in the presence of fatty acid free bovine serum albumin at concentrations 
ranging from 0.5-2%.
The presence of bovine serum albumin in the test medium was shown not to 
affect the rates of basal and insulin-stimulated rates of incorporation of acetate into 
saponifiable fat (Figure 2.8) and so was included only in the studies where rates of 
lipolysis were estimated simultaneously with fatty acid synthesis.
2.7 MEASUREMENT OF LIPOLYSIS IN ADIPOSE TISSUE EXPLANTS
2.7.1 Incubation
Explants were incubated as described above. However, the following additions 
were made to the Medium 199 in studies where lipolysis was estimated 
simultaneously. Fatty acid free bovine serum albumin was added at a concentration 
of 4% (w/v) to act as a fatty acid acceptor to prevent accumulation of fatty acids in 
the medium resulting in the inhibition of lipolysis. Adenosine, from damaged tissue, 
is known to exhibit insulin-like effects on lipolysis (Di Girolamo and Fried, 1987) 
therefore it was necessary to include adenosine deaminase in the medium at a
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Figure 2.8 Effect of inclusion of fatty acid free bovine serum albumin on rates of 
basal and insulin-stimulated (2nM) incorporation of acetate into 
saponifiable fatty acids by explants of rat epididymal adipose tissue 
(values denote mean ± S.D. (n=4) per 2 hour incubation).
Acetate incorporation (nmol/mg/2h)
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concentration of lU/ml (Honnor, Dhillon and Londos, 1985). Adenosine deaminase 
catalyses the deamination of adenosine to inosine thus removing it from the medium 
and preventing interference with any effects of the various hormones on lipolysis.
Lipolysis rates were estimated by measuring the accumulation of glycerol in 
the medium. Glycerol is assumed not to be reutilised by the adipocytes to a 
significant extent (Shapiro, Chowers and Rose, 1957; Cahill, LeBoeuf and Renold, 
1960; Lynn, MacLeod and Brown, 1960) due to the lack of glycerol kinase activity 
in adipose tissue (Wieland and Suyter, 1957; Margolis and Vaughan, 1962). In order 
to enable reliable measurement of glycerol the concentration of glycerol was increased 
by reducing the volume of test medium used to 0.5ml in each well.
At the end of the incubation period the medium (0.5ml) was removed from the 
explants and transferred to microcentrifuge tubes containing 50pl of perchloric acid 
(5M), in order to remove the protein, and tubes were then centrifuged at 4476g for 5 
minutes in a microcentrifuge. The supernatant was transferred to a further set of 
microcentrifuge tubes and the pellet washed with 200pl perchloric acid (0.5M) and 
centrifuged at 4476g for a further 5 minutes in a microcentrifuge. The supernatant 
was pooled with the previous collection, the pH adjusted to 9.8 using potassium 
hydroxide (lOM) and the volume adjusted to 1ml with distilled water. The extracted 
medium was then stored at -20”C prior to the measurement of the glycerol content.
2.7.2 Glycerol assay
Glycerol was measured using an enzymatic method (Wieland, 1984) resulting 
in the production of reduced nicotinamide adenine dinucleotide (NADH) which is 
measured spectrophotometricaUy by determining the change in absorbance (AA) at 
339nm. As protein also absorbs at this wavelength, it is necessary to deproteinise the 
samples.
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Principle of assay
1 Glycerol + ATP L-(-)-glycerol 3-P + Adenosine 5’-diphosphate (ADP)
*=catalysed by glycerokinase
2 L-(-)-Glycerol 3-P + NAD^ dihydroxyacetone-P + NADH + H^
*=catalysed by glycerophosphate dehydrogenase
Glycerol in the sample is phosphorylated by ATP to glycerol 3-phosphate in 
the presence of the enzyme glycerokinase. Glycerol 3-phosphate is then converted to 
dihydroxyacetone phosphate in the presence of the enzyme glycerophosphate 
dehydrogenase resulting in the formation of NADH. The increase in the concentration 
of NADH is measured by the change in absorbance at 339nm and is proportional to 
the amount of glycerol present in the sample.
Since the equilibrium of the second reaction lies to the left it is necessary to 
displace it to the right which is achieved by carrying out the reaction at pH 9.8 and 
trapping the dihydroxyacetone phosphate in hydrazine.
Procedure
The samples were thawed, mixed and centrifuged at 4476g for 5 minutes in a 
microcentrifuge to pellet the KCIO4 precipitate prior to the determination of glycerol 
content.
The following reagents were added successively to a small volume (2ml) UV 
grade cuvette with 1cm light path :
Hydrazine buffer (containing glycine (0.2M), hydrazine (IM), MgCL (2mM)
jOkjDSphoJbe
pH9.8) - 0.7ml, glycerc^ dehydrogenase - lOpl, ATP (50mM) - 25pl, NAD (20mM) - 
25pl and deproteinised sample (pH9.8) - 250pl.
The solutions were then mixed and absorbance at 339nm read when constant. 
Glycerokinase was then added (lOpl) and cuvette contents mixed again. The 
absorbance was read again when it was constant, after approximately 90 minutes.
A blank containing deproteinised Medium 199 with no glycerol and a standard 
sample containing 80pM glycerol were always included in each batch of assays.
54
The concentration of glycerol present in the samples was calculated using the 
following formula derived from Lambert-Beer’s law using the linear molar absorption 
coefficient for NADH of 6.3 x 10^  l.mol'\mm'^
cor®dUlr^ cLiLuJjuyi coitKLv. th e  oovetfce 
A Absorbance x 0.656 = glycerol mM
The values obtained were then corrected for the dilution factor resulting from 
the deproteinisation of the samples and for the weight of tissue in the appropriate well. 
The results were expressed as nmol glycerol produced/mg tissue per 2 hour incubation.
T h e  in tr o L -a ssa y  c o e f f i c i e n t  o f  v a r ia n c e  a t  63.0pM g l y c e r o l  w a s  5.4% a n d  t h e  
in t e r ' - a s s a y  c o e f f i c i e n t  o f  v a r ia n c e  a t  80pM g l y c e r o l  w a s  5.4%.
2.8 OPTIMISATION OF CONDITIONS FOR MEASUREMENT OF
LIPOLYSIS
2.8.1 Glucagon dose response
Explants were prepared from the epididymal pads of adipose tissue of male 
Wistar Albino rats (150-160g) and incubated as described in section 2.5.1. Eight 
explants per well were used and the volume of medium used was 0.5ml per well. The 
effect of glucagon at concentrations ranging from 0.5-8nM was investigated in the 
explants. It was intended to ascertain a concentration to use as a positive control for 
the determination of lipolysis rates.
Incubation of epididymal adipose tissue explants with glucagon resulted in a 
significant stimulation of lipolysis in a dose-dependent manner (Figure 2.9) and at all 
concentrations investigated. It was decided to include glucagon in all lipolysis 
investigations at a concentration of 4nM.
2.8.2 Length of incubation
The optimum length of incubation, where lipolysis had attained a rate that was 
linear, and before the cells in the explants began to die leading to reduced rates of
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Figure 2.9 Effect of glucagon on production of glycerol by explants of rat 
epididymal adipose tissue (values denote mean ± S.D. (n=4) per 2 hour 
incubation).
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lipolysis when expressed per hour, was determined.
Explants were prepared from the epididymal fat pads of male Wistar Albino 
rats (150-160g) and incubated as described in section 2.5.1. Eight explants per well 
were used and the volume of medium used was 0.5ml per well. Rates of both basal 
and glucagon-stimulated (2nM) lipolysis were determined for incubation periods 
ranging from 30 minutes to 6 hours following a standard 90 minute resting period.
The results are shown in Figure 2.10. The rate of glucagon-stimulated lipolysis 
had attained linearity during an incubation of 2 hours. The rate was still linear after 
a 6 hour incubation suggesting that the explants were still viable at this stage.
An incubation length of 2 hours was decided upon as the rate of lipolysis was 
linear, of a sufficient magnitude to be measured accurately and the explants were still 
viable. This also corresponds to the favoured length of incubation for the 
determination of rates of fatty acid synthesis which is necessary in order to be able 
to carry out simultaneous measurements of fatty acid synthesis and lipolysis.
2.9 MEASUREMENT OF LIPOPROTEIN LIPASE ACTIVITY
2.9.1 Incubation of explants
Explants were prepared as described previously except that they were cut to 
be larger than those used for fatty acid synthesis and lipolysis (l-2mg) determinations 
to produce more lipoprotein lipase, the volume of test medium used was 0.5ml and 
15 explants were used per well. Fatty acid free bovine serum albumin was added at 
4% (w/v). After the 2 hour incubation period heparin was added (lU in 5pl) to each 
well to release lipoprotein lipase into the medium and a further 45 minute incubation 
period added in order for the lipoprotein lipase to be released into the incubation 
medium.
At the end of the incubation the medium was removed and immediately frozen 
at -80®C prior to the determination of lipoprotein lipase activity in the samples. The 
explants were blotted dry and weighed.
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Figure 2.10 Effect of incubation time on basal and glucagon-stimulated (2nM) rates 
of glycerol production by explants of rat epididymal adipose tissue 
(values denote mean ± S.D. (n=4)).
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2.9.2 Lipoprotein lipase assay for determination of activity in plasma or 
medium from incubation of explants.
Principle of assay
The reaction taking place in the lipoprotein lipase assay is as follows :
Lipoprotein lipase 
Triolein (^H) —> (^H) oleic acid + glycerol
The liberation of tritium (^ H) labelled oleic acid from the tritium labelled 
triolein tracer was extracted using a non-polar solvent, measured and hence activity 
of lipoprotein lipase in the sample was determined.
Preparation of the emulsion
^H-Triolein (50pl), triolein (250pl) and phosphatidyl choline (80pl) were 
pipetted into a glass sonication vial and the solvents removed by placing the tube in 
the fume cupboard at room temperature under a stream of nitrogen for 1 hour. The 
tube was kept covered with aluminium foil as phosphatidyl choline, which is used as 
an emulsifier, is photosensitive.
Glycerol (5ml) was then added to the vial and the contents mixed. The 
emulsion was then prepared by sonication using a Soniprep probe in bursts not 
exceeding 30 seconds. In between sonications the emulsion was mixed using a vortex 
mixer and cooled on ice for 2-3 minutes to prevent it becoming too warm. This was 
repeated 6-7 times until no oil was visible on the surface of the glycerol. Emulsions 
were then pooled, mixed and stored in glass tubes wrapped in aluminium foil at room 
temperature. The emulsion was stable for 5-6 weeks.
Each emulsion was tested for linearity by constructing a dose-response curve 
using lipoprotein lipase standards derived from unpasteurised cow’s milk. An example 
of such a curve is shown in Figure 2.11.
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Figure 2.11 Dose-response curve using lipoprotein lipase standards derived from 
unpasteurised cow’s milk to test the linearity of response for 
Triolein emulsion for use in lipoprotein lipase assay.
Regression equation:
Lipoprotein lipase = (0.0704 x Volume of milk) - 0.11286 
Standard error of estimate of slope = 0.0038
LPL activity (nmol oleate per minute)
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60
Procedure
The assay was carried out in disposable 15ml centrifuge tubes and each sample 
assayed in duplicate according to the assay described by Nilsson-Ehle and Schotz
v '
(1976) with minor modifications.
The assay was carried out in the presence of 0.2M NaCl to measure the total 
lipase activity content of the sample. In order to obtain a measure for the lipoprotein 
lipase activity the assay was also carried out in the presence of 4M NaCl which 
suppresses the activity of lipoprotein lipase (Nilsson-Ehle and Schotz, 1976); and an 
estimate of lipoprotein lipase activity obtained by calculating the difference between 
the two measurements.
The substrate emulsions were prepared on the day of the assay and were 
produced by adding triolein emulsion, human serum (to provide the enzyme co-factor 
apolipoprotein CII which is necessary for lipoprotein lipase activity) and Tris-HCl 
buffer (50mM, pH 8.1, 0.2M NaCl (or 4M NaCl) and 2U/ml heparin) containing 3% 
(w/v) fatty acid free bovine serum albumin in the ratio of 1:1:4. These were then 
incubated for 10 minutes at 37”C prior to addition to the assay tubes.
To the assay tubes was added up to lOOpl of sample (if a smaller volume was 
used the volume was made up to lOOpl with Tris-HCl (50mM, pH 8.1, 2U/ml heparin 
and appropriate (0.2 or 4M) concentration of NaCl). Blank measurements were 
obtained by adding lOOpl Tris-HCl (50mM, pH 8.1, 2U/ml heparin and 0.2 or 4M 
NaCl) to the assay tubes. Substrate emulsion (lOOpl) was then added to the tubes 
which were then incubated for 30 minutes in a shaking water bath (approximately 150 
cycles per minute) at 37®C.
At the end of the incubation period the tubes were immediately placed in ice 
and the reaction terminated by the addition of 3.25ml chloroform : heptane : methanol 
(1.25 : 1 : 1.41), followed by 1.05ml of K2CO3 (O.IM adjusted to pH 10.5 using boric 
acid). The tubes were then vortexed and centrifuged for 10 minutes at 1850g. An 
aliquot (0.5ml) of the upper aqueous/methanolic phase (2.45ml total) was transferred 
to scintillation vials and glacial acetic acid (75pl), to prevent chemiluminescence, and 
scintillant, Optiphase ‘Safe’ (4ml), added. The vials were then thoroughly mixed and 
the radioactivity was counted using a Wallac 1410 beta counter programmed to count 
each vial for 5 minutes on a ^H programme. The results were calculated according
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to the following formula :
E =(dpm - dpm blanl^x 1/t x 1/S A x 3 x 4.9 x 1/0.76
Where E = enzyme activity (pmol oleate released min'Jt t = incubation time (minute), 
SA = specific activity (dpm/pmol), 3 refers to the molar ratio of fatty acids released 
to triglyceride hydrolysed, 4.9 refers to the dilution factor, and 0.76 is the partition 
coefficient for oleate into the upper aqueous/methanolic phase.
The results were expressed as pmol oleate released minute'^ per ml plasma for 
plasma samples, and pmol oleate released minute'^ per mg wet weight adipose tissue 
per incubation.
The inter-assay coefficient of variation was calculated by including a milk 
standard in each assay. For assays measuring heparin-releasable lipoprotein lipase in 
plasma samples the inter-assay coefficient of variation at 263.2 nmol min'^ per ml was 
7.9%. For assays measuring heparin-releasable lipoprotein lipase from explants of 
adipose tissue the inter-assay coefficient of variation at 34 nmol min^ per ml was 
9.4%.
2.10 MEASUREMENT OF PLASMA GLUCOSE
Blood samples were collected in fluoride oxalate tubes, centrifuged for 5 
minutes at 1200g and the plasma removed and stored at -20”C prior to assay. The 
analysis was performed by the Biochemistry Department at the Royal Surrey County 
Hospital. The assay utilised a glucose oxidase reaction linked to a colorimetric end 
point as follows :
Glucose oxidase
1) Glucose + 2H2O + O2 —^ Glucuronic acid + 2H20g
Peroxidase
2) H2O2 + o-Dianisidine —> o-Dianisidine (oxidised)
(Colourless) (Brown)
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The analysis was performed using an Encore centrifugal analyser and the inter­
assay coefficients of variation for quality control samples at 6.2mM and 13.8mM were 
calculated to be 1.3% and 2.6% respectively.
2.11 MEASUREMENT OF SERUM TRIGLYCERIDE
For the analysis of serum triglyceride, blood samples were collected in glass 
clotting tubes, the blood allowed to clot for 1 hour before centrifugation at 1200g for 
5 minutes, the serum removed and stored at -20°C prior to assay. The analysis was 
performed by the Biochemistry Department at the Royal Surrey County Hospital. The 
assay utilised lipase to liberate glycerol followed by reaction with glycerokinase and 
glycerol phosphate oxidase. In the presence of peroxidase the hydrogen peroxide 
produced reacts with chlorophenol and 4-aminophenazone to form a red coloured 
quinoneimine adduct as follows :
Lipase
1) Triglycerides —^ Fatty acids + Glycerol
Glycerokinase
2) Glycerol + ATP —^ glycerol 3-phosphate + ADP
Glycerol Phosphate Oxidase
3) Glycerol 3-phosphate + O2 —^ Dihydroxyacetone-phosphate + H2O2
Peroxidase
4) H2O2 + Chlorophenol 4- 4-aminophenazone —^ Quinoneimine adduct
(red)
The analysis was performed using an Encore centrifugal analyser; the inter­
assay coefficients of variation at 0.54mM, 1.93mM and 3.44mM were calculated to 
be 11.1%, 2 .1% and 2 .0% respectively.
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2.12 MEASUREMENT OF C-PEPTIDE IN PLASMA
C-peptide was measured in human plasma samples using a commercial 
radioimmunoassay kit (Guildhay, Guildford).
Briefly, the assay used a ^^ l^odine labelled C-Peptide tracer, antiserum to C- 
Peptide raised in sheep and a polyethylene glycol accelerated double antibody 
separation stage. The detection limit of the assay was O.Olng/ml and the inter-assay 
coefficient of variation for the quality control samples at 0.56, 1.12 and 1.26 nM were 
3.1, 3.1 and 12.6% respectively.
2.13 MEASUREMENT OF INSULIN IN PLASMA
Plasma concentrations of insulin were measured in the Biochemistry 
Department of the Royal Surrey County Hospital utilising a commercial 
radioimmunoassay kit (Guildhay, Guildford).
Briefly, the assay used a ^^ l^odine labelled insulin tracer, antiserum to insulin 
raised in guinea pigs and a polyethylene glycol accelerated double antibody separation 
stage. The detection limit of the assay was 22.5pM and the inter-assay coefficient of 
variation for the quality control samples at 62.2, 266.1 and 448.0 pM were 25.9, 12.3 
and 6 .8% respectively.
2.14 PREPARATION OF CHARCOAL STRIPPED PLASMA
Charcoal stripped plasma was necessary for the addition of plasma to the tubes 
containing the standards in the radioimmunoassays for GIP and GLP-1, Charcoal 
stripping has the effect of removing small proteins including peptide hormones from 
the plasma.
The charcoal (Norit OL) was first de-fined in order to remove very fine 
particles of charcoal. This was performed by suspending the charcoal in 2-3 volumes 
of distilled water. The slurry was gently mixed and then the charcoal allowed to settle 
for 10 minutes. The water was then decanted and the procedure repeated until no fine 
particles of charcoal were seen in the water after being left to stand for 10 minutes.
64
The charcoal was then placed in an oven at 55°C and allowed to dry overnight.
A pool of fasting plasma from healthy human volunteers was obtained and the 
total volume measured. Charcoal was then added, 20g charcoal per 100ml plasma, 
and suspended. The slurry was then left overnight on a roller mixer at 4°C.
The slurry was then centrifuged (1850g at 4®C for 30 minutes) in order to 
remove most of the charcoal from the plasma. The supernatant was removed and 
vacuum filtered through Seitz filters using a Buchner flask and Buchner funnel. The 
filtration was repeated until no more charcoal could be seen to be deposited on the 
filters and the plasma was clear and straw-coloured. The charcoal stripped plasma 
was stored in aliquots of 10 ml at -20°C.
2.15 MEASUREMENT OF GIF IN PLASMA
Plasma concentrations of GIF were determined using a radioimmunoassay 
technique based on the method described by Morgan, Morris and Marks (1978). 
Synthetic human GIF was used for preparation of the standards and GIF tracer, and 
the antiserum used was raised in rabbits against natural porcine GIF.
Briefly, the assay used a ^^ l^odine labelled synthetic human GIF tracer, 
antiserum to porcine GIF raised in rabbits and a polyethylene glycol accelerated 
double antibody separation stage. The detection limit of the assay was 16pM and the 
inter-assay coefficient of variation for the quality control samples at SOOpM and 497 
pM were 8.6% and 8.9% respectively.
2.15.1 Reagents
Stock phosphate buffer (0.4M, pH 6.5)
This was produced by preparing 0.4M solutions of KH2FO4 and Na2HF04 and 
adding the KH2FO4 solution to the Na2HF04 solution until the pH of 6.5 is achieved.
Assav diluent
This was prepared producing a 10 x dilution (0.04M) of the stock phosphate 
buffer (0.4M) containing human serum albumin (0.5% (w/v)) and aprotinin (50 000
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kallikrein inhibitory units (KIU)/100ml.
Antiserum
Antiserum which had been raised in rabbits to natural porcine GIF was used 
at a dilution of 1:9000 with assay diluent.
Standards
These had been previously prepared using synthetic human GIF in the 
laboratory according to the method described by Kwasowski (1986).
Hormone-free plasma
Prepared as described in section 2.11 and used in the assay tubes containing 
the standards to simulate conditions in the sample tubes.
^^ l^odine labelled GIF
This had been previously prepared in the laboratory according to the method 
described by Elliott (1992).
Second antibodv
Antiserum raised in donkeys to rabbit immunoglobulin G (IgG) was used as 
the second antibody in this assay to precipitate the antigen (GIF) - antibody (anti 
porcine GIF antiserum) complex in the assay. This is referred to as donkey anti-rabbit 
IgG.
Normal rabbit serum (NRS)
This was added along with the second antibody to the assay tubes since it is 
also bound by the second antibody so aiding the precipitation of the double antibody 
complex. It was added to the assay at a dilution of 1:135 in assay diluent.
Folvethvlene glvcol (PEG)
A solution of 14% PEG 6000 in 0.04M phosphate buffer, pH 6.5 was added 
along with the second antibody and normal rabbit serum to accelerate the precipitation
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of the double antibody complex.
2.15.2 Procedure
Assays were carried out at 4°C in duplicate. Plasma samples were defrosted, 
vortexed and centrifuged gently at 205g for 10 minutes at 4°C to remove fibrin clots 
and hence improve duplicate values.
Assay diluent was added to the polystyrene LP3 assay tubes (lOOpl to the 
standard sample tubes; 200pl to the zero standard and sample tubes; 300pl to tubes 
designated to determine non-specific binding (NSB) for the standards and samples). 
GIP standards (lOOpl) ranging from 25-800pM were added to the tubes designated for 
the standard curve. Samples (lOOpl) were added to the assay tubes and tubes for non­
specific binding (one sample, usually a fasting sample, in duplicate for each meal for 
each subject used for NSB). Charcoal stripped plasma (lOOpl) was then added to the 
tubes containing the standards. Anti-GIP antiserum was then diluted 1:4000 in assay 
diluent and added to all tubes (lOOpl) except those designated for the measurement of 
NSB. The tubes were then vortex mixed and left to incubate overnight at 4”C.
The GIP tracer was affinity purified just before addition to the assay tubes. 
This was performed by using a solid phase consisting of anti-GIP antibodies, that had 
been raised in sheep, chemically coupled to silica beads which were stored in a small 
(approximately 7ml) plastic column (Elliott, 1992).
Before addition of the ^^Todine labelled GIP the column was washed by 
passing HCl (total of 20ml (0.5%) ( ) followed by distilled water (total of 20ml). 
The solid phase was then equilibrated by allowing assay diluent (total of 15ml) to drip 
through. The column was then stoppered just before it ran dry. The required amount 
of ^^ l^odine labelled GIP was then added to the column and the volume made up to 
approximately 5ml with assay diluent. The column was then stoppered at the bottom 
and the top and inverted several times to suspend the solid phase in the assay diluent. 
The column and contents were then roller mixed at room temperature for 30 minutes.
. The column was then unstoppered and the liquid allowed to drip out. The 
solid phase was then washed by allowing distilled water to drip through (10ml). The 
GIP tracer was then eluted by the addition of 0.5% HCl (5ml) which was allowed to
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drip through and the eluent collected in a 10ml Minisorp tube.
The column was then washed as described earlier before being stored at 4°C 
under Na2C03/NaHC03 buffer, pH 9.8.
The affinity purified GIP tracer was then diluted to give 5000 counts per 
minute (c.p.m.) in assay diluent and the pH checked to be 6.5 before addition (lOOpl 
to all tubes). In general the hydrochloric acid from the elution of the tracer from the 
column was sufficiently diluted not to affect the pH of the buffer. Tracer was also 
added to two empty assay tubes so the total amount of radioactivity added to the tubes 
could be determined. The tubes were then vortexed and left to incubate at 4°C for 48 
hours.
For the separation stage of the assay the following were added to all the assay 
tubes except those designated for determination of the total amount of radioactivity: 
Normal rabbit serum was diluted 1:135 with assay diluent and added (50pl) to tubes. 
Donkey anti-rabbit IgG was diluted 1:20 and added (50pl) to tubes.
PEG (14% w/v PEG6000 in 0.04M phosphate buffer, pH 6.5) was added (lOOpl) to
tubes.
The tubes were then thoroughly vortexed and allowed to incubate at 4”C for 
4 hours before centrifugation at 1850g at 4®C for 30 minutes.
The supernatant was then carefully aspirated and the tubes containing the pellet 
counted using a multiwell Wallac gamma counter. The concentration of GIP in the 
samples was interpolated from a standard curve produced by the programme 
automatically constructing a cubic spline fit of standard data.
2.16 MEASUREMENT OF GLP-1 (7-36) AMIDE IN PLASMA
Plasma concentrations of GLP-1 (7-36) amide were determined using a 
radioimmunoassay technique based on the method described by Elliott et al., (1993).
Briefly, the assay used a ^^ l^odine labelled GLP-1 (7-36) amide tracer, 
antiserum to GLP-1 (7-36) amide raised in rabbits and a dextran coated charcoal 
precipitation stage. The detection limit of the assay was lOpM and the inter-assay 
coefficient of variance for the quality control samples at 22.9 and 64.5pM were 17.8
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and 15.4% respectively.
2.16.1 Reagents
Stock phosphate buffer (0.4M, pH 6.5)
This was produced by preparing 0.4M solutions of KH2PO4 and Na2HP04 and 
adding the KH2PO4 solution to the Na2HP04 solution until the pH of 6.5 is achieved.
Assav diluent
This was prepared producing a 10 x dilution (0.04M) of the stock phosphate 
buffer (0.4M) containing human serum albumin (0.5% (w/v)) and aprotinin (50 000 
KlU/lOOml.
Antiserum
Antiserum had been raised in rabbits to synthetic GLP-1 (7-36) amide (Elliott, 
1992). This antiserum is specific for the amidated forms of the peptide and so reacts 
100% with GLP-1 (1-36) amide. The antiserum was used in the assay at a dilution 
of 1:6000 with assay diluent.
Standards
These had been previously prepared using synthetic GLP-1 (7-36) amide in the 
laboratory according to the method described for GIP standards by Kwasowski (1986).
Hormone-ffee plasma
Prepared as described in section 2.11. Dilutions of the standards were prepared 
in hormone-free plasma.
^^ l^odine labelled GLP-1 (7-36) amide tracer
Sephadex G-25 was allowed to swell in O.IM acetate buffer (pH 5.0 with 
glacial acetic acid. This was then poured into a small plastic column (approximate 
volume of 7ml) to a volume of about 5ml. The column was then equilibrated with 
15ml of column buffer (O.IM acetate buffer, pH 5.0 with glacial acetic acid and
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containing 0.5% w/v human serum albumin and 50 000 KIUA aprotinin) which was 
allowed to drip through.
Synthetic GLP-1 (7-36) amide (3pg) was weighed out into an autoanalyser cup 
and dissolved in lOpl 0.4M phosphate buffer, pH 7.4. To this was added ImCi (lOpl) 
sodium iodide and then chloramine-T (15pg in lOpl of 0.4M phosphate buffer, pH 
7.4). The solution was mixed for 25 seconds using the pipette. The reaction was then 
terminated by the addition of sodium metabisulphite (40pg in 20pl 0.4M phosphate 
buffer, pH 7.4). Column buffer (approximately 200pl) was then added to the mixture 
and the solution transferred quantitatively onto the top of the Sephadex column. More 
column buffer was continually added to the top of the column whilst collecting 27 
fractions each of 10 drops (approximately 0.5ml). Aliquots (lOpl) of the fractions 
were counted on a gamma counter. The fraction (7) containing the highest amount 
of radioactivity from the first peak of radioactivity, corresponding to radiolabelled 
GLP-1 (7-36) amide, eluted was divided into aliquots (20pl) and stored at -20°C until 
required for the radioimmunoassay.
Dextran coated charcoal
This was used in the separation stage of the radioimmunoassay and was 
prepared fresh immediately before the separation was required. It was prepared by 
first allowing bovine serum albumin (2% w/v) to dissolve in stock phosphate buffer. 
Dextran (0.25% w/v) and activated charcoal (1.25% w/v) were then suspended in the 
solution which was then stirred vigorously for 1 hour at 4°C before addition to the 
tubes.
The separation is achieved by the free hormone, i.e. hormone that is not bound 
by antiserum, becoming adsorbed by the dextran coated charcoal particles. This 
leaves the bound hormone, i.e. hormone bound to antibody, in the supernatant.
2.16.2 Procedure
The assay was carried out at 4°C and all determinations were made in 
duplicate. The plasma samples were defrosted, vortexed and centrifuged gently at 
205g for 10 minutes at 4°C to remove the fibrin clots and hence improve the duplicate
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values.
Minisorp tubes (3ml) were used in the assay to minimise the adsorption of the 
peptide to the walls of the assay tubes.
Assay diluent was added to the Minisorp assay tubes (lOOpl to the zero 
standard, standard and sample tubes; 200pl to the tubes designated to determine non­
specific binding for the standards and samples). GLP-1 (7-36) amide standards 
(200pl) ranging from 5-lOOpM were added to the tubes designated for the standard 
curve. Samples (200pl) were added to the assay tubes and tubes for non-specific 
binding (one sample, usually a fasting sample, in duplicate for each meal for each 
subject used for NSB). Charcoal stripped plasma (200pl) was then added to the tubes 
containing the zero standard and NSB for the standard curve. The anti-GLP-1 (7-36) 
amide antiserum was then diluted 1:6000 in assay diluent and added to all tubes 
(lOOpl) except those designated for the measurement of NSB. The tubes were then 
vortex mixed and left to incubate overnight at 4®C.
The GLP-1 (7-36) amide tracer was affinity purified just before addition to the 
assay tubes. This was performed as described for the GIP assay using a solid phase 
consisting of anti-GLP-1 antibodies, that had been raised in rabbits, coupled to silica 
beads which were stored in a small (approximately 7ml) plastic column (Elliott, 1992).
Tracer was also added to two empty LP4 assay tubes so the total amount of 
radioactivity added to the tubes could be determined. The volume in these tubes was 
subsequently adjusted to that in the sample tubes (approximately 1ml) so that the 
efficiency of the radioactive counting is similar in these tubes. The tubes were then 
vortexed and left to incubate at 4®C for 48 hours.
For the separation stage of the assay the Dextran Coated Charcoal suspension 
was stirred continuously whilst rapidly added (1ml) to the assay tubes.
The tubes were then allowed to incubate at 4”C for precisely 20 minutes before 
centrifugation at 1850g at 4®C for 30 minutes.
The supernatant was then carefully decanted into a labelled set of LP4 assay 
tubes which were then counted using a Wallac gamma counter. The concentration of 
GLP-1 (7-36) amide in the samples was interpolated from a standard curve produced 
by the programme automatically constructing a cubic spline fit of standard data.
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2.17 STATISTICAL ANALYSES
Statistical analysis of the results was carried out using the SPSS statistic 
analysis system (SPSS Inc., Chicago, Illinois, USA). The normality of distribution of 
each set of data was confirmed using the Kolmogorov-Smimov goodness of fit test. 
Statistical comparisons between experimental groups were then made by one-way 
analysis of variance with significance assumed at p<0.01. Differences were localised 
using Duncan’s multiple ranges test with a  = 0.01 and 0.05.
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CHAPTER 3
EFFECT OF ALTERATIONS IN THE FATTY ACID 
COMPOSITION OF DIETARY LIPID ON FATTY ACID 
SYNTHESIS IN ADIPOSE TISSUE OF RATS
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3.1 INTRODUCTION
It is estimated that fat contributes approximately 40% of the dietary energy 
intake in the UK. Current recommendations suggest that this be reduced and also the 
proportio^of polyunsaturated fat be increased at the expense of saturated fat (Gregory 
et al., 1990).
Lipids are transported in blood in association with proteins termed 
apolipoproteins which facilitate the formation of the structure of lipid particles, act as 
ligands for receptors for clearance of lipid particles or cofactors for the enzymes 
involved in lipid transport. These particles are termed lipoproteins and vary in size 
and composition (Table 3.1). The classification and role of the apolipoproteins are 
discussed in a review by Erkelens (1989).
In man, the ingestion of large amounts of fat not only leads to obesity 
(Danforth, 1985) but is also linked to elevated circulating triglyceride concentrations 
(Connor and Connor, 1990) which in turn are associated with high incidence of 
coronary heart disease as are elevated circulating cholesterol concentrations (Carlson 
and Bottiger, 1972; Betteridge, 1989).
It has also been established that the type of fat ingested, particularly the degree 
and position of saturation of the constituent fatty acids, is of greater importance than 
amount in determining the circulating lipid concentrations (Connor and Connor, 1990).
Saturated fatty acids have no double bonds and are readily synthesised in vivo 
from acetate. They are not essential nutritionally and are particularly abundant in 
animal fats, apart from those obtained from marine sources. Diets rich in saturated 
fatty acids have been demonstrated to have a hypercholesterolaemic effect in humans 
(Ahrens, Hirsch and Insull, 1957; Keys, Anderson and Grande, 1957) and in rats 
(Groot et al., 1988; Manorama and Rutmini, 1992). This effect was shown in 
hamsters to be due to a decrease in hepatic L ow dLensity Lipoprotein (LDL) receptor 
activity hence LDL are not cleared from the circulation resulting in elevated 
circulating concentrations of LDL-cholesterol (Spady and Dietschy, 1985); this effect 
is augmented by increased dietary cholesterol intake (Spady and Dietschy, 1988).
Monounsaturated fatty acids are present in all animal and vegetable fats, the 
only significant dietary contribution being oleic acid (C18:lco9). The double bond is
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present in the (0-9 position, that is 9 carbons from the terminal methyl group (Connor 
and Connor, 1990). Monounsaturated fatty acids are not essential fatty acids as they 
are readily synthesised in the body (Connor and Connor, 1982). Some studies have 
shown that dietary inclusion of this class of fatty acid has no effect on fasting 
circulating cholesterol (Becker et al., 1983) or triglyceride (Mattson and Grundy, 
1985; Grundy, 1986) concentrations in humans.
Polyunsaturated fatty acids are not synthesised by the body and since they must 
be obtained from the diet are termed ‘essential’ fatty acids (Neuringer and Connor,
1986). These fatty acids are vital constituents of cell membranes and form the 
precursors for prostaglandin synthesis (Goodnight et al., 1982). There are two classes 
of polyunsaturated fatty acids depending on the position of the first double bond from 
the terminal methyl group: co-6 , found in oils of vegetable origin, and (0-3, found in 
oils of marine origin (Connor and Connor, 1990). The most common dietary (0-6 fatty 
acid is linoleic acid (C18:2(o6) and the two common dietary forms of (0-3 are 
eicosapentaenoic acid (C20:5(o3) and docosahexaenoic acid (C22:6(o3) which are 
highly concentrated in fish oils (Connor and Connor, 1990).
The beneficial effects of cod liver oil have been known for centuries and the 
effects were attributed to the high vitamin A and vitamin D content. The free 
distribution of cod liver oil to young children, pregnant and nursing women during the 
second world war by the Ministry of Food meant that the nutritional importance had 
been officially recognised. Cod liver oil was a popular supplement given to children 
until as recently as the 1950s.
More recently the profile of cod liver oil has been raised again since it was 
suggested that ingestion of eicosapentaenoic acid, of which fish oil is a rich supply, 
may protect against myocardial infarction (Dyerberg et al., 1978). This is thought to 
be achieved through its effects on circulating blood lipids and blood clotting 
mechanisms.
The theory that a high level of dietary fat intake confers a high risk of 
coronary heart disease has been challenged by the observations in the now-classic
study that the diet of Eskimos contains the highest levels of fat (Bang and Dyerberg,
l/
1980) yet the population exhibits low rates of coronary heart disease (Kromann andU'
Green, 1980). It is believed that the Eskimo’s high dietary intake of fish oil is
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responsible for this discrepancy but the mechanisms by which it offers protection are 
not clear. Possible actions include inhibiting synthesis of thromboxane Ag with 
stimulation of prostacyclin production, reducing blood viscosity, enhanced fibrinolysis 
as well as the effects on circulating lipids (Connor and Connor, 1990).
High levels of the LDL-cholesterol and VLDL-triglycerides along with low 
levels of h igh density Lipoprotein (HDL) are associated with the development of 
atherosclerosis (Havel, 1982). In their study of Greenland Eskimos, Bang and 
Dyerberg (1980) showed that Eskimos consuming a seafood diet had elevated levels 
of HDL, lower levels of LDL-cholesterol and much lower levels of VLDL- 
triglycerides compared with those consuming a Western-style diet.
The principal effect of the ingestion of fish oil on plasma lipids is to reduce 
circulating concentrations of triglycerides (Sanders and Roshanai, 1983; Deck and 
Radack, 1989; Connor and Connor, 1990). The mechanism for this effect appears to 
be a decreased rate of triglyceride synthesis by the liver since a marked reduction in 
the synthesis of VLDL-triglyceride has been demonstrated in hyperlipidaemic patients 
whose diet is being supplemented by the addition of fish oils (Nestel et al., 1984). 
Fish oil has also been shown to lower circulating triglycerides in rats (Haug and 
Hpstmark, 1987; Lakshman, Chirtel and Chambers, 1988) which was accompanied by 
a reduction of hepatic triglyceride production.
The ingestion of fish oil in humans at intakes in excess of 8g per day also has 
a pronounced hypocholesterolaemic effect (Ahrens et al., 1959; Kingsbury et al., 
1961) which has been attributed to the high levels of polyunsaturated fatty acids in 
fish oil. The reduction appears to be in the cholesterol associated with LDL and 
VLDL (Harris, Connor and McMurry, 1983) and is mainly due to a decrease in the 
synthesis of LDL (Illingworth, Harris and Connor, 1984). Supplementation of the diet 
with fish oil has also been shown to lower circulating concentrations of cholesterol in 
rats (Haug and Hpstmark, 1987; Lakshman, Chirtel and Chambers, 1988).
Hepatic lipogenesis has been demonstrated to be inhibited in perfused livers 
from rats fed a diet supplemented with fish oil as opposed to safflower oil (Topping, 
Trimble and Storer, 1987). They also showed hepatic synthesis of cholesterol to be 
depressed in these animals and that insulin was without effect on hepatic lipogenesis 
in rats fed the fish oil diet.
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The effect of dietary polyunsaturated fatty acids on lipoprotein lipase activity 
has been studied in rats (Coiffier, Paris and Lecerf, 1987; Haug and Hpstmark, 1987; 
Herzberg and Rogerson, 1989). When lipoprotein lipase activity was assessed in post­
heparin plasma of rats, those fed diets containing polyunsaturated fatty acids exhibited 
a higher activity than those fed saturated fatty acids. This increase was thought to be 
due to enhanced activity of muscle lipoprotein lipase (Coiffier, Paris and Lecerf,
1987). When the activity of lipoprotein lipase was assessed in adipose tissue, 
inclusion of fish oil in the diet of rats where the total fat content was 33% (w/w) led 
to a decrease in the activity of lipoprotein lipase compared to that found in rats fed 
saturated fat. Also, hepatic lipase activity was decreased suggesting that decreased 
plasma lipid levels did not result from enhanced lipase activity in liver or adipose 
tissue (Haug and Hpstmark, 1987). In a study where rats were fed diets where the 
total fat content was 10% (w/w) and the fatty acids were contributed by tallow, corn 
oil or fish oil, the lipoprotein lipase activity of adipose tissue was similar in each 
group of animals. However, the lipoprotein lipase activity of muscle was found to be 
elevated in the fish oil-fed group suggesting that muscle lipoprotein lipase contributes 
to the hypolipidaemic effect of fish oil feeding (Herzberg and Rogerson, 1989).
It is obvious that the fatty acid composition of the diet and in particular the 
relative contribution of polyunsaturated fatty acids to the fatty acid content has an 
important effect on lipid metabolism. The effects of fish oil have been demonstrated 
on circulating levels of triglycerides and cholesterol, on hepatic lipogenesis, muscle 
and adipose tissue lipoprotein lipase activity and hepatic lipase activity. There are no 
reports in the literature of investigations into the effect of the dietary inclusion of 
these oils on rates of lipogenesis in adipose tissue and in particular the hormonal 
responsiveness of this tissue. With the observation that dietary fish oil results in 
decreased rates of lipogenesis in the liver of rats (Topping, Trimble and Storer, 1987) 
and alterations in lipoprotein lipase activity (Haug and Hpstmark, 1987; Herzberg and 
Rogerson, 1989) it is clear the pattern of lipid deposition is altered by the fatty acid 
composition of the diet. Assessment of the contribution of changes in fatty acid 
synthesis in adipose tissue to the altered patterns of lipid deposition resulting from 
dietary 0)3 fatty acids may lead to a clearer understanding of the actions of the co-3 
fatty acids. The rat was used in this study as this type of investigation is not possible
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in human subjects, but any changes observed may be cautiously extrapolated to 
humans, bearing in mind the species differences, and may point to areas of 
investigation in the human subject.
The aim of the investigation was to compare the effects of diets containing 
com, fish or mixed (replicating the UK dietary fatty acid intake) oil on the rate of 
fatty acid synthesis in the adipose tissue of fed rats. Also it was intended to 
investigate any alterations in the insulin sensitivity of the adipose tissue associated 
with changes in fatty acid composition of the three diets. Circulating concentrations 
of cholesterol, triglycerides and insulin are also reported in order that any changes 
could be related to alterations in fatty acid synthesis rates or insulin sensitivity in the 
adipose tissue.
The diets were formulated by a co-worker in the laboratory and co-workers 
measured rates of hepatic lipid synthesis along with the circulating concentrations of 
cholesterol, triglycerides and insulin. The animals were pair-fed with respect to the 
com oil diet group as it was necessary that the animals consumed similar amounts of 
food so that lipid metabolism was not influenced by varying levels of food intake 
between the groups.
3.2 STUDY DESIGN
Thirty male Wistar/Albino rats were obtained from the Surrey stock and 
randomly allocated into three groups of ten and pair-fed on diets formulated so that 
the oil component was contributed by com, fish or mixed oil. The mean weights at 
the beginning of the study are shown in Table 3.5. At the completion of the study one 
animal from each group was sacrificed per day, therefore they were added to the study 
over a period of 10 days, adding one animal per group each day so that at the 
completion of the study the animals would have consumed the diet for identical 
periods of time. The composition of the diets (shown in Table 3.2) was such that the 
oil comprised 5% of the diet in terms of weight and 10% in terms of energy. The 
fatty acid composition of the diets is shown in Table 3.3. The composition of the 
vitamin and mineral mix (Special Diets Services, Witham) used in the study is given 
in Table 3.4. The oil content was selected as it was similar to the amount of oil fed
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Table 3.2 Composition of rat diets (Zampelas, 1993). (Values denote g/lOOg).
DIETARY
COMPONENT
CORN OIL 
DIET
MIXED OIL 
DIET
FISH OIL 
DIET
STARCH 60.0 60.0 60.0
SUCROSE 5.0 5.0 5.0
CASEIN 20.0 20.0 20.0
CELLULOSE 4.0 4.0 4.0
COCONUT OIL 0.0 1.1 0.0
OLIVE OIL 0.0 1.1 0.0
CORN OIL 5.0 0.6 0.0
PALM OIL 0.0 2.2 0.0
FISH OIL 0.0 0.0 5.0
METHIONINE 0.2 0.2 0.2
VITAMIN & 
MINERAL MIX
5.0 5.0 5.0
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Table 3.3 Fatty acid composition of rat diets (Zampelas, 1993). (Values denote
g/lOOg).
FATTY ACID CORN OIL 
DIET
MIXED OIL 
DIET
FISH OIL 
DIET
€ 12:0 0.0 10.7 0.0
€14:0 0.6 4.1 7.1
€16:0 14.0 24.7 17.5
€18:0 2.3 3.2 4.2
€ 20:0 0.3 0.5 0.0
€ 22:0 0.0 0.0 0.0
€24:0 0.0 0.0 0.0
€14:1 0.0 0.0 0.3
€16:1 0.3 0.6 9.9
€18:1 30.0 39.0 12.9
€ 20:1 0.2 0.0 2.5
€ 22:1 0.2 0.0 1.1
€18:2 50.0 12.0 4.2
€ 20:2 0.0 0.0 4.4
€18:3 1.6 0.5 0.0
€20:4 0.0 0.0 1.6
€22:4 0.0 0.0 1.2
€20:5 0.0 0.0 18.2
€22:5 0.0 0.0 2.1
€ 22:6 0.0 0.0 12.8
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Table 3.4 Composition of vitamin/mineral mixture used in formulation of rat diets
(Zampelas, 1993).
VITAMIN/MINERAL AMOUNT IN DIET
Vitamin A 5.0 miu/kg
Vitamin D3 1.0 miu/kg
Vitamin E 25.0 g/kg
Vitamin B2 5.0 g/kg
Vitamin K 10.0 g/kg
Nicotinic acid 10.0 g/kg
Calcium Pantothenate 10.0 g/kg
Folic acid 0.5 g/kg
Vitamin 5.0 g/kg
Vitamin Bg 5.0 g/kg
Biotin 20.0 mg/kg
Vitamin Bj2 5.0 mg/kg
Vitamin C 20.0 g/kg
Inositol 100.0 g/kg
Choline 100.0 g/kg
p-Aminobenzoic acid 50.0 g/kg
Potassium 5000.0 pg/kg
Iron 50.0 g/kg
Cobalt 0.5 g/kg
Manganese 50.0 g/kg
Copper 10.0 g/kg
Zinc 20.0 g/kg
Iodine 0.5 g/kg
Magnesium 1000.0 pg/kg
Sodium Chloride 5000.0 pg/kg
Phosphorus 5000.0 pg/kg
Calcium 7000.0 pg/kg
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in the standard laboratory chow diet for rats and does not represent a high dietary fat 
intake.
The animals from each dietary treatment group were housed together and were 
fed the diet for 2 weeks during which time they were allowed ad libitum access to 
fresh drinking water at all times.
The animals were allowed access to food overnight prior to sacrifice. On each 
study day, between 8.30am and 9.30am, one rat from each of the dietary groups was 
taken for the determination of adipose tissue lipogenesis. Animals (300-400g) were 
first anaesthetised using diethyl ether and a blood sample collected via cardiac 
puncture into heparinised tubes for the determination of plasma insulin. Blood was 
also collected into a glass tube, allowed to clot and the serum separated and used for 
the determination of serum concentrations of triglycerides and cholesterol. The 
animals were then killed by cervical dislocation and the livers (for determination of 
hepatic lipogenesis by a co-worker) and epididymal fat pads (for determination of 
adipose tissue fatty acid synthesis in six rats from each group) were rapidly excised. 
The epididymal fat pads were placed into universal tubes containing prewarmed 
Medium 199 and transported to the laboratory for preparation and culture of explants 
as described in Chapter 2.
Basal and insulin-stimulated (2nM) rates of fatty acid synthesis, estimated by 
measurement of incorporation of acetate into saponifiable fat, were determined in 
quadruplicate in explants prepared from the epididymal adipose tissue of rats from 
each diet. At the end of the incubation period the explants were washed as described 
in Chapter 2 and stored at -20°C until the extraction and measurement of saponifiable 
fat could be performed. This was carried out within two weeks of the completion of 
the study.
Plasma concentrations of insulin were determined using the radioimmunoassay 
technique described in Chapter 2. Serum concentrations of cholesterol and 
triglycerides were determined using assay kits (Boehringer, Mannheim, Lewes) on a 
Cobas Bio centrifugal analyser. Also basal and insulin-stimulated rates of hepatic 
lipogenesis were investigated in liver slices by other workers in the laboratory 
(Zampelas, 1993).
For each set of data the normality of distribution was confirmed using the
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Kolmogorov-Smirnov goodness of fit test. Statistical comparisons between the 3 
experimental groups were then made by one-way analysis of variance with 
significance assumed at p<0.05. Differences were identified a posteriori using 
Duncan’s multiple ranges test with a=0.05 and 0.01.
3.3 RESULTS
Rats in the com oil fed group exhibited the lowest rates of food consumption 
and so the other two groups were pair fed to this level. Food intake was similar for 
all three dietary treatments and weight gains were not significantly different between 
the three dietary treatments (Table 3.5).
Table 3.5 Weight gain and food intake of rats fed diets containing mixed, com or fish 
oil. (Values denote mean with ± S.D shown in parentheses (n=10)).
DIETARY
OIL
INITIAL WEIGHT 
(g/rat)
WEIGHT GAIN 
(g/day/rat)
FOOD INTAKE 
(g/day/rat)
FISH 300.5 (44.1) 3.9 (1.4) 20.1
CORN 307.8 (47.1) 3.4 (1.2) 20.8
MIXED 312.3 (25.0) 3.4 (0.8) 20.7
3.3.1 Serum cholesterol
The serum concentrations of total circulating cholesterol in the rats are shown 
in Figure 3.1 with the values given in Appendix 1, Table l.A. There were no 
significant differences found between the three treatment groups.
3.3.2 Serum triglyceride
The serum concentrations of circulating triglycerides in the rats are shown in 
Figure 3.2 with the values given in Appendix 1, Table l.A. The mean circulating 
concentrations of triglycerides were highest in the mixed oil group. The concentration
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Figure 3.1 Circulating concentrations of cholesterol in serum of rats fed diets
containing fish, com or mixed oil (values denote mean ± S.D. (n=9)).
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Figure 3.2 Circulating concentrations of triglycerides in serum of rats fed diets
containing fish, com or mixed oil (values denote mean ± S.D. (n=9)).
* = Fish com or mixed oil groups (p<0.05).
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of triglycerides were found to be significantly lower (p<0.05) in the fish oil fed group 
than in either the corn or mixed oil fed groups of animals.
3.3.3 Plasma insulin
The plasma concentrations of circulating insulin in the rats are shown in Figure
3.3 with the values given in Appendix 1, Table l.A. The mean circulating 
concentrations were found to be significantly higher (p<0 .01) in the mixed oil fed 
group compared with either the com or fish oil fed groups of animals.
3.3.4 Adipose tissue fatty acid synthesis
The rates of basal and insulin-stimulated fatty acid synthesis in the explants of 
epididymal adipose tissue from the rats are shown in Figure 3.4 with the values given 
in Appendix 1, Table I.B. Both the basal and insulin-stimulated rates of lipogenesis 
were found to be significantly higher (p<0 .01) in the group of animals fed on the diet 
containing fish oil than in those fed diets containing com or mixed oil.
3.4 DISCUSSION
Circulating concentrations of cholesterol were not significantly different
between the treatment groups whereas hepatic synthesis of cholesterol was reported
in this study (Zampelas, 1993) to be significantly lower in the fish oil fed group than
com oil fed group. Circulating concentrations of triglycerides were lower in the fish
oil fed group than either the com oil or mixed oil fed groups. Hepatic synthesis of
total triglycerides were reported to be significantly lower in the fish oil fed group
compared with the mixed oil fed group. Circulating insulin concentrations were
significantly higher in the mixed oil fed group compared to the fish or com oil fed
\a acUpoSÉ. tissoe
group. Basal and insulin-stimulated rates of fatty acid synthesis)^were significantly 
higher in the fish oil fed group when compared to either the com or mixed oil fed 
groups.
Previous studies have reported a reduction in cholesterol following the feeding
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Figure 3.3 Circulating concentrations of insulin in plasma of rats fed diets
containing fish, com or mixed oil (values denote mean ± S.D. (n=9)).
* = Mixed oil vs fish or com oil groups (p<0.01).
Plasma insulin (nM)
4.0 r
3.0
2.0
1.0
0.0
FISH CORN
Dietary oil
MIXED
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Figure 3.4 Basal and insulin-stimulated rates of incorporation of acetate into 
saponifiable fatty acids by explants of epididymal adipose tissue of rats 
fed diets containing fish, com or mixed oil (values denote mean ± S.D. 
(n=6) per 2 hour incubation).
* = Insulin-stimulated vs basal (p<0.01). 
a = Fish vs com or mixed oil groups (p<0.01).
Acetate incorporation (nmol/mg)
8.00 r
6.00
4.00
2.00
0.00
a
FISH CORN MIXED
Basal Insulin (2nM)
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of fish oil to rats (Haug and H0stmark, 1987; Lakshman, Chirtel and Chambers, 1988). 
The effect was thought to be due to decreased hepatic synthesis of cholesterol which 
was confirmed in the present study. The lack of hypocholesterolaemic effect in the 
present study may be due in part to the lower level of inclusion of fish oil in the diet. 
The above mentioned studies used approximately 30% fat (w/w) whereas the present 
study used 5% (w/w) and it is feasible that the hypocholesterolaemic effect is only 
observed when cholesterol concentrations have been previously elevated. The actual 
concentrations of cholesterol observed in the fish oil fed group are similar to those 
observed in a previous study (Haug and Hpstmark, 1987) where, however, the high 
level of fat inclusion in the diet in their study may have led to much higher 
cholesterol concentrations in the rats fed diets containing saturated fat.
It was also noted that the fish oil concentrate contained cholesterol resulting 
in higher dietary intakes of cholesterol (approximately 4.5 mg/day) by the fish oil fed 
group (Zampelas, 1993). Determinations of cholesterol synthesis in the livers of the 
rats, performed by a co-worker, demonstrated.that the inclusion of fish oil in the diet 
led to lower rates of synthesis in the fish oil fed group in comparison to the corn oil 
fed group (Zampelas, 1993). This would support the idea that the dietary cholesterol 
may be sufficient to inhibit the hepatic synthesis of cholesterol in the fish oil fed 
group and future studies designed to investigate the effect of fatty acid composition 
on circulating lipids should ensure constant levels of dietary cholesterol in all 
treatment groups.
The observed reduction in circulating triglycerides in the present study is in 
agreement with previous pubhshed studies (Haug and Hpstmark, 1987; Lakshman, 
Chirtel and Chambers, 1988). Determination of the rate of hepatic triglyceride 
synthesis by observing the rate of incorporation of [U-^ '^ C] glucose into total hepatic 
triglycerides which was performed by a co-worker in the same animals demonstrated 
a reduced rate in the fish oil fed group compared with the mixed oil fed group 
(Zampelas, 1993). This may be a mechanism involved in the reduction of circulating 
triglycerides. Other possible mechanisms for this reduction could include inhibition 
of the synthesis and secretion of lipoproteins responsible for the transport of 
triglycerides, an increase in fatty acid oxidation, or a decrease in the activity of the 
enzymes involved in fatty acid estérification (Coniglio, 1992).
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The possibility of decreased absorption of triglycerides due to ingestion of fish 
oils is not thought to be a possible mechanism as a recent study reported fish oil not 
to have any effect on this process in rats (Herzberg et al., 1992).
The rats fed the diet containing the mixed oil exhibited significantly higher 
circulating concentrations of insulin than those fed diets containing com or fish oil. 
This finding is consistent with the hypothesis that the feeding of the diets containing 
high proportions of saturated and co-6 fatty acids may lead to the development of 
insulin resistance in rats. The inclusion of fish oil in the diet of rats consuming a high 
fat diet has been shown to prevent the development of insulin resistance in these 
animals (Storlien et at., 1987).
Basal and insulin-stimulated rates of fatty acid synthesis were found to be 
greater in adipose tissue from the rats fed on the diet containing fish oil than in those 
fed on the mixed or com oil diets. This observation suggests that the insulin 
sensitivity of the epididymal adipose tissue is enhanced by the inclusion of fish oil in 
the diet. This effect is not due to increased levels of polyunsaturated fatty acid in the 
diet since the com oil diet, which contains comparable amounts of polyunsaturated 
fatty acids, resulted in similar rates of fatty acid synthesis in the adipose tissue of the 
animals to those observed in the mixed oil fed group. This effect was also unlikely 
to be due to up-regulation of insulin receptors associated with lower circulating 
concentrations of insulin since animals fed the com oil diet had similar circulating 
concentrations of insulin to those fed the fish oil diet.
There have been several reports of the alteration of the fatty acid composition 
of cell membranes both in vitro and induced by the fatty acid composition of the diet. 
Supplementation of the media with different fatty acids led to alterations in the 
enrichment of the membrane phospholipids in cultures of hepatocytes. Similar 
changes were observed in hepatocytes isolated from rats accustomed to diets 
containing different fatty acid compositions. These changes were accompanied by 
alterations in the rates of hepatic triglyceride synthesis with cells having membranes 
rich in co-3 polyunsaturated fatty acids exhibiting lowest rates (Stmm-Odin et al., 
1987).
The fatty acid composition of dietary fat has also been shown to alter the fatty 
acid composition of the plasma membrane of adipocytes from rats. Animals fed a diet
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containing a high proportion of polyunsaturated fatty acids in relation to saturated fatty 
acids were found to have increased amounts of polyunsaturated fatty acids present in 
the phospholipid membrane of the adipocytes. Diabetic (streptozotocin-induced) rats 
were found to have lower levels of polyunsaturated fatty acids in the adipocyte cell 
membrane compared with normal (control) rats when fed the control diet; when fed 
the diet rich in polyunsaturated fatty acids composition of their adipocyte plasma 
membranes more closely resembled those in the normal rats fed the control diets 
(Field et al., 1988).
The composition of the plasma membrane of a cell is critical for its function 
since this is a highly selective and permeable barrier important in the communication 
of external signals and the transport of substances both to and from the cell. Any 
changes in the composition of the membrane might therefore be expected to affect the 
function of the cell. Increasing the proportion of polyunsaturated fatty acids in cell 
membranes by dietary means has been demonstrated to increase the fluidity of various 
membranes (Wahle, 1983). However, the nature of the fluidity of the membrane is 
extremely complex and measures of fluidity do not necessarily parallel changes in 
physical properties, reflecting the difficulties in definition of membrane fluidity as it 
relates to membrane function (Stubbs and Smith, 1984).
One of the many membrane functions found to be affected by alterations in 
membrane fluidity is that of the insulin receptor. It is thought that changes in 
membrane properties may contribute to the development of insulin resistance due to 
decreased numbers of insulin receptors with unchanged affinity for insulin which 
results in inhibition of effects of this hormone on various tissues (Tepperman and 
Tepperman, 1985).
In a study where rats were fed diets varying in the proportion of 
polyunsaturated fatty acids and saturated fatty acids, the increase of incorporation of 
CO-3 polyunsaturated fatty acids in the adipocyte cell membranes was accompanied by 
an increase in the binding of insuhn to these cells (Field et al., 1988).
In summary, rates of fatty acid synthesis in the adipose tissue removed from 
rats which had been fed a diet containing fish oil and therefore a high proportion of 
CO-3 polyunsaturated fatty acids were significantly higher than in adipose tissue of 
animals fed diets containing corn (with a similar proportion of polyunsaturated fatty
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acids) or mixed oil. This effect may be due to the incorporation of these fatty acids 
into the plasma membrane of adipocytes of these animals and thereby influencing the 
sensitivity of the adipose tissue to insulin. The increased sensitivity to insulin could 
be attributable to changes in membrane fluidity affecting the function of the insulin 
receptor or alterations in membrane phospholipids resulting in changes in insulin 
receptor number. These results substantiate the observation of fish oil feeding 
reducing insulin resistance indicating that the inclusion of co-3 polyunsaturated fatty 
acids results in increased peripheral sensitivity to this hormone (Storlien et al., 1987).
In summary, in a diet where the fatty acids were contributed by fish oil 
circulating concentrations of cholesterol were unaffected whilst hepatic cholesterol 
synthesis was decreased. This may be due to differences in cholesterol content of the 
diet but is more likely to be due to the low fat content of the diet failing to produce 
hypercholesterolaemia in these animals. Suppressed circulating concentrations of 
triglycerides and decreased hepatic triglyceride synthesis observed in the fish oil fed 
group of animals compared to the diet rich in saturated fatty acids suggests that the 
hypotriglyceridaemic effect of fish oil results from decreased secretion of triglycerides 
from the liver. It is unclear whether this results from an actual decrease in hepatic 
triglyceride synthesis or from increased fatty acid oxidation, and investigation into the 
activities of the regulatory enzymes may clarify the mechanism for this observed 
effect. The mixed oil diet which contained a high proportion of saturated fatty acids 
was associated with higher concentrations of insulin and this effect could lead to 
greater understanding of the mechanism of development of insulin resistance. The 
high proportion of co-3 polyunsaturated fatty acids in the fish oil diet resulted in 
increased rates of fatty acid synthesis in the adipose tissue and increased sensitivity 
of this tissue to insulin. If this effect is confirmed to result from changes in 
membrane fluidity it may lead to elucidation of mechanisms for amelioration of 
insulin resistance in disease states such as obesity or NIDDM.
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CHAPTER 4
EFFECT OF DIETARY NON-STARCH POLYSACCHARIDE 
COMPOSITION ON FATTY ACID SYNTHESIS 
IN RAT ADIPOSE TISSUE
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4.1 INTRODUCTION
It has been reported that in man the incidence of coronary heart disease rises 
linearly with increasing circulating triglycerides and with cholesterol concentrations 
(Carlson and Bottiger, 1972). Elevated levels of LDL-cholesterol and VLDL- 
triglycerides accompanied by reduced levels of HDL are associated with the 
development of atherosclerosis (Havel, 1982).
There is increasing evidence that the consumption of diets containing high 
proportions of dietary fibre may protect against the development of coronary heart 
disease (Kromhout, Bosschieter and de Lezenne Coulander, 1982; Lichenstein et al., 
1986; Khaw and Barret-Connor, 1987). This effect is believed to be as a result of 
reduced circulating concentrations of total cholesterol achieved by consumption of this 
type of diet. In two populations of black Africans the observation that they had lower 
concentrations of circulating cholesterol (149 ± 36 and 153 ± 37 mg/100ml (mean ± 
S.D.) compared to 178 ± 36 in the Europeanised control group) was proposed to be 
due, at least partly, to the high proportion of fibre in their diet (Walker and Arvidsson, 
1954).
The term dietary fibre refers to the non-starch polysaccharide (NSP) and lignin 
component of the diet which can be divided into two types : insoluble fibre and 
soluble fibre. Insoluble fibre is important in the function of the large intestine by 
acting as a bulking agent aiding transport of digesta and elimination of waste. The 
main health benefits linked with this form of fibre are restricted to its function in the 
large intestine. The soluble NSP component, mainly P-glucans, appears to reduce 
postprandial circulating concentrations of insulin and glucose (Haber et al., 1977; 
O’Dea, Snow and Nestel, 1981; Jenkins et al., 1982; Jenkins et al., 1986; Heaton et 
al., 1988). This component is linked to the beneficial effects of dietary fibre on lipid 
metabolism such as the reduction of circulating concentrations of cholesterol in rats 
(Ide, Moriuchi and Nihamito, 1991) and humans (Jenkins et al., 1975; Hagander et al., 
1988; Tredger et al., 1991).
Guar gum, oat bran and pectin have been found to exhibit the most marked 
effects on circulating cholesterol concentrations and have become the focus of recent 
research since they have been reported to reduce circulating concentrations of
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cholesterol in man by 10-20% (Schneeman, 1986). Sugar beet fibre has also been 
reported to produce hypocholesterolaemic and hypolipidaemic effects and this effect 
appears to be mediated through the reduction of LDL-cholesterol and VLDL- 
triglycerides and not HDL-cholesterol (Morgan et al., 1988; Hagander et al., 1989; 
Travis et al., 1990).
The exact mechanisms by which these NSPs exert their hypocholesterolaemic 
effects have not been fully elucidated but there are currently three hypotheses of how 
they influence lipid metabolism.
Firstly there may be intraluminal binding of bile acids in the intestine. Soluble 
NSP in the intestine binds to the bile acids and results in higher losses of bile acids 
in the faeces. This theory is supported by results obtained in man and rats (Hansen 
et al., 1983; Illman and Topping, 1985). Since bile acids are synthesised from 
cholesterol, increased faecal losses of bile acids may allow more of circulating 
cholesterol to be diverted into the synthesis of replacement bile acids. A similar 
mechanism could also account for the postprandial hypolipidaemic effects of soluble 
NSP resulting from increased faecal fat loss. This hypothesis is based on the 
assumption that components of soluble NSP contain specific binding sites for bile 
acids.
Secondly, the hypocholesterolaemic effect may occur by modulation of the 
bulk phase diffusion via changes in viscosity of the digesta. The (J-glucans present 
in oat bran and guar gum are highly viscous in solution and can delay the transit of 
digesta through the gastrointestinal tract which may result in reduced rates of fat and 
cholesterol absorption (Newman, Newman and Graham, 1989). Support for this 
proposed mechanism comes from the observation that high viscosity guar gum exhibits 
a more pronounced hypocholesterolaemic effect than low viscosity guar gum in man 
(Superko et al., 1988). This effect is thought to be largely due to inhibition of the 
mixing of digesta by the peristaltic movements of the intestine, due to the high 
viscosity of the soluble NSP (Morris, 1990).
Finally, the third proposed mechanism is that volatile fatty acids, in particular 
propionate, produced from the fermentation of NSP in the large intestine may control 
the activity of enzymes involved in hepatic cholesterol synthesis (Chen, Anderson and 
Jennings, 1984). Propionate has been shown to inhibit cholesterol synthesis in vitro
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but the effective concentration is much higher than that which would be expected to 
occur postprandially and this mechanism is unlikely to be of physiological importance 
(Illman et al,, 1988).
Dietary fibre can have beneficial effects on lipid metabolism through a variety 
of mechanisms. It can affect the daily calorific intake since the energy available from 
fibre is low but the increased bulk may produce satiety as viscous polysaccharides 
delay gastric emptying (Di Lorenzo et a l, 1988). This effect may be of some use in 
the treatment of obesity. NSP can also affect lipid metabolism indirectly by delaying 
the absorption of glucose and therefore blunting the insulin response to a meal. This 
attenuation of insulin response may be important in the control of lipogenesis or 
lipoprotein lipase activity and the reduced circulating insulin concentrations may alter 
the insulin-sensitivity of adipose tissue. Insulin is known to stimulate lipogenesis by 
increasing the activity of key enzymes of this pathway, in particular that of pyruvate 
dehydrogenase and the rate-limiting enzyme, acetyl CoA carboxylase (Denton, 
Brownsey and Belsham, 1981). These effects are distinct from the 
hypocholesterolaemic and hypotriglyceridaemic effects of ingestion of soluble NSP.
It is apparent that dietary fibre, in particular the soluble NSP component, is 
capable of modulating lipid metabohsm. It would therefore be of interest to assess 
the impact of ingestion of different soluble NSPs on the rate of fatty acid synthesis 
in adipose tissue in order to elucidate further the role of this substance in the control 
of adipose tissue metabolism.
There are no previous reports of investigations into possible alterations in the 
metabolism of lipids within adipose tissue in response to changes observed due to the 
ingestion of different types of dietary NSP. Therefore, the aim of the investigation 
was to compare the effects of diets containing bran, cellulose, guar gum or sugar beet 
fibre on the rate of fatty acid synthesis in adipose tissue explants from fed rats. 
Changes in insulin-sensitivity of this tissue associated with the differing NSP 
componenet of the diet were also investigated. Because of the nature of the 
investigations it is not possible to use human subjects but any observed changes may 
be cautiously extrapolated, bearing in mind the species differences, and may point to 
further areas of investigation into lipid metabolism including that observed in adipose 
tissue in the human subject.
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The circulating concentrations of cholesterol and triglycerides are also reported 
here to provide comparison with any observed changes in the rates of basal and 
insulin-stimulated fatty acid synthesis.
The diets were formulated and animals managed by co-workers in the 
laboratory who also measured circulating concentrations of cholesterol, triglycerides, 
rates of hepatic lipogenesis, hepatic cholesterol, hepatic triglycerides and the activities 
of enzymes involved in the metabolism of cholesterol. The major aim of the study 
was to investigate the mechanism of action for the hypocholesterolaemic effect of 
sugar beet fibre. A preliminary experiment had confirmed that the animals on all 
dietary treatments consumed similar amounts of diet which was important so that 
differences in food intake between the treatment groups could not affect lipid 
metabolism.
4.2 STUDY DESIGN
Forty male Wistar/Albino rats (initial weights shown in Table 4.2) were 
obtained from the Surrey stock at the rodent breeding unit at the University of Surrey. 
They were randomly allocated to four groups of ten and fed diets formulated so that 
the dietary NSP component was supplied in the form of wheat bran (Boots Co. PLC, 
Nottingham), cellulose (Special Diet Services, Witham), guar gum (Rybar Laboratories 
Ltd., Amersham) or sugar beet fibre (SBF) (British Sugar Technical Centre, Norwich). 
The animals had all been fed the cellulose diet for two weeks prior to commencing 
the experimental diets. At the completion of the study one animal from each group 
was sacrificed per day, therefore they were added to the study over a period of 10 
days, adding one animal per group each day so that at the completion of the study the 
animals would have consumed the diet for identical periods of time. The composition 
of the diets is depicted in Table 4.1 and was such that the fibre comprised 10% of the 
diet (w/w).
The animals from each experimental group were housed together in groups of 
4-6 and were fed the experimental diets for four weeks. Animals were allowed ad 
libitum access to fresh drinking water and diet at all times throughout the study.
The animals were allowed access to food overnight prior to sacrifice. On each
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Table 4.1 Composition of rat diets (Overton et al., 1994). Composition of 
vitamin and mineral mix as described in Table 3.3 (values denote g).
DIETARY
COMPONENT
CELLULOSE
DIET
BRAN
DIET
GUAR
DIET
SBF
DIET
STARCH 310 310 310 310
SUCROSE 310 310 310 310
CASEIN 198 198 198 198
CORN OIL 80 80 80 80
METHIONINE 2 2 2 2
CELLULOSE 105 0 0 0
GUAR GUM 0 0 105 0
SBF 0 0 0 105
WHEAT BRAN 0 105 0 0
VITAMIN & 
MINERAL MIX
50 50 50 50
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study day, between 8.30am and 9.30am, one animal from each dietary treatment group 
was removed for the determination of fatty acid synthesis in adipose tissue. The 
animals (400-550g) were first anaesthetised using diethyl ether and a blood sample 
collected via cardiac puncture into a glass tube. The animals were then immediately 
sacrificed by cervical dislocation and the livers (for determination of hepatic 
lipogenesis, enzyme activities, cholesterol and triglyceride content by co-workers in 
the laboratory) and epididymal fat pads (for the determination of fatty acid synthesis 
in eight rats from each group) were rapidly excised. The epididymal fat pads were 
placed into universal tubes containing prewarmed Medium 199 and immediately 
transported to the laboratory for the preparation and culture of explants as described 
in Chapter 2. The serum was separated from the blood samples and used for the 
determination of circulating concentrations of cholesterol and triglycerides.
Basal and insulin-stimulated (2nM) rates of fatty acid synthesis, estimated by 
measurement of the incorporation of "^^C acetate into saponifiable fat, were determined 
in quadruplicate in explants prepared from the epididymal adipose tissue of rats fi'om 
each diet. At the end of the incubation period the explants were washed as described 
in Chapter 2 and stored at -20”C until the extraction and measurement of saponifiable 
fat could be performed.
Serum concentrations of cholesterol and triglycerides were measured by a co­
worker using enzymatic colorimetric assay kits (Roche Diagnostic Systems Inc. 
Welwyn Garden City) for use on a Cobas Bio analyser.
For each set of data the normality of distribution was confirmed using the 
Kolmogorov-Smimov goodness of fit test. Statistical comparisons between the 
experimental groups were then made by one-way analysis of variance with 
significance assumed at p<0.05. Any differences between groups were identified a 
posteriori using Duncan’s multiple ranges test with a=0.05 and 0.01.
4.3 RESULTS
Animals from each of the four dietary treatment groups exhibited similar rates 
of food intake and weight gain (Table 4.2) throughout the duration of the feeding of 
the experimental diets.
100
Table 4.2 Weight gain and food intake of rats fed diets containing cellulose, bran, 
guar gum or sugar beet fibre (values denote mean with ± S.D shown in 
parentheses (n=10)).
DIETARY
NSP
INITIAL WEIGHT 
(g/rat)
WEIGHT GAIN 
(g/rat/day)
FOOD INTAKE 
(g/day/rat)
CELLULOSE 299 (20.6) 6.4 (1.3) 25.5
BRAN 303 (17.7) 6.4 (1.0) 25.3
GUAR GUM 298 (20.9) 6.1 (0.9) 24.4
SBF 300 (21.5) 6.2 (1.3) 26.1
4.3.1 Serum cholesterol
The circulating concentrations of serum cholesterol are shown in Figure 4.1. 
with the values given in Appendix 2, Table 2.A. Animals from the guar and sugar 
beet fibre dietary treatment groups exhibited lower circulating levels of cholesterol 
than those fed either of the control diets containing bran or cellulose as the fibre 
source. For the guar treatment group the differences were significant at the p<0.01 
level and for the sugar beet fibre treatment group the differences were significant at 
the p<0.05 level.
4.3.2 Serum triglyceride
The circulating concentrations of serum triglycerides as determined in the 
serum are shown in Figure 4.2 with the values given in Appendix 2, Table 2.A. 
Animals from the guar and sugar beet fibre dietary treatment groups exhibited lower 
circulating concentrations of triglycerides (p<0.05) than those fed either of the control 
diets containing bran or cellulose as the fibre source.
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Figure 4.1 Circulating concentrations of cholesterol in serum of rats fed diets 
containing cellulose, bran, guar or sugar beet fibre (values denote mean 
± S.D. (n=10)).
* = SBF vs bran and cellulose groups (p<0.05).
** = Guar vs bran and cellulose groups (p<0.01).
Serum cholesterol (mM) 
2 .0  r
1.5
1.0
0.5
0.0
CELLULOSE BRAN GUAR
DIETARY FIBRE
SBF
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Figure 4.2 Circulating concentrations of triglycerides in serum of rats fed diets 
containing cellulose, bran, guar or sugar beet fibre (values denote mean 
± S.D. (n=10)).
* = SBF and guar vs bran and cellulose groups (p<0.05).
Serum triglycerides (mM)
4.00 r
3.50
3.00
2.50
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0.00
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4.3.3 Adipose tissue fatty acid synthesis
The rates of basal and insulin-stimulated (2nM) incorporation of acetate 
into saponifiable fats by explants of epididymal adipose tissue are shown in Figure 4.3 
with the values given in Appendix 2, Table 2.B.
No significant differences were detected in the rates of fatty acid synthesis, 
estimated by measurement of incorporation of acetate into saponifiable fats, 
between any of the four dietary treatment groups.
Also, the stimulation of fatty acid synthesis by insulin (2nM) was not sufficient 
to achieve statistical significance for any of the four dietary treatment groups.
4.4 DISCUSSION
Circulating concentrations of cholesterol and triglycerides were lower in guar- 
fed and sugar beet fibre-fed animals than in cellulose-fed or wheat bran-fed animals. 
The type of dietary fibre was found to be without effect on rates of basal and insulin- 
stimulated fatty acid synthesis in explants of rat epididymal adipose tissue.
Results obtained by co-workers, also using these animals, showed that the type 
of dietary fibre was found to affect aspects of hepatic lipid metabolism. Hepatic 
cholesterol (w/w) was lower in guar-fed than in animals from any other treatment 
group and lower in sugar beet fibre-fed animals than in cellulose-fed or bran-fed 
animals. Hepatic triglycerides (w/w) were unaffected by dietary treatment. The 
activity of cholesterol 7a-hydroxylase, the rate-limiting enzyme in the conversion of 
cholesterol to bile acids, was found to be higher in the livers of animals fed the guar 
diet compared to those from the other three dietary treatment groups. The activity of 
3-hydroxy-3-methylglutaryl-CoA (HMG CoA) reductase, a key enzyme in hepatic 
synthesis of cholesterol, was unaffected by dietary treatment. Circulating 
concentrations of bile acids were lower in guar-fed and sugar beet fibre-fed animals 
than in cellulose-fed and bran-fed animals. Faecal bile acids were higher in guar-fed 
animals than in animals from the other three treatment groups.
The observation that rats fed diets containing guar gum or sugar beet had lower 
circulating concentrations of cholesterol is in agreement with previous published
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studies in rats (Johnson et al., 1990, Ide, Moriuchi and Nihamato, 1991) and with 
results obtained from human subjects (Morgan et al., 1988; Hagander et al., 1989; 
Travis et al., 1990; Tredger et al., 1991).
As expected, inclusion of wheat bran or cellulose was without effect on 
circulating cholesterol concentrations. This is because these two fibre sources do not 
contain high levels of soluble NSP which is the component most important in the 
hypocholesterolaemic effect of dietary fibre.
Results obtained in the present study support the hypothesis that the 
hypocholesterolaemic effect of guar gum is accomplished by intraluminal binding of 
bile acids. Rats fed guar gum were found to eliminate more bile acids in their faeces 
leading to lower circulating concentrations of bile acids. This was accompanied by 
an increase in the activity of hepatic cholesterol 7a-hydroxylase, a key enzyme 
involved in the conversion of cholesterol to bile acids, to compensate for the loss of 
bile acids. This was not accompanied by an increase in activity of HMG CoA 
reductase which is a key enzyme in the synthesis of cholesterol. This would lead to 
a diversion of cholesterol into bile acid production resulting in lower circulating 
concentrations of cholesterol and reduced amounts of hepatic cholesterol. Evidence 
previously obtained from this laboratory suggests guar gum exerts its 
hypocholesterolaemic effect via a similar mechanism in human subjects. An acute test 
meal supplemented with guar gum led to lower postprandial concentrations of bile 
acids than meals containing cellulose, bran or sugar beet fibre (Morgan et al., 1993).
The mechanism for the hypocholesterolaemic effect of sugar beet fibre is less 
clear. Reduced levels of circulating cholesterol and hepatic cholesterol were not 
accompanied by effects on cholesterol 7a-hydroxylase or faecal bile acid excretion 
although plasma bile acids were reduced. Sugar beet fibre may inhibit the absorption 
of cholesterol from the gastrointestinal tract resulting in decreased circulating 
concentrations of cholesterol and reduced bile acid production. This would result in 
reduced circulating concentrations of bile acids. Further studies investigating the 
effects of sugar beet fibre on cholesterol absorption are required to establish whether 
this process is involved in the hypocholesterolaemic effect.
The observation that rats fed diets containing guar gum or sugar beet fibre as 
the source of fibre have lower circulating concentrations of triglycerides than those fed
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diets containing wheat bran or cellulose is consistent with previously reported studies 
in rats (Vahouny et al., 1980) and humans (Travis et al., 1990).
Since the amount of hepatic cholesterol was unaffected it is possible that the 
reduction in circulating triglyceride concentrations is due to a decrease in the 
absorption of dietary triglyceride. This would result in increased faecal loss of 
triglycerides. Increased clearance of circulating triglyceride due to modification of the 
activity of lipoprotein lipase may also account for the hypotriglyceridaemic effect. 
Lipoprotein lipase activity was not determined in the animals in this study but further 
studies could include measurements in order to ascertain the potential role of this 
enzyme.
The fact that different dietary fibres did not result in alterations in rates of 
basal and insuhn-stimulated fatty acid synthesis in adipose tissue removed from the 
animals suggests that the differences in postprandial responses are without effect on 
adipose tissue lipid metabolism. This suggests that hepatic and adipose tissue 
lipogenesis do not contribute to the hypotriglyceridaemic effect of fibre. Due to the 
limited amount of blood available from the animals we were unable to assay 
circulating concentrations of insulin and so are unable to compare the hormonal 
responses with rates of lipogenesis.
It was also interesting to observe that the response of the adipose tissue to 
insuhn was reduced in all groups compared to measurements in other studies (i.e. 
Chapters 2, 3 and 5). This may be related to the fact that the animals used in this 
study were older than those used in the other studies and may have become less 
sensitive to insuhn. Older animals were selected in this study as they show a more 
pronounced hypocholesterolaemic effect when fed soluble NSP than do younger 
animals. It has been reported that lipogenesis in adipocytes is less sensitive to insulin 
when the weight of the rat exceeded 300g (Hansen, Nielsen and Gliemann, 1974). A 
dose of 2nM insuhn was selected as this was demonstrated to stimulate fatty acid 
synthesis in rat adipose tissue (see Chapter 2) and was used in the dietary oil study 
(see Chapter 3) but may not have been sufficient to demonstrate insulin-stimulation 
in these larger animals.
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CHAPTER 5
THE EFFECT OF GASTROINTESTINAL HORMONES 
ON FATTY ACID SYNTHESIS AND LIPOLYSIS 
IN RAT ADIPOSE TISSUE
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5.1 INTRODUCTION
In white adipose tissue lipid deposition results from de novo lipogenesis and 
from re-esterification, within the adipocyte, of free fatty acids which result from the 
hydrolysis of circulating triglycerides, in the form of chylomicrons and VLDL, by the 
action of lipoprotein lipase at the luminal surface of the vascular endothelium. The 
main substrate for de novo lipogenesis is glucose although acetate, pyruvate (Martin, 
1987) and lactate (Katz and Wals, 1974) can also be utilised.
Lipid mobilisation from adipocytes results from the action of hormone-sensitive 
lipase on stored triglycerides (Hales, Luzio and Siddle, 1978). The glycerol that is 
released along with non-esterified fatty acids during lipolysis is not reutilised by the 
adipose tissue to a significant extent (Shapiro, Chowers and Rose, 1957; Cahill, 
LeBoeuf and Renold, 1960; Lynn, MacLeod, and Brown, 1960) due to the absence of 
glycerokinase activity in white adipose tissue (Wieland and Suyter, 1957; Margolis 
and Vaughan, 1962).
The role of insulin and glucagon in the control of these pathways is well 
established, and discussed in Chapter 1. The major effects of insulin include 
stimulation of lipogenesis via activation of the rate-limiting enzymes, whilst glucagon 
stimulates lipolysis by increasing hormone-sensitive lipase activity. Some 
gastrointestinal hormones have been shown to have direct effects on lipid metabolism.
Several gastrointestinal hormones have been shown to be released in response 
to the ingestion of fat. These are GIF (Falko et al., 1975), the structurally related 
secretin, which requires fat to have been hydrolysed for secretion (Fahrenkrug and 
Schaffalitzky de Muckadell, 1977), GLP-1 (7-36) amide (Elliott et al., 1993), 
somatostatin (Penman et al., 1981), pancreatic polypeptide (Schwartz et al., 1976), 
peptide YY (Adrian et al., 1985a) and neurotensin (Rosell and Rdkaeus, 1979; Go et 
al., 1980). It is hypothesised that these hormones, released in response to the presence 
or absorption of nutrients in the gastrointestinal tract, may have a direct role to play 
in their disposal in the body. This could be achieved by controlling the rate limiting 
enzymes in the processes of de novo lipogenesis, lipolysis and uptake of circulating 
triglycerides.
Much previous work has centred around the direct anabolic effects of GIP on
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adipose tissue metabolism and previous studies, including those from our laboratory 
have shown that GIP can stimulate lipogenesis (Haji Baba and Buttery, 1991; Oben 
et a i, 1991b; McCarthy, 1993), inhibit glucagon-stimulated lipolysis (Dupre et aL, 
1976) and increase lipoprotein lipase activity (Eckel, Fujimoto and Brunzell, 1979; 
Oben et aL. 1991c). Little work has been carried out using other gastrointestinal 
hormones but some studies have implicated GLP-1 (7-36) amide, secretin, VIP, PYY 
and NPY as detailed in Chapter 1.
The aim of this study was to investigate the effect of these hormones, released 
in response to the ingestion of fat, on fatty acid synthesis and lipolysis in explants 
prepared from the epididymal fat pads of male Wistar/Albino rats.
Some metabolic differences exist between human and rat adipocytes. The 
overall metabolic rate is lower in rats than humans and de novo fatty acid synthesis 
is more important in rat adipocytes than in those from human subjects. It is also 
believed that human adipocytes are responsive to a-adrenergic inhibitory effects on 
lipolysis, and lipolysis is not inhibited by adenosine in these cells (Smith, 1977). 
Therefore results obtained from rat adipose tissue cannot be directly extrapolated to 
human tissue. However, preliminary investigations in rat tissue may identify 
hormones important in the regulation of lipid deposition or mobilisation which could 
then be confirmed in human tissue, which is less readily available.
Hormones selected for investigation were GIP, secretin, GLP-1 (7-36) amide 
and other products of the proglucagon gene (GLP-1 (7-37), GLP-1 (1-37), GLP-2 and 
oxyntomodulin), somatostatin in the form of somatostatin-14 and somatostatin-28 and 
the long lasting somatostatin analogue octreotide (Creutzfeldt et aL, 1987), pancreatic 
polypeptide, peptide YY and neurotensin.
Fatty acid synthesis was determined by measuring the incorporation of 
acetate into saponifiable lipids. Acetate was used as the substrate in order to confine 
analysis of the control of fatty acid synthesis to the regulation of the rate-limiting 
enzyme acetyl CoA carboxylase. Acetate is converted to acetyl CoA, by the catalytic 
action of acetyl CoA synthetase, which is the substrate for the acetyl CoA carboxylase 
catalysed conversion to malonyl CoA before conversion into fatty acids.
Lipolysis was estimated by measurement of release of glycerol into the 
medium resulting from the action of hormone-sensitive lipase. Since glycerol is not
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reutilised in the adipocyte to any significant extent, glycerol accumulates in the 
medium. Following the extraction of protein from the medium the amount of glycerol 
produced can be determined spectrophotometrically. Determinations were made in the 
presence of adenosine deaminase in order to abolish the antilipolytic effect of 
adenosine.
The hormones were also administered in conjunction with insulin, to 
approximate the fed state, and glucagon, to approximate the fasted state, in order to 
assess any synergistic effects with these hormones. Stimulation of lipolysis by 
isoproterenol was also carried out in the initial study.
Comparisons of the effect of a hormone on fatty acid synthesis and lipolysis 
will give useful information on the role of the hormone in de novo lipogenesis and 
lipolysis. More specifically their control of the enzymes acetyl CoA carboxylase and 
hormone-sensitive lipase could be assessed. This in turn will lead to a clearer picture 
of the role of gastrointestinal hormones in the control of lipid deposition and 
mobilisation in adipose tissue.
5.2 STUDY DESIGN
5.2.1 Stimulation of lipolysis by isoproterenol and glucagon
Explants were prepared from the epididymal pads of adipose tissue of male 
Wistar/Albino rats from the Surrey stock (150-160g), which had not been fasted, and 
were incubated as described in section 2.5.1. Eight explants per well were added and 
the volume of medium used was 0.5ml per well. The following investigations into 
basal and stimulated rates of lipolysis were performed :
Basal; isoproterenol, a pure P-adrenergic agonist (5pM), to stimulate lipolysis; 
isoproterenol (5pM) and insulin (2nM), to attempt to inhibit isoproterenol-stimulated 
lipolysis; glucagon (2nM), to stimulate lipolysis; glucagon (2nM) and insulin (2nM), 
to attempt to inhibit glucagon-stimulated lipolysis; insulin (2nM), to attempt to inhibit 
basal lipolysis.
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Media containing insulin (2nM) or glucagon (2nM) were prepared from stock 
solutions which had been prepared prior to the study days. The stock solutions were 
prepared by diluting the hormone in O.IM HCl to give a concentration of Img/ml and 
stored at -20”C.
Isoproterenol was diluted to a stock solution of lOmM in O.IM HCl before 
storage at -20°C.
Following the 2 hour incubation the medium was removed and deproteinised 
for the glycerol assay and the explants washed with Medium 199 containing lOmM 
acetate. The deproteinised medium and explants were then stored at -20°C until 
analyses of incorporation of "^^C acetate incorporation into saponifiable fats and 
glycerol, which were performed within a week.
5.2.2 Investigation of the effect of gastrointestinal and pancreatic hormones 
on concurrent fatty acid synthesis and lipolysis
Epididymal fat pads were excised from male Wistar/Albino rats (150-160g) 
obtained from the Surrey stock, which were not fasted, and explants were prepared as 
described in section 2.5.1. Eight explants per well were used and the volume of test 
medium was 0.5ml. Rates of fatty acid synthesis and lipolysis were measured 
simultaneously in each well according to the methods described in sections 2.4.1, 
2.4.2, 2.5.1 and 2.5.2.
The effects of each hormone under test on fatty acid synthesis and lipolysis 
were investigated alone, with insulin (2nM) and with glucagon (4nM). The hormones 
which were used in this study were :
GIP; Secretin; GLP-1 (7-36) amide; GLP-1 (7-37); GLP-1 (1-37); GLP-2; 
Oxyntomodulin; Somatostatin-14; Somatostatin-28; Octreotide; Pancreatic polypeptide; 
Peptide YY; Neurotensin.
Media containing insulin (2nM) or glucagon (4nM) were prepared using pre­
prepared stock solutions. The stock solutions were prepared by diluting the hormone 
in O.IM HCl to give a concentration of 1 mg/ml.
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The test hormones were weighed out immediately prior to preparation of the
test medium and were diluted in O.IM HCl to give a working stock solution of
1 mg/ml. They were then diluted to the concentrations required in Medium 199 
supplemented with fatty acid-free bovine serum albumin (4%), adenosine deaminase, 
and glucagon (4nM) or insulin (2nM) where appropriate.
After the 2 hour incubation the medium was removed and deproteinised for 
glycerol assay and the explants washed with lOmM acetate in medium 199. Explants 
and deproteinised test media were stored at -20°C until analysis. For each experiment 
measurements of ^^ C acetate incorporated into saponifiable fats and of glycerol were 
performed within two weeks.
For each set of data normality of distribution was confirmed using the
Kolmogorov-Smimov goodness of fit test. Statistical comparisons between the
experimental groups were then made by one-way analysis of variance and significance 
was assumed at p<0.05. Differences between groups were identified a posteriori 
using Duncan’s multiple ranges test with a  = 0.01 and 0.05.
5.3 RESULTS
5.3.1 Stimulation of lipolysis by isoproterenol and glucagon
The results are shown in Figure 5.1 with values given in Appendix 3, Table 
3.A, and all values represent per 2 hour incubation. The basal rate of lipolysis was 
found to be 3.82 ± 0.86 (mean ± S.D.) nmol glycerol produced/mg tissue per two hour 
incubation. The inclusion of isoproterenol in the medium resulted in a statistically 
significant (p<0.01) increase in the rate of lipolysis compared with basal. When 
insulin was included in the medium along with isoproterenol there was a further 
statistically significant increase (p<0.01) in the rate of lipolysis compared with 
isoproterenol alone. Glucagon was found significantly to stimulate (p<0.01) the rate 
of lipolysis compared with basal and this effect was diminished (p<0.01) in the 
presence of insulin. Insulin alone in the medium had the effect of significantly 
stimulating (p<0.05) the rate of lipolysis above basal.
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Figure 5.1 Effect of insulin, isoproterenol and glucagon on glycerol production by 
explants of rat epididymal adipose tissue (values denote mean ± S.D. 
(n=4) per 2 hour incubation). IS = Isoproterenol (5pM); IN = Insulin 
(2nM); GL = Glucagon (2nM). 
a = Isoproterenol vs Basal (p<0.01). 
b = Isoproterenol & Insulin vs Isoproterenol (p<0.01). 
c = Glucagon vs Basal (p<0.01). 
d = Glucagon & Insulin v.s Glucagon (p<0.01). 
e = Insulin vs Basal (p<0.05).
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5.3.2 Investigation of the effect of gastrointestinal and pancreatic hormones 
on concurrent fatty acid synthesis and lipolysis
Insulin
Insulin significantly stimulated incorporation of acetate into saponifiable 
fat (p<0.01) in comparison to basal or incubation with glucagon. The results are 
shown in Figure 5.2 with values given in Appendix 3, Table 3.B.
Glucagon
Glucagon was found significantly to stimulate glycerol production (p<0.01) in 
comparison to basal or incubation with insulin. The results are shown in Figure 5.3 
with values given in Appendix 3, Table 3.C.
GIF
The effects of co-administered GIF on concurrent rates of incorporation of 
acetate into saponifiable fat and of glycerol production are shown, as a log plot for 
clarity, in Figure 5.4 with the values given in Appendix 3, Table 3.D. GIF was 
without effect at any dose.
Secretin
The effects of co-administered secretin on concurrent rates of incorporation of 
acetate into saponifiable fats and of glycerol production are shown, as a log plot 
for clarity, in Figure 5.5 with the values given in Appendix 3, Table 3.E.
Inclusion of secretin alone in the test medium resulted in reduced incorporation 
of acetate into saponifiable fats at all concentrations of secretin investigated 
(p<0.01). Secretin reduced (p<0.01) insulin-stimulated incorporation of acetate 
into saponifiable fats at concentrations of 40 and 400nM and increased (p<0.01) 
incorporation of acetate in the presence of glucagon.
The presence of secretin at all concentrations investigated significantly 
stimulated glycerol production (p<0.01) whether alone, in the presence of insulin, or 
in the presence of glucagon.
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Figure 5.2 Effect of insulin and glucagon on incorporation of acetate into 
saponifiable fatty acids by explants of rat epididymal adipose tissue 
(values denote mean ± S.D. (n=13) per 2 hour incubation).
** = Insulin vj basal (p<0.01).
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Figure 5.3 Effect of insulin and glucagon on glycerol production by explants of 
rat epididymal adipose tissue (values denote mean ± S.D. (n=13) per 
2 hour incubation).
** = Glucagon vs Basal (p<0.01).
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Figure 5.4 Effect of GIF on incorporation of acetate into saponifiable fatty acids 
and on glycerol production by explants of rat epididymal adipose tissue 
(values denote mean ± S.D. (n=4) per 2 hour incubation).
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Figure 5.5 Effect of secretin on incorporation of acetate into saponifiable fatty 
acids and on glycerol production by explants of rat epididymal adipose 
tissue (values denote mean ± S.D. (n=4) per 2 hour incubation).
** = Significantly different from OnM secretin (p<0.01).
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GLP-1 (7-36) amide
The effects of co-administered GLP-1 (7-36) amide on concurrent rates of 
incorporation of acetate into saponifiable fats and of glycerol production are 
shown, as a log plot for clarity, in Figure 5.6 with the values given in Appendix 3, 
Table 3.F.
GLP-1 (7-36) amide had no effect on incorporation of acetate into 
saponifiable fats at any concentration or when in the presence of insulin or glucagon.
This hormone also had no effect on the production of glycerol at any 
concentration or when in the presence of insulin or glucagon.
GLP-1 (7-37)
The effects of co-administered GLP-1 (7-37) on concurrent rates of
incorporation of acetate into saponifiable fat and of glycerol production are shown, 
as a log plot, in Figure 5.7 with the values given in Appendix 3, Table 3.G.
GLP-1 (7-37) (4nM) stimulated the incorporation of acetate into 
saponifiable fats in the presence of glucagon (p<0.05).
GLP-1 (7-37) significantly stimulated glycerol production, in the presence of 
insulin, when included in the incubation medium at 40nM (p<0.05) and 400nm 
(p<0.01) compared with insulin alone.
GLP-1 (7-37) had no significant effects on lipolysis when alone, but enhanced 
glucagon-stimulated glycerol production at 40nM (p<0.05).
GLP-1 (1-37)
The effects of co-administered GLP-1 (1-37) on concurrent rates of
incorporation of acetate into saponifiable fats and of glycerol production are
shown, as a log plot, in Figure 5.8 with the values given in Appendix 3, Table 3.H.
GLP-1 (1-37) (4nM) stimulated incorporation of acetate into saponifiable 
fats (p<0.05) but was without effect when administered with insulin or with glucagon.
GLP-1 (1-37) enhanced glucagon-stimulated glycerol production (p<0.01) at 
a concentration of 400nM but was without effect when administered with insulin or 
when administered alone.
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Figure 5.6 Effect of GLP-1 (7-36) amide on incorporation of acetate into 
saponifiable fatty acids and on glycerol production by explants of rat 
epididymal adipose tissue (values denote mean ± S.D. (n=4) per 2 hour 
incubation).
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Figure 5.7 Effect of GLP-1 (7-37) on incorporation of acetate into saponifiable 
fatty acids and on glycerol production by explants of rat epididymal 
adipose tissue (values denote mean ± S.D. (n=4) per 2 hour 
incubation).
* = Significantly different from OnM GLP-1 (7-37) (p<0.05).
** = Significantly different from OnM GLP-1 (7-37) (p<0.01).
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Figure 5.8 Effect of GLP-1 (1-37) on incorporation of acetate into saponifiable 
fatty acids and on glycerol production by explants of rat epididymal 
adipose tissue (values denote mean ± S.D. (n=4) per 2 hour 
incubation).
* = Significantly different from OnM GLP-1 (1-37) (p<0.05).
** = Significantly different from OnM GLP-1 (1-37) (p<0.01).a
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GLP-2
The effects of co-administered GLP-2 on concurrent rates of incorporation of 
acetate into saponifiable fats and of glycerol production are shown, as a log plot, 
in Figure 5.9 with the values given in Appendix 3, Table 3.1.
At concentrations of 40 and 400nM GLP-2 enhanced incorporation of 
acetate into saponifiable fats in the presence of insulin (p<0.01) and in the presence 
of glucagon (p<0.05) but was without effect when administered alone.
GLP-2 was without effect on glycerol production.
Oxvntomodulin
The effects of co-administered oxyntomodulin on concurrent rates of 
incorporation of acetate into saponifiable fats and of glycerol production are 
shown, as a log plot, in Figure 5.10 with the values given in Appendix 3, Table 3.J.
Oxyntomodulin stimulated incorporation of acetate into saponifiable fats 
at all concentrations tested (p<0.05) but was without effect in the presence of insulin 
or glucagon.
Oxyntomodulin was without effect on rates of glycerol production. Due to 
non-homogenous variances the Kruskall-Wallis test was used to attempt to detect 
differences between groups at the 0.01 level.
Somatostatin-14
The effects of co-administered somatostatin-14 on concurrent rates of 
incorporation of acetate into saponifiable fats and of glycerol production are 
shown, as a log plot, in Figure 5.11 with the values given in Appendix 3, Table 3.K.
Somatostatin-14 was without effect on rates of incorporation of acetate into 
saponifiable fats or of glycerol production.
Somatostatin-28
The effects of co-administered somatostatin-28 on concurrent rates of 
incorporation of acetate into saponifiable fats and of glycerol production are 
shown, as a log plot, in Figure 5.12 with the values given in Appendix 3, Table 3.L. 
Somatostatin-28 was without effect on incorporation of acetate into
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Figure 5.9 Effect of GLP-2 on incorporation of acetate into saponifiable fatty 
acids and on glycerol production by explants of rat epididymal adipose 
tissue (values denote mean ± S.D. (n=4) per 2 hour incubation).
* = Significantly different from OnM GLP-2 (p<0.05).
** = Significantly different from OnM GLP-2 (p<0.01).
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Figure 5.10 Effect of oxyntomodulin on incorporation of acetate into saponifiable 
fatty acids and on glycerol production by explants of rat epididymal 
adipose tissue (values denote mean ± S.D. (n=4) per 2 hour 
incubation).
* = Significantly different from OnM oxyntomodulin (p<0.05).
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Figure 5.11 Effect of somatostatin-14 on incorporation of acetate into saponifiable 
fatty acids and on glycerol production by explants of rat epididymal 
adipose tissue (values denote mean ± S.D. (n=4) per 2 hour 
incubation).
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Figure 5.12 Effect of somatostatin-28 on incorporation of acetate into saponifiable 
fatty acids and on glycerol production by explants of rat epididymal 
adipose tissue (values denote mean ± S.D. (n=4) per 2 hour 
incubation).
** = Significantly different from OnM somatostatin-28 (p<0.01).
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saponifiable fats, alone or in conjunction with insulin or glucagon.
Somatostatin-28 (400nM) enhanced glucagon-stimulated glycerol production 
(p<0.01), but was otherwise without effect.
Octreotide
The effects of co-administered octreotide on concurrent rates of incorporation 
of acetate into saponifiable fats and of glycerol production are shown, as a log 
plot, in Figure 5.13 with the values given in Appendix 3, Table 3.M.
In the presence of insulin, octreotide at concentrations of 4 and 40 nM was 
found to significantly (p<0.01) enhance the incorporation of acetate into 
saponifiable fats compared to incubation with insulin alone. This effect was lost when 
the concentration of octreotide was increased to 400nM. There were no differences 
observed in response to incubation with this hormone alone or in conjunction with 
glucagon.
In the presence of glucagon, octreotide at concentrations of 40 and 400 nM 
enhanced the rate of glycerol production (p<0.01) when compared to glucagon alone. 
There were no significant differences when explants were incubated with octreotide 
alone or in conjunction with insulin.
Pancreatic polvneptide
The effects of co-administered pancreatic polypeptide on concurrent rates of 
incorporation of acetate into saponifiable fats and of glycerol production are 
shown, as a log plot, in Figure 5.14 with the values given in Appendix 3, Table 3.N.
Pancreatic polypeptide was without effect on incorporation of acetate into 
saponifiable fats whether alone or in conjunction with either insulin or with glucagon.
Pancreatic polypeptide (4 and 40nM) significantly diminished glucagon- 
stimulated glycerol production (p<0.05) but was without effect when administered 
alone or in conjunction with insulin.
Peptide Y Y
The effects of co-administered peptide YY on concurrent rates of incorporation 
of acetate into saponifiable fats and of glycerol production are shown, as a log
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Figure 5.13
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acids and on glycerol production by explants of rat epididymal adipose 
tissue (values denote mean ± S.D. (n=4) per 2 hour incubation).
* = Significantly different from OnM octreotide (p<0.05).
** = Significantly different from OnM octreotide (p<0.01).
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Figure 5.14 Effect of pancreatic polypeptide on incorporation of acetate into 
saponifiable fatty acids and on glycerol production by explants of rat 
epididymal adipose tissue (values denote mean ± S.D. (n=4) per 2 hour 
incubation).
* = Significantly different from OnM pancreatic polypeptide (p<0.05).
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plot, in Figure 5.15 with the values given in Appendix 3, Table 3.0.
Peptide YY (4, 40 and 400nM) significantly diminished (p<0.01) insulin- 
stimulated incorporation of acetate into saponifiable fats but was without effect 
when administered alone or with glucagon.
Peptide YY alone (400nM) stimulated (p<0.01) glycerol production. When 
administered in conjunction with insulin, peptide YY enhanced glycerol production at 
4nM (p<0.05) 40 and 400 nM (p<0.01). Glucagon-stimulated glycerol production was 
significantly inhibited (p<0.01) by peptide YY at all concentrations investigated.
Neurotensin
The effects of co-administered neurotensin on concurrent rates of incorporation 
of acetate into saponifiable fats and of glycerol production are shown, as a log 
plot, in Figure 5.16 with the values given in Appendix 3, Table 3.P.
Neurotensin (400nM) stimulated (p<0.01) incorporation of acetate into 
saponifiable fats but was without effect when administered in conjunction with either 
insulin or with glucagon.
Neurotensin was without effect on glycerol production when administered alone 
or in conjunction with either insulin or with glucagon.
The effects of the gastrointestinal and pancreatic hormones studies on lipolysis 
and fatty acid synthesis are summarised in Table 5.1.
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Figure 5.15 Effect of peptide YY on incorporation of acetate into saponifiable fatty 
acids and on glycerol production by expiants of rat epididymal adipose 
tissue (values denote mean ± S.D. (n=4) per 2 hour incubation).
* = Significantly different from OnM peptide YY (p<0.05).
** = Significantly different from OnM peptide YY (p<0.01).
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Figure 5.16 Effect of neurotensin on incorporation of acetate into saponifiable fatty 
acids and on glycerol production by explants of rat epididymal adipose 
tissue (values denote mean ± S.D. (n=4) per 2 hour incubation).
** = Significantly different from OnM neurotensin (p<0.01).
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Table 5.1 Summary of effects of gastrointestinal and pancreatic hormones on 
lipogenesis and lipolysis in rat adipose tissue (Ins = Insulin (2nM) and 
Glue = Glucagon 4nM)).
HORMONE
FATTY ACID 
SYNTHESIS
LIPOLYSIS
Basal +Ins 4-Gluc Basal +Ins +Gluc
GIF - - - - - -
Secretin 4 T T T T
GLP-1 (7-36) amide - - - - - -
GLP-1 (7-37) - - T - T T
GLP-1 (1-37) Î - - - - T
GLP-2 - t T - - -
Oxyntomodulin Î - - - - -
Somatostatin-14 - - - - - -
Somatostatin-28 - - - - - T
Octreotide - T - - - T
Pancreatic polypeptide - - - - - 4-
Peptide YY - 4 - Î T 4
Neurotensin r - - - - -
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5.4 DISCUSSION
5.4.1 Stimulation of lipolysis by isoproterenol and glucagon
The stimulation of lipolysis by glucagon is in agreement with previously 
published data in rats (Hagen, 1961; Vaughan, 1961).
The stimulation of lipolysis by insuhn in the present study was an unexpected 
observation as insulin is generally considered an antilipolytic hormone. This is due 
to its action of dephosphorylating, therefore deactivating, the enzyme hormone- 
sensitive lipase and of stimulating the activity of phosphodiesterase. Recently, an 
increase in lipolysis due to activation of hormone-sensitive lipase has been reported 
in response to incubation with insulin in rat adipose tissue and adipocytes in long term 
culture (Kang et al., 1993). The authors had previously observed elevated activity of 
hormone-sensitive lipase in hyperinsulinaemic ferrets. In the present study the results 
suggest, rather unexpectedly, that insulin stimulates the activity of hormone-sensitive 
lipase in explants of rat adipose tissue under the conditions studied. However, 
contamination of the insulin preparation with trace amounts of glucagon cannot be 
ruled out since enquiries to the company from which it was obtained. Sigma, revealed 
that high-performance liquid-chromatography of the hormone showed there were 
unidentified contaminants contributing approximately 5% of the product.
Incubation of the explants with isoproterenol led to an increase in the amount 
of glycerol produced as expected. However, the attempt to reduce the effect by 
including insulin in the medium resulted in a potentiation of the lipolytic effect. The 
determination of activity of hormone-sensitive lipase is influenced by signals at the 
cell surface and it is interesting to note that recently it has been demonstrated that 16 
hour exposure of rat adipocytes to insulin resulted in an increase in the number of 
receptors for catecholamines in the plasma membranes of these cells (Maynard et at.,
i /
1992). Therefore, a possible explanation for this surprising effect of insulin on the 
isoproterenol-stimulated rate of lipolysis is that exposure of explants of adipose tissue 
to insulin leads to up-regulation of catecholamine receptors, resulting in an augmented 
stimulus for the increase of activity of hormone-sensitive lipase. This requires further 
investigation as the incubation length of two hours used in this study is unlikely to be
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sufficient to stimulate synthesis of new receptors. It is possible that incubation with 
insuhn may decrease the turnover of the receptors which would also result in 
increased numbers at the plasma membrane.
In human adipocytes, regional differences in the antilipolytic response to 
insuhn have been identified. Human adipose tissue exhibits a dual response to 
catecholamines; stimulation via P-receptors and inhibition via a-receptors. The net 
effects of these two processes vary depending on adipose region and physiological 
state, with omental sites being less responsive to antilipolyhc effects of insuhn than 
subcutaneous regions. There are also variations within the subcutaneous regions with 
gluteal/femoral regions being less responsive to antilipolytic effects of insuhn than 
abdominal, whereas antilipolytic effects of catecholamines are higher in 
gluteal/femoral regions (Amer, 1988).
The observation that insuhn was capable of inhibiting lipolysis that had been 
induced by the presence of glucagon in the medium is consistent with this explanation 
and suggests that there is no such up-regulation of glucagon receptors as a result of 
exposure of adipose tissue to insuhn.
5.4.2 Investigation of the effect of gastrointestinal and pancreatic hormones 
on concurrent fatty acid synthesis and lipolysis
A summary of the effects of gastrointestinal and pancreatic hormones on 
concurrent fatty acid synthesis and hpolysis are shown in Table 5.1. GIF, GLF-1 (7- 
36) amide and somatostatin-14 were found to be without effect either on acetate 
incorporation into saponifiable fats or on hpolysis in rat epididymal adipose tissue. 
Secretin displayed the most pronounced effects; it strongly suppressed basal and 
insuhn-stimulated acetate incorporation into saponifiable fats whilst reversing 
inhibition by glucagon, and greatly enhanced basal and glucagon-stimulated lipolysis 
with the highest rates of hpolysis observed in conjunction with insuhn. GLF-1 (1-37), 
oxyntomodulin and neurotensin all ehcited weak stimulation of acetate incorporation 
into saponifiable fats when administered alone. Insuhn-stimulated acetate 
incorporation into saponifiable fats was enhanced by GLF-2, weakly enhanced by 
octreotide and inhibited by peptide YY. The reduction in acetate incorporation into
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saponifiable fats by glucagon was weakly reversed by GLP-1 (7-37) and GLP-2. 
Peptide YY weakly stimulated lipolysis but was more effective in the presence of 
insulin. GLP-1 (7-37) also showed weak stimulation of lipolysis in conjunction with 
insuhn. Octreotide enhanced glucagon-stimulated hpolysis, with GLP-1 (7-37), GLP-1 
(1-37) and somatostatin-28 showing weak enhancement. Peptide YY inhibited 
glucagon-stimulated hpolysis, with pancreatic polypeptide having a weak inhibitory 
effect.
Attempts to verify the stimulatory effect of GIP on fatty acid synthesis in 
explants already demonstrated by our laboratory (Oben et al., 1991b) were 
unsuccessful despite extensive investigations into the experimental conditions. 
Altering the content of fatty acid free bovine serum albumin, including GIP in the 
medium during the recovery pre-incubation, using glucose as the substrate, changing 
the medium to Krebs-Ringer bicarbonate and comparing natural porcine GIP, synthetic 
human GIP and synthetic porcine GIP were all investigated and all failed to elicit a 
lipogenic effect with GIP. A strong lipogenic effect of GIP has been demonstrated 
in ovine adipose tissue (Haji Baba and Buttery, 1991) and recently a weak response 
has been obtained in the same species (McCarthy, 1993). A lipogenic effect with GIP 
in rat adipose tissue was also obtained when measuring the incorporation of D-[U- '^‘C] 
glucose into saponifiable fatty acids (McCarthy, 1993). It is concluded that the lack 
of lipogenic effect of GIP in the present study is attributable either to differences of 
the batch of GIP or to rapid degradation in the system used in this study. The reason 
for this discrepancy is unclear. In order to test the latter possibility, incubations were 
also carried out with the protease inhibitor aprotinin, bacitracin or both, or soya bean 
trypsin inhibitor in the medium to attempt to prevent any degradation, but again were 
without effect.
Attempts to confirm the lipogenic effect of GLP-1 (7-36) amide (Oben et al., 
1991b) were also unsuccessful. Using D-[U- '^^C] glucose as the substrate was without 
effect. It is concluded that the lack of lipogenic effect could be attributable either to 
batch variability or to degradation of GLP-1 (7-36) amide. Also, this study was 
unable to confirm the weak lipolytic effect of this hormone, compared with that of 
glucagon, previously demonstrated in isolated rat adipocytes (Ruiz-Grande et al., 
1992).
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A further possible explanation for the failure to confirm the previous 
observations from our laboratory that GIP and GLP-1 (7-36) amide stimulated fatty 
acid synthesis is that these hormones exert a ‘permissive ’ effect. For example 
glucose transport is known to be rate-limiting in metabolism of glucose by adipose 
tissue in the absence of insulin (Gould and Holman, 1993). It has been previously 
reported that GIP can stimulate glucose transport in rat adipocytes (Hauner et al.,
1988). GLP-1 (7-36) amide has also been shown to stimulate glucose transport 
(Gutniak et al., 1992). Glucose is required in the synthesis of triglyceride in the 
present system to supply the glycerol backbone via glycolysis. It is possible that 
under certain incubation conditions basal rates of fatty acid synthesis are limited by 
the supply of glucose to the cells and this is reversed by GIP or GLP-1 (7-36) amide 
resulting in increased observed rates of fatty acid synthesis in response to these 
hormones. Consistent with this explanation, personal communications with the other 
workers in this field (McCarthy; Buttery) have revealed similar problems in achieving 
reproducible stimulation of fatty acid synthesis with GIP and GLP-1 (7-36) amide.
The lipolytic effect of secretin observed in this study is in agreement with 
previous reports (Rudman and Del Rio, 1969; Butcher and Carlson, 1970). This 
suggests that secretin is capable of stimulating the activity of hormone sensitive lipase. 
Incubation of explants in the presence of both glucagon and secretin resulted in an 
additive effect of their lipolytic actions. As observed with isoproterenol, simultaneous 
incubation with insulin resulted in a potentiation of the lipolytic effect of secretin. It 
is possible that exposure of the adipose tissue to insulin results in increased receptor 
number or affinity for secretin and therefore potentiation of the lipolytic effect via 
activation of hormone sensitive lipase. This would suggest that glucagon and secretin 
do not exert their effects through a common receptor since insulin was capable of 
inhibiting glucagon-stimulated lipolysis. This is supported by demonstration that 
secretin is incapable of displacing glucagon from adipocyte membrane receptors 
(Bataille, Freychet and Rosselin, 1974). The observed decrease in the incorporation 
of acetate into saponifiable fats by explants of rat adipose tissue may result from the 
increased mobilisation of lipids by secretin and, assuming release of fatty acids from 
cells, it is unreliable to interpret this observation as true inhibition of fatty acid 
synthesis.
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The physiological importance of the ability of secretin to stimulate lipolysis, 
when secretin is released in response to the ingestion of fat, when it is expected that 
metabolic pathways would be directing lipids towards storage, is unclear and requires 
further investigation. However, it has been reported that secretion of secretin is also 
increased in response to prolonged fasting (Henry, Flanagan and Buchanan, 1975; 
Mason et al., 1979; Oktedalen et al., 1983; Oktedalen et al., 1984) or intensive 
exercise in the form of cross-country skiing (Oktedalen, Opstad and Schaffalitzky de 
Muckadell, 1983). In these physiological states the ability of this hormone to 
stimulate the activity of hormone-sensitive lipase and mobilise lipids to contribute to 
energy requirements would be more understandable. Therefore it may be the case that 
the secretion of secretin in these circumstances may be of greater physiological 
significance than postprandial secretion and warrants further study in order to establish 
whether secretin has an important role to play in lipid metabolism under these 
conditions. The lipolytic effect of secretin postprandially may be overridden by 
lipogenic pathways such as the increased activity of lipoprotein lipase resulting in 
increased lipid deposition. In order to confirm the lipolytic effect of secretin it is 
necessary to demonstrate the activation of hormone-sensitive lipase by this hormone 
and to determine that the effect occurs at a concentration within the physiological 
range in vivo.
GLP-2 enhanced insulin-stimulated fatty acid synthesis suggesting a possible 
role for this peptide in lipid deposition. Since GLP-2 is secreted from the same ileal 
cells and simultaneously with GLP-1, it is presumably secreted in response to nutrient 
ingestion (0rskov et al., 1986). A biological role for this peptide has not been 
previously demonstrated. The effect could be due to enhancement of the activation 
of acetyl CoA carboxylase resulting in increased fatty acid synthesis, by increasing 
glucose transport into adipocytes or by increasing insulin receptor number or affinity. 
The effect could be of physiological importance since GLP-2 would be secreted at a 
similar time to insulin following a carbohydrate meal and the two hormones could 
have a synergistic effect in adipose tissue. To confirm a physiological role for this 
peptide the mechanism of action needs to be elucidated and to be demonstrated in vivo 
at physiological concentrations. The precise mechanism of action of GLP-2 could be 
investigated by determining its effect on glucose transport by adipocytes, insulin
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binding to adipocyte membrane receptors and activity of acetyl CoA carboxylase.
The conflicting effects of peptide YY on lipolysis imply that this peptide has 
more than one site of action. An antilipolytic effect for this peptide has been 
demonstrated in canine and human fat cells via the cx2-adrenergic pathway (Valet et 
al., 1990) but this cannot be responsible for inhibiting glucagon-stimulated lipolysis 
in the present study as rat adipocytes do not appear to possess 02-adrenergic receptors 
(Smith, 1977). Inhibition of glucagon-stimulated lipolysis is likely to occur via 
dephosphorylation of hormone-sensitive lipase and this can occur through a variety of 
mechanisms. There may be competition with the glucagon receptor, interruption of 
the action of the G-protein responsible for stimulating adenylate cyclase, 
dephosphorylation of hormone-sensitive lipase via an independent mechanism or 
stimulation of phosphodiesterase activity. The action of peptide YY in stimulating 
lipolysis both alone and in conjunction with insulin suggests that the peptide may act 
via a separate mechanism to phosphorylate hormone-sensitive lipase. This surprising 
discrepancy in the action of peptide YY requires further investigation to elucidate its 
mechanism of action in adipose tissue. The observed decrease in insulin-stimulated 
acetate incorporation into saponifiable fat is likely to result from the increased 
lipolytic effect in adipose tissue in response to the combination of these hormones. 
Since this hormone is released in response to a fat meal, it would be expected to direct 
lipids towards storage as opposed to mobilisation. Thus, it would be interesting to 
assess its effect on the activity of lipoprotein lipase. Pancreatic polypeptide, which 
is related to peptide YY and shares sequence homology, also weakly inhibited 
glucagon-stimulated lipolysis and this is likely to occur via the same mechanism as 
peptide YY.
The weak enhancement of glucagon-stimulated lipolysis by GLP-1 (7-37) and 
GLP-1 (1-37) is likely to have occurred via the glucagon receptor as these peptides 
are all structurally related. The interaction could then result in activation of hormone- 
sensitive lipase. These effects are unlikely to be of physiological importance but 
degradation of the peptides in the medium may occur and this should be assessed 
before ruling out a role in lipid mobilisation. GLP-1 (1-37) and oxyntomodulin both 
very weakly stimulated fatty acid synthesis possibly by stimulating the activity of 
acetyl CoA carboxylase but the effect is unlikely to be of physiological importance.
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Somatostatin-28 and octreotide both enhanced glucagon-stimulated lipolysis at 
the highest concentrations used. This could occur by altering the membrane receptor 
affinity for glucagon or by control of hormone-sensitive lipase activity. These 
mechanisms would need to be investigated and also the extent of peptide degradation 
in order to assess whether this is of physiological importance. Somatostatin-28 is 
released in response to fat ingestion and so it would be surprising if this hormone had 
a physiological role in lipid mobilisation. Octreotide also weakly enhanced insulin- 
stimulated incorporation of acetate into saponifiable fats by explants of rat adipose 
tissue and so probably elicits an effect via more than one site.
The ability of neurotensin to promote a weak stimulation of fatty acid synthesis 
in explants of adipose tissue suggests this hormone may have a role to play in the 
deposition of lipid. This may occur through stimulation of the activity of acetyl CoA 
carboxylase. However, the concentration (400nM) at which this effect was observed 
is 4000-fold higher than the physiological range, approximately lOOpM (Rosell and 
Rokaeus, 1979). Verification of the concentration present in the incubation allowing 
for any degradation would need to be assessed before deciding on its importance in 
the direct control of lipid metabolism.
In conclusion, apart from the effects of secretin seen in this study, any effects 
of gastrointestinal hormones investigated on fatty acid synthesis and lipolysis were 
weak and of questionable physiological importance. Therefore this suggests that, with 
the exception of secretin, the gastrointestinal hormones released in response to the 
ingestion of lipid and studied here do not have a physiological role to play in the 
control of fatty acid synthesis or lipolysis as estimated using rat epididymal adipose 
tissue. It is possible that the gastrointestinal hormones may be able to control the 
activity of lipoprotein lipase of adipose tissue and future studies could be carried out 
to compare the effects, if any, of gastrointestinal hormones on this enzyme’s activity 
in adipose tissue and muscle. The interesting effects of secretin warrant closer 
investigation as does the apparent potentiation by insulin of isoproterenol-stimulated 
lipolysis in order to establish the physiological importance and mechanisms for these 
observations.
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CHAPTER 6
HORMONAL CONTROL OF ADIPOSE TISSUE 
LIPOPROTEIN LIPASE IN RATS AND HUMAN VOLUNTEERS
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6.1 INTRODUCTION
The contribution of de novo lipogenesis to the accumulation of lipids in 
humans is a relatively minor pathway (Hellerstein et al., 1991). The re-esterification 
of fatty acids in adipose tissue, derived from hydrolysis of circulating chylomicrons 
and VLDL, is the major pathway through which deposition of lipids can be regulated. 
This pathway is dependent on the activity of lipoprotein lipase which is responsible 
for catalysing the hydrolysis of triglycerides from circulating lipoproteins.
Adipose tissue is one of the sites where lipoprotein lipase is synthesised 
(Bensadoun, 1991). The enzyme is then secreted to the endothelial cell surface where 
it as anchored by heparan sulphate proteoglycans integrated into the glycocalyx on the 
plasma membrane (Eckel, 1989). Here, at the luminal end of this complex, it 
hydrolyses the triglycerides from chylomicrons and VLDL, the fatty acids from which 
pass back into the adipocytes where they are converted back to triglycerides for 
storage.
Many factors control the activity of lipoprotein lipase including
nutritional and hormonal factors. Increasing the food intake of rat pups results in 
increased lipoprotein lipase in the adipose tissue (Cryer and Jones, 1979). Ingestion 
of various dietary components has been shown to control adipose tissue lipoprotein 
lipase. High levels of fat intake have been shown to result in increased lipoprotein 
lipase in rat adipose tissue (Paik and Yearick, 1978). The fatty acid composition of 
the dietary fat also has an effect on adipose tissue lipoprotein lipase. Diets rich in 
polyunsaturated fatty acids have been shown to enhance the activity of lipoprotein 
lipase in rat adipose tissue (Pawar and Tidwell, 1968) but have also been reported to 
be without effect in this tissue (Herzberg and Rogerson, 1989). Diets containing 
fructose lower adipose tissue lipoprotein lipase activity (Katayama, Bou and 
Katayama, 1981). The mechanisms by which diets can control the activity of 
lipoprotein lipase have not been fully elucidated.
Lipoprotein lipase activity has been demonstrated in the brain of rats and the 
activity decreases after fasting. The largest changes occurred in the hypothalamic 
region of the brain in response to starvation. The enzyme can be synthesised by the 
brain and is functional in the brain, at least in in vitro studies (Eckel and Robbins,
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1984).
Glucose is important for the glycosylation of lipoprotein lipase which is 
essential for the catalytic action of this enzyme (Ong and Kem, 1989a). Glucose also 
stimulates the synthesis, translation and post-translational processing of lipoprotein 
lipase.
The accumulation of free fatty acids is known to result in inhibition of 
lipoprotein lipase activity in vitro (Bengtsson and Olivecrona, 1980b). This is thought 
to occur by fatty acids binding to particular domains on the lipoprotein lipase enzyme 
(Olivecrona et ai, 1990) resulting in dissociation of the enzyme from the endothelial 
surface of cells in vitro (Saxena, Witte and Goldberg, 1989).
It is also well known that phospholipids and apolipoprotein CII are required 
for maximum activity of this enzyme (Bengtsson and Olivecrona, 1980a).
Substances known to stimulate cAMP production in adipocytes, such as 
glucagon, adrenaline and noradrenaline, decrease the activity of lipoprotein lipase 
(Eckel, 1987). It is proposed that the mechanism for control by adrenaline is through 
enhanced degradation of the enzyme (Ball, Speake and Robinson, 1986).
Circulating insulin concentrations have an established association with 
lipoprotein lipase. Diurnal variations in circulating insulin concentrations were shown 
to parallel the changes observed in lipoprotein lipase activity in meal-fed rats (Reichl,
1972). Another in vivo study also revealed a positive correlation between circulating 
insulin concentrations in rats and the activity of lipoprotein lipase (Cryer et al., 1976). 
An in vitro study has demonstrated regulation of lipoprotein lipase activity and release 
from 3T3-L1 adipocytes in culture by insulin (Spooner et al., 1979). Isolated 
adipocytes from rat adipose tissue have also been used to investigate the role of 
insulin in the control of lipoprotein lipase activity (Eckel et al., 1984). These authors 
measured both heparin-releasable and total intracellular activities of lipoprotein lipase 
from these cells. The presence of insulin in the culture medium resulted in increases 
in both heparin-releasable and intracellular activities of this enzyme. Insulin did not 
appear to have a direct effect on the mechanism of secretion of this enzyme. The 
stimulation of lipoprotein lipase synthesis by insulin has been shown to be potentiated 
by glucose (Ong and Kern, 1989a).
GIF has also been shown to have a role in the control of lipoprotein lipase.
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It has been demonstrated that GIF is capable of releasing lipoprotein lipase activity 
from 3T3-L1 cells and to stimulate the lipoprotein lipase activity within these cells 
(Eckel, Fujimoto and Brunzell, 1979).
GIF promotes the clearance of chylomicron triglycerides in dogs following a 
triglyceride rich meal (Wasada et ai, 1981) and this may be due to stimulation of 
lipoprotein lipase activity. It has been suggested that GIF may facilitate the transport 
of free fatty acids, released following the hydrolysis of the triglyceride-rich particles, 
into adipocytes and therefore acts by preventing accumulation of the inhibitory product 
of lipoprotein lipase activity (Beck and Max, 1983).
A study published from our laboratory reported that GIF stimulates the total 
cellular activity of lipoprotein lipase in explants of rat adipose tissue and that GLF-1 
(7-36) amide was without effect (Oben et al., 1991c).
The control of lipoprotein lipase activity is influenced by many factors 
including nutritional status and diet composition. The exact mechanisms for this 
control are not fully elucidated and it is possible that some of the effects observed 
may be mediated by gastrointestinal hormones. There is already evidence that GIF 
can increase the total amount of cellular lipoprotein lipase activity within the 
adipocyte.
The aim of this study was to investigate the control of heparin-releasable 
lipoprotein lipase activity from explants of adipose tissue from rats and human 
volunteers. Heparin interacts with lipoprotein lipase binding through an ionic binding 
process which is specific and very strong (Olivecrona et al., 1971). This property has 
been utilised in order to purify the enzyme. This binding has also been utilised to 
release lipoprotein lipase activity from isolated adipocytes where it was demonstrated 
that heparin not only releases the enzyme from adipocytes but also is involved in its 
activation (Stewart and Schotz, 1974).
Since small amounts of tissue are used in each investigation it would be 
difficult to measure the total lipoprotein lipase activity of the tissue. Therefore 
heparin was utilised in the present study to release lipoprotein lipase from the explants 
of adipose tissue into the incubation medium so that its activity could be measured. 
The assay for lipoprotein lipase in extracts of adipose tissue may also detect small 
amounts of hormone-sensitive lipase although this possibility is minimised by the
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different conditions required for the two assays and by using salt-inhibition of 
lipoprotein lipase activity to differentiate between the lipases.
The aim of the study was to compare the heparin-releasable activity of 
lipoprotein lipase in explants of human and rat adipose tissue in response to incubation 
with insulin, GIF or both.
In addition the effects of octreotide and secretin on heparin-releasable 
lipoprotein lipase activity in rat adipose tissue were also investigated. Octreotide is 
a long lasting analogue of somatostatin and is known to inhibit pancreatic secretion, 
including that of insulin, in humans (Creutzfeldt et al., 1987). In order to ascertain the 
value of using this substance to study in vivo hormonal control of lipoprotein lipase 
activity, a direct effect on basal and hormone-stimulated adipose tissue lipoprotein 
lipase activity was to be assessed.
In the previous chapter secretin was shown to stimulate lipolysis in rat adipose 
tissue and it was intended to gain a fuller picture of the role of this hormone in the 
mobilisation and deposition of lipids in adipose tissue by studying its effect on 
lipoprotein lipase activity.
Also a method for obtaining biopsies of human adipose tissue was developed 
in conjunction with Dr J.W. Wright at the Royal Surrey County Hospital and its use 
in the determination of lipoprotein lipase activity was assessed.
6.2 STUDY DESIGN
6.2.1 Heparin-releasable lipoprotein lipase from rat adipose tissue
Epididymal fat pads were obtained from non-fasted male Wistar/Albino rats 
(250-300g) from the Surrey stock. They were transferred to universal tubes containing 
prewarmed Medium 199 and transported to the laboratory. Explants were prepared 
and incubated as described in section 2.6.1. They were incubated in the presence of 
the following hormones :
Basal (no hormone); Insulin (2nM); GIF (8nM); Octreotide (8nM); Secretin (lOnM); 
Insulin (2nM) and GIF (8nM); Insulin (2nM) and Octreotide (8nM); GIF (8nM) and 
Octreotide (8nM); Insulin (2nM), GIF (8nM) and Octreotide (8nM).
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Insulin and secretin solutions were prepared using stock preparations of Img 
peptide per ml O.IM HCl. Octreotide (Sandoz, Basle) was supplied dissolved in saline 
(50pg/ml). The GIF used in the present study had been previously prepared in lOOng 
freeze dried aliquots as for radioimmunoassay standards (see section 2.12.1).
At the end of the incubation heparin was added to the culture medium to 
release lipoprotein lipase as described in section 2.6.1.
The medium removed from the explants was assayed for lipoprotein lipase 
activity as described in section 2.6.2.
6.2.2 Heparin-releasable lipoprotein lipase from human adipose tissue
This was a preliminary study into the use of human adipose tissue for in vitro 
investigations. Having established techniques in rat adipose tissue, it was intended to 
explore the effects of hormones on adipose metabolism in human adipose tissue. 
Human adipose tissue is more difficult to obtain than that from laboratory animals and 
needs to be acquired under some form of anaesthetic. Some studies use tissue 
obtained from subjects undergoing general anaesthesia for routine abdominal surgery 
but it is difficult to plan investigations where recruitment of specific groups of 
subjects is required. In particular it precludes comparisons between dietary treatments 
or effects of exercise. Therefore a biopsy technique using local anaesthesia was 
developed.
Ethical approval for the study was obtained from the Royal Surrey County 
Hospital Ethical Committee and volunteers were recruited from the University of 
Surrey. All the volunteers were female, BMI between 20 and 30, and were not asked 
to fast overnight prior to the biopsy. On the day of biopsy they were admitted to the 
Clinical Investigation Unit at the Royal Surrey County Hospital between 8.30 and 9.30 
am.
Lignocaine (2ml, Antigen Fharmaceuticals, Roscrea, Ireland) was administered 
intradermally at the biopsy site as a local anaesthetic before a 2mm incision in the 
skin was made in the paraumbilical region. More lignocaine was administered into 
the incision before the biopsy was taken. A metal bone marrow needle (14 gauge) 
attached to a 20ml syringe was used in order to remove the biopsy. The needle was
148
inserted at an angle of approximately 30° and about 3-6cm through the small incision 
and whilst withdrawing the needle tissue was aspirated by applying a vacuum using 
the syringe. This was repeated until sufficient adipose tissue had been collected in the 
syringe. The syringe and the biopsy needle were then rinsed with M sdium 199, which 
had been prewarmed to 37°C, into a universal tube in order to remove all the particles 
of adipose tissue. The tube containing the adipose tissue was transferred to the 
laboratory in a vacuum flask that had been warmed to 37°C.
Once in the laboratory, explants of the required size were rapidly prepared 
from the fragments of adipose tissue as described in section 2.6.1. They were then 
incubated as previously described in the same section. They were incubated in the 
presence of the following hormones:
Basal (no hormone); Insulin (2nM); GIF (8nM); Insulin (2nM) and GIF (8nM).
The solutions containing insulin were made using stock preparations of Img 
peptide per ml O.lM HCl. The GIF used in the present study had been previously 
prepared in lOOng freeze dried aliquots as for radioimmunoassay standards (see 
section 2.12.1).
At the end of the incubation heparin was added to the culture medium to 
release lipoprotein lipase as described in section 2.6.1.
The medium removed from the explants was assayed for lipoprotein lipase 
activity as described in section 2.6.2.
For each set of data the normality of distribution was confirmed using the 
Kolmogorov-Smimov goodness of fit test. Statistical comparisons between the 
experimental groups were then made by one-way analysis of variance and significance 
was assumed at p<0.05. Differences between groups were identified a posteriori 
using Duncan’s multiple ranges test with a  = 0.01 and 0.05.
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Table 6.1 Details of female volunteers recruited for study of lipoprotein lipase activity 
in adipose tissue biopsies.
Subject Height
(m)
Weight
(kg)
BMI
(kg/m^)
LM 1.70 59 20
JL 1.75 64 21
CW 1.54 52 22
GI 1.60 59 23
IE 1.70 75 26
BM 1.63 71 27
MM 1.64 82 30
6.3 RESULTS
6.3.1 Heparin-releasable lipoprotein lipase from rat adipose tissue
The measurements of activity of heparin-releasable lipoprotein lipase from 
explants of rat epididymal adipose tissue cultured with various combinations of 
insulin, GIF, octreotide and secretin are shown in Figure 6.1 with the values given in 
Appendix 4, Table 4. A.
Insulin (2nM) was found significantly (p<0.01) to stimulate the activity of 
heparin-releasable lipoprotein lipase in explants of rat adipose tissue when compared 
to basal measurements. This effect was maintained when explants were cultured in 
the presence of insulin with GIF (p<0.05), insulin with octreotide (p<0.05) or insulin 
with GIF and octreotide (p<0.05).
GIF (8nM) was shown to inhibit the activity of heparin-releasable lipoprotein 
lipase (p<0.05) in the explants when compared to basal measurements of activity and 
the effect was similar when explants were cultured in the presence of GIF and 
octreotide.
Octreotide (8nM) was without effect on basal measurements of heparin-
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Figure 6.1 Effects of insulin, GIF, octreotide and secretin on heparin-releasable 
lipoprotein lipase activity from explants of rat epididymal adipose 
tissue (values denote mean ± S.D. (n=6) per incubation). B = Basal; 
I = Insulin (2nM); G = GIF (8nM); O = Octreotide (8nM); S = Secretin 
(lOnM).
* = Significantly different from basal (p<0.05).
** = Significantly different from basal (p<0.01).
Oleate released (pmol/min per mg) 
30 r
G O S I+G  I+O G+O I+G+O  
Hormone treatment
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releasable lipoprotein lipase activity when explants were cultured in the presence of 
octreotide alone.
Secretin, which was shown in the previous chapter to stimulate lipolysis, also 
was shown to inhibit (p<0.05) the activity of heparin-releasable lipoprotein lipase in 
the explants when compared to the basal measurements of activity obtained.
6.3.2 Heparin-releasable lipoprotein lipase from human adipose tissue
The technique developed to obtain biopsies of adipose tissue from human 
volunteers was capable of yielding approximately 350-500mg of tissue although this 
was not possible in all cases. Although this represented a good yield when compared 
to previous studies which involved removal of fat biopsies (Hirsch and Goldrick, 
1964; Pykalisto, Smith and Brunzell, 1975; Cigolini et al., 1988; Handelman et al., 
1988; Wahrenberg, Lônnqvist, and Amer, 1989) the number of investigations that 
could be carried out on each sample was more restricted than that possible with the 
relatively large amount of tissue available from rat epididymal adipose tissue.
The measurements of the activity of heparin-releasable lipoprotein lipase from 
explants prepared from biopsies of human subcutaneous adipose tissue and cultured 
in the presence of no hormone, insulin, GIF, or both, are shown in Figure 6.2 with the 
values given in Appendix 4, Table 4.B. The same results are expressed as a % of 
basal measurements in Figure 6.3. There was no correlation between BMI and basal 
activity of heparin-releasable lipoprotein lipase in explants of human adipose tissue 
(correlation coefficient (r) = -0.133 (p=0.78) using Fearson parametric correlation), 
shown plotted in Figure 6.4.
There were no significant differences from basal measurements in the activity 
of heparin-releasable lipoprotein lipase activity from the explants prepared from 
biopsies of human adipose tissue observed when cultured with insulin, GIF or insulin 
and GIF.
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Figure 6.2 Effects of insulin (2nM) and GIF (8nM) on heparin-releasable 
lipoprotein lipase activity from explants of human adipose tissue 
(values denote mean ± S.D. (n=7) per incubation).
Oleate released (pmol/min per mg) 
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8
0
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Figure 6.3 Effects of insulin (2nM) and GIF (8nM) on heparin-releasable 
lipoprotein lipase activity from explants of human adipose tissue 
(values denote mean ± S.D. (n=7) per incubation, with data expressed 
as % of basal values).
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Figure 6.4 Effect of BMI on basal heparin-releasable lipoprotein lipase activity 
from explants of human adipose tissue.
Correlation coefficient (r) = -0.133. NSD from zero (p=0.78)
Oleate released (pmol/min per mg)
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6.4 DISCUSSION
6.4.1 Measurement of lipoprotein lipase activity in explants using heparin
Other studies have utilised the ability of heparin to displace lipoprotein lipase 
from adipocytes (Stewart and Schotz, 1974; Eckel et al., 1984) and adipose fragments 
(Ong and Kem, 1989b) to determine the activity of this enzyme. It has been reported 
that heparin has the effect of activating and preserving the activity of lipoprotein 
lipase (Stewart and Schotz, 1974; Olivecrona et al., 1977; Eckel et al., 1988). It is 
also possible that the act of stripping lipoprotein lipase from the cell surface may 
contribute to alterations in the apparent activity or release of activity of this enzyme.
Measurements of lipoprotein lipase in acetone-ether extracts have been shown 
to correlate with heparin-releasable activity in adipose tissue biopsies from normal 
human subjects. The values found in acetone-ether extracts were lower than those 
seen in the heparin-releasable pool of lipoprotein lipase. It was suggested that 
lipoprotein lipase is present in different forms and multiple compartments. The two 
methods utilised to determine lipoprotein lipase activity detected different forms of the 
enzyme: the acetone-ether extract measured newly synthesised intra-cellular enzyme, 
and heparin-releasable activity measured a processed form of lipoprotein lipase activity 
thought to represent the intravascular activity of the enzyme. The heparin-releasable 
fraction is believed to be more representative of the lipoprotein lipase involved in 
clearance of circulating triglycerides (Pykalisto, Smith and Brunzell, 1975).
It is however difficult to be certain which measure of lipoprotein lipase best 
represents functional in vivo activity. There are limitations to the current methodology 
especially with the role of heparin in activating the enzyme. These methods may need 
to be replaced by more refined methods to tease out at which level the various factors 
known to control lipoprotein lipase activity exert their effects. A recent review 
outlined results from recent studies of control of lipoprotein lipase activity by 
investigating the biosynthesis, secretion and degradation of the enzyme in cultured 
cells. It appears that control of lipoprotein lipase activity occurs at several levels in 
cultured adipocytes including transcription, translation and post-translational processing
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of the enzyme (Bensadoun, 1991). Therefore, estimation of all these processes may 
be necessary in order to obtain a complete picture of functional in vivo activity.
6.4.2 Heparin-releasable lipoprotein lipase from rat adipose tissue
Culturing explants of rat adipose tissue in the presence of insulin resulted in 
increased activity of heparin-releasable lipoprotein lipase. This is in agreement with 
a previous study which used rat adipocytes (Eckel et al., 1984). The same authors 
reported that the heparin-releasable lipoprotein only represents a small portion of the 
total cellular pool but suggest that this pool is able to demonstrate an earlier and 
greater response to insulin. This implies that insulin may have a role in the transport 
of lipoprotein lipase to the vascular endothelium.
In the present study a decrease in heparin-releasable lipoprotein lipase activity 
was observed when GIF was included in the culture medium. Previous reports from 
our laboratory demonstrated an increase in total cellular lipoprotein lipase activity in 
explants of rat adipose tissue in response to incubation with GIF (Oben et al., 1991c). 
It is possible that the stimulatory effect of GIF is restricted to an increase in the total 
cellular pool of lipoprotein lipase and therefore, not necessarily detected by measuring 
the heparin-releasable lipoprotein lipase. However, a more recent study from our 
laboratory has demonstrated an increase in heparin-releasable lipoprotein lipase 
activity, using the same study protocol as that described in this chapter, in response 
to incubation with GIF (Knapper et al, 1993). The reason for these discrepancies are 
not clear. Due to insufficient time, repetition of this experiment in order to investigate 
the possible causes of failure to find GIF stimulation of heparin-releasable lipoprotein 
lipase activity was not possible.
Octreotide was found to be without a direct effect on heparin-releasable 
lipoprotein lipase activity in rat adipose tissue and it is concluded that this long lasting 
analogue of somatostatin may be a useful tool in the study of in vivo regulation of 
lipoprotein lipase in humans by insulin and gastrointestinal hormones. The substance 
also had no effect on the insulin-stimulation of heparin-releasable lipoprotein lipase 
in the explants of adipose tissue.
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There appear to be no reports of the effect of secretin on lipoprotein lipase 
activity in the literature but its stimulatory effect on lipolysis in rat adipose tissue has 
been established here and elsewhere (Rudman and Del Rio, 1969; Butcher and 
Carlson, 1970).
The observation in the present study that secretin was capable of decreasing 
the activity of lipoprotein lipase in rat adipose tissue is consistent with previous 
reports that substances responsible for raising cAMP levels also cause a reduction in 
lipoprotein lipase activity. These substances include glucagon, adrenalin and 
noradrenaline (Eckel, 1987). These results give further support to the possibility of 
a role for secretin in the diversion of lipid towards mobilisation to meet energy 
requirements rather than deposition and storage.
6.4.3 Heparin-releasable lipoprotein lipase from human adipose tissue
The technique developed for obtaining biopsies of adipose tissue from human 
volunteers was capable of yielding sufficient tissue to perform limited investigations 
into lipoprotein lipase activity. The volunteers did not experience any pain during the 
removal of the biopsy but some reported the area feeling bruised the following day.
The basal measurements of heparin-releasable lipoprotein lipase activity were 
much lower than those seen in rat adipose tissue (4.8 ± 2.3 and 16.25 ± 2.55 nmol 
oleate released/min per mg tissue (mean ± S.D.) in human and rat respectively). This 
is in agreement with results obtained in previous studies where lipoprotein lipase 
activity was measured in acetone-ether extracts of adipose tissue of humans and rats. 
Rat adipose tissue was found to contain approximately 7 fold more total cellular 
lipoprotein lipase activity than human adipose tissue (Elkeles, 1974).
Insulin and GIF were found to be without effect on measurements of heparin- 
releasable lipoprotein lipase when included in the incubation medium. There were 
also very large variations in values obtained from different subjects. Normalising the 
data, by expressing each subject’s values as a percentage their basal values, did not 
improve the variations, nor was there a correlation between subject BMI and basal 
heparin-releasable lipoprotein lipase activity. This could be due to a number of factors 
including possible differences in cell size of the adipocytes. The adipose tissue
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obtained from different subjects may contain adipocytes of different sizes resulting in 
varying numbers of cells per gram of tissue. This could then be reflected in cellular 
release of lipoprotein lipase from these cells. This effect would not be observed in 
rats as animals of very similar ages and weights were selected and so their adipocyte 
cell sizes would be expected to be similar.
There could also be large variations in the diets of the various volunteers and 
as has already been discussed the composition of the diet has an important role in the 
control of lipoprotein lipase activity, at least in rats (Pawar and Tidwell, 1968; Paik 
and Yearick, 1978; Katayama, Bou and Katayama, 1981; Herzberg and Rogerson,
1989). This effect would not be observed in the rats used in this study as they were 
all fed on the standard laboratory chow diet.
Viable tissue is of paramount importance when investigating hormonal control 
of adipose tissue metabolism and aspects of the technique employed for this study 
give cause for concern. It is possible that lignocaine used as a local anaesthetic may 
have affected the lipoprotein lipase synthesis, transport or release in explants. There 
are no reports in the literature of investigation into the effects of lignocaine or in fact 
of any local anaesthetic on the activity of lipoprotein lipase. However, it has been 
reported that lignocaine increases fluidity of membrane lipids of erythrocytes (Haque 
and Poddar, 1983) and this is believed to be part of the mechanism of action of 
anaesthetics. The insulin receptor is known to be affected by membrane fluidity 
(Tepperman and Tepperman, 1985) and so more consideration should be given to the 
possible effects of anaesthetic on the hormonal control of lipoprotein lipase activity. 
There are several reports that local anaesthetics have a powerful antilipolytic effect on 
adipocytes. Prilocaine chloride, a commonly used local anaesthetic, has been shown 
to inhibit basal and stimulated lipolysis in human adipose tissue and to abolish the 
antilipolytic effects of insulin (Amer, Amer and Ôstman, 1973). Also, incubation of 
rat adipocytes with 3.8mM lignocaine resulted in a 50% inhibition of adrenaline- 
(55pM)-stimulated lipolysis (Siddle and Hales, 1974). It is therefore possible that 
control of lipoprotein lipase activity is affected by the administration of local 
anaesthetic and future studies should investigate the extent and duration of anaesthetic- 
induced alterations in adipose tissue. A field block technique of administering the 
anaesthetic has been suggested (Amer, Arner and Ôstman, 1973) but volunteers used
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in this study found the biopsy uncomfortable unless anaesthetic was administered at 
the biopsy site. It is not possible to remove biopsies without local anaesthetic for 
ethical reasons. The effect of anaesthetic may be minimised by increasing the length 
of the 90 minute pre-incubation time allowed in these studies for tissue recovery, 
coupled with thorough rinsing of the tissue during this time in order to minimise the 
effect of the anaesthetic agent. A preliminary investigation into the effect of 
lignocaine on hormonal control of lipoprotein lipase activity could be carried out using 
rat adipose tissue or adipose tissue obtained from patients undergoing general 
anaesthesia, which are more readily available sources, in order to assess the duration 
of its effects. Obviously the data obtained would have to be cautiously extrapolated 
to the human situation but may give an indication of the extent of the effects.
It has been suggested that human adipose tissue is very sensitive to the various 
manipulations involved in preparation of isolated fat cells since the cells are extremely 
fragile (Smith, 1981). The use of explants in this study should have eliminated 
problems associated with the collagenase digestion necessary to liberate cells. Tissue 
was immediately transferred to medium that had been warmed to 37°C and explants 
prepared with the minimum of pulling or tearing the tissue. However, removal of the 
biopsy by aspiration may have resulted in damage to the tissue. Investigations, similar 
to those outlined for studying effects of local anaesthetics, into the damage caused by 
aspiration of adipose tissue during the biopsy could be carried out and the extent of 
reversal of the effects by refining the incubation conditions during the recovery phase 
assessed.
Once the variability of measurements of lipoprotein lipase has been minimised 
then studies of hormonal responsiveness in response to parameters such as obesity, 
diet composition and gastrointestinal hormone administration can be investigated using 
these methods.
160
CHAPTER 7
IN VIVO INVESTIGATION OF THE FUNCTIONAL 
INTERRELATIONSHIPS BETWEEN THE GASTROINTESTINAL 
PEPTIDES GIP AND GLP-1 (7-36) AMIDE AND HEPARIN- 
RELEASABLE LIPOPROTEIN LIPASE ACTIVITY IN OBESE 
AND LEAN SUBJECTS
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7.1 INTRODUCTION
The amount of fat stored in adipose tissue ultimately depends on the relative 
rates of fat deposition (from lipogenesis and free fatty acid uptake) and fat 
mobilisation (lipolysis). These pathways are described in detail in Chapter 1. In the 
obese condition more fat is being deposited in the adipose tissue lipid stores than is 
being utilised for energy by the body. Obesity is common in Western society where 
40% of middle-aged females have been classified as obese according to the Quetelet 
Index (Skouge, 1990). It has been implicated in several predominantly ‘Western 
diseases’, for example NIDDM and cardiovascular disease.
It has been well documented that de novo lipogenesis in humans is a minor 
pathway (Hellerstein et a/., 1991; Leitch and Jones, 1993) even after a meal containing 
500g carbohydrate (Acheson, Hatt and Jéquier, 1982). However, a more recent study 
by these authors has demonstrated that when the body glycogen stores have become 
saturated by massive carbohydrate overfeeding, the lipogenic pathway can dispose of 
approximately 475g carbohydrate per day resulting in the synthesis of 150g lipid per 
day (Acheson et ai, 1988). This type of feeding regime is however unlikely to occur 
in free-living humans and the pathway whereby dietary fat is deposited via the action 
of lipoprotein lipase is therefore of greater importance in humans.
It has been reported that levels of lipoprotein lipase activity are elevated in 
obese humans when expressed in terms of lipoprotein lipase activity per cell, but not 
when expressed per unit mass of adipose tissue (Pykalisto, Smith and Brunzell, 1975; 
Taskinen and Nikkila, 1977).
Lipoprotein lipase activity is also known to be regulated by insulin (Cryer et 
al., 1976; Spooner et al., 1979; Sadur and Eckel, 1982; Eckel et al., 1984). It is well 
established that hyperinsulinaemia is common in obesity (Karam, Grodsky and 
Forsham, 1963; Glass et al., 1981). In turn, the secretion of insulin is known to be 
modulated by a group of gastrointestinal hormones termed incretins as discussed in 
Chapter 1 (Creutzfeldt and Nauck, 1992). Examples of these are GIF (Dupre et al.,
1973) and GLP-1 (7-36 amide) (Kreymann et al., 1987; 0rskov, Holst and Nielsen, 
1988; Shima, Hirota and Ohboshi, 1988).
It has been speculated that an over-active enteroinsular axis may contribute to
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the hyperinsulinaemia of obesity. However, investigations into the possible 
involvement of GIP have yielded contradictory results. Fasting circulating 
concentrations of GIP have been reported to be elevated in obese subjects (Elahi et 
al., 1984; Mazzaferri et al., 1985; Salera et al., 1982). Postprandial GIP responses to 
nutrient ingestion have been shown to be enhanced (Creutzfeldt et al., 1978; Ebert, 
Frerichs and Creutzfeldt, 1979; Elahi et al., 1984; Mazzaferri et al., 1985), unaffected 
(Lauritsen, Christensen and Stockholm, 1980; Amland et al., 1984; Morgan et al., 
1992), or diminished (Service et al., 1984; Groop, 1989). These discrepancies are 
partly due to the different meals used in the above studies as a stimulus for GIP 
secretion. For example, in earlier studies where large volume liquid meals were used, 
the enhanced secretion of GIP was later established to result from increased rates of 
gastric emptying. Both GIP responses and gastric emptying were normalised in obese 
subjects when smaller volume meals of a lower energy content were used (Ebert and 
Creutzfeldt, 1989). Postprandial GIP responses to a test meal by obese subjects are 
also diminished if their food intake is restricted for the preceding five days (Willms, 
Ebert and Creutzfeldt, 1978). In addition, circulating concentrations of somatostatin 
have been shown to be reduced in obese subjects in both fasting and postprandial 
states (Schusdziarra et al., 1985). Somatostatin inhibits the secretion of pancreatic and 
gastrointestinal hormones (Schusdziarra, 1983), including insulin and GIP (Pederson, 
Dryburgh and Brown, 1975) and may therefore also be involved in the 
hyperinsulinaemia of obesity. The possible role of GLP-1 (7-36) amide in the 
hyperinsulinaemia of obesity has not been investigated.
The gastrointestinal hormones of the enteroinsular axis may affect the 
accumulation of dietary triglyceride indirectly via augmentation of insulin secretion 
and its subsequent effect on lipoprotein lipase activity, or by a direct action on 
lipoprotein lipase activity itself. Both these actions may be modified in the obese 
state. Other workers have documented direct effects of GIP on chylomicron clearance 
in vivo; our failure in previous chapters to find direct effects of GIP in rat adipose 
tissue in vitro may not reflect the human in vivo situation.
The following study investigates postprandial hormones secretion and 
lipoprotein lipase activity in lean and obese human subjects in response to fat and 
carbohydrate test meals.
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The objectives of the study were twofold. Firstly to compare the postprandial 
secretion of GIP, GLP-1 (7-36) amide and insulin in response to the test meals and 
to correlate these with post-heparin plasma lipoprotein lipase activity in lean and obese 
subjects. Secondly to attenuate postprandial gastrointestinal hormone and insulin 
secretion by the infusion of octreotide, a long lasting analogue of somatostatin, and 
to observe the effect of this attenuation on post-heparin plasma lipoprotein lipase 
activity in order to evaluate the role of these hormones in lipoprotein lipase 
activation in lean and obese states.
7.2 STUDY DESIGN
7.2.1 Subjects
Approval for the study was obtained from the Royal Surrey County Hospital 
Ethical Committee. The study was carried out in association with Dr L. Ranganath 
from the Royal Surrey County Hospital, Guildford. Six obese volunteers (defined as 
having a BMI greater than 30kg/m^) were recruited from an obesity clinic at the Royal 
Surrey County Hospital and six age matched lean controls (defined as having a BMI 
less than 25kg/m^) were recruited from University students and staff of Royal Surrey 
County Hospital. All the volunteers were female, aged between 19 and 42 and were 
all premenopausal. Subject details are given in Table 7.1.
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Table 7.1 Details of subjects participating in study of functional interrelationships 
between the gastrointestinal peptide GIF and GLP-1 (7-36) amide and post­
heparin lipoprotein lipase activity in obese and lean subjects.
SUBJECT AGE HEIGHT
(m)
WEIGHT
(kg)
BMI
(kg/m^)
J.M.B. 26 1.69 57.1 20.0
P.D. 21 1.65 56.0 20.6
L.S. 21 1.73 64.5 21.6
H.M. 39 1.66 60.0 21.8
J.F. 42 1.66 60.6 22.0
J.P. 37 1.68 62.0 22.0
J.B. 18 1.74 96.3 31.8
K.G. 38 1.70 93.0 32.2
S.B.(a) 41 1.63 91.5 34.4
S.B.(b) 19 1.65 126.5 46.5
B.C. 40 1.55 113.0 47.0
C.M. 25 1.53 113.0 48.3
7.2.2 Experimental
The volunteers made three separate visits to the Clinical Investigation Unit of 
the Royal Surrey County Hospital after an overnight fast of at least 12 hours. For the 
first two visits the subjects were asked to consume, in random order, either a double 
cream or an isoenergetic (375kcal) carbohydrate meal. The double cream meal 
consisted of 84ml double cream (Sainsbury’s, London) mixed with 216ml of water to 
give a total liquid volume of 300ml. The carbohydrate meal consisted of 155ml of 
lemon flavoured Hycal (Beecham Products, Brentford) mixed with 145ml of water to 
give a total liquid volume of 300ml. On the third visit, the carbohydrate meal of 
Hycal was given during intravenous infusion (lOOpg in 50ml saline at a rate of 
29pg/hour) of Sandostatin (Sandoz, Basle) which contains octreotide, a synthetic
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analogue of somatostatin. The infusion was commenced 30 minutes before the 
ingestion of the meal in order to stabilise circulating levels of octreotide and continued 
throughout the blood sampling period.
7.2.3 Blood sampling
Blood samples were removed from an indwelling cannula previously inserted 
in a forearm vein and maintained patent by flushing with 3.8% citrate after withdrawal 
of each blood sample. Blood samples (20 or 24ml) were taken before the meal and 
throughout the 3 hour postprandial period. The samples were taken at 30 minutes 
(24ml) prior to ingestion of the meal and then at the following intervals after the meal 
- 0 (20ml), 15 (20ml), 30 (20ml), 45 (20ml), 60 (20ml), 90 (20ml), 120 (24ml), 125 
(4ml), 130 (4ml), 135 (24ml), 150 (20ml), 180 (24ml) minutes.
In order to assess lipoprotein lipase activity, heparin (10 000 units in 10ml 
saline) was administered as a bolus 120 minutes after the ingestion of each meal. 
Lipoprotein lipase activity was measured in 120, 125, 130, 135, 150, 180 minute 
samples.
7.2.4 Treatment of blood samples
Blood was collected in :
1) Lithium heparin tubes (10 or 14ml), for the determination of insulin, C-peptide, 
GIF, and heparin-released lipoprotein lipase.
2) Fluoride oxalate tubes (2.5ml), for the determination of glucose.
3) Lithium heparin tubes (5ml) containing aprotinin (1000 KIU per ml blood), for 
determination of GLF-1.
4) The remaining blood was allowed to clot for one hour at room temperature in 
glass tubes and the serum thus obtained stored at -20®C for later assay of 
triglycerides.
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All the blood samples were immediately centrifuged at 1200g for 5 minutes 
and plasma immediately aliquotted into LP3 tubes. The tubes were then frozen 
without delay so that plasma samples were placed in a freezer at -20”C within 15 
minutes of being removed from the subject. The samples were then stored frozen at 
■20®C until analysis.
7.2.5 Analysis of plasma and serum samples
The methods employed for analyses of various analytes are described in 
Chapter 2.
Glucose, triglyceride and insulin analyses were carried out at the Royal Surrey 
County Hospital. C-peptide and GIF measurements were carried out using 
radioimmunoassays with a double antibody separation stage. GLF-1 (7-36) amide 
determinations were made using a radioimmunoassay utilising a dextran coated 
charcoal separation stage. Lipoprotein lipase activity was determined using an assay 
based upon the release of labelled fatty acids from ^H labelled triolein.
7.2.6 Statistical analyses
For each set of data the normality of distribution was confirmed using the 
Kolmogorov-Smirnov test. Repeated measures analysis of variance was used to check 
for paralellity or non-parallelity of the response profiles. For each parameter, in each 
subject, the total area under the curve was calculated using the trapezoidal rule over 
the postprandial sampling period. The incremental area under the curve was then 
calculated by subtracting the area corresponding to the fasting value (multiplied by the 
postprandial sampling time) from the total area under the curve.
Statistical comparisons between the experimental groups were then made by 
one-way analysis of variance and any differences identified using Duncan’s multiple 
range test with a  = 0.05 and 0.01.
Comparison of fasting levels of each parameter between the obese and lean 
subjects and also comparisons at selected time points, for example comparison
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between fasting values during octreotide infusion, were made using Student’s paired 
t-tests. Values of p<0.05 were taken to be significant.
7.3 RESULTS
7.3.1 Glucose responses
The glucose responses are shown in Figures 7.1, 7.2 and 7.3 with the values 
given in Appendix 5, Table 5.A. The total and incremental areas under the curve are 
shown in Figure 7.4.
There were no significant differences between the fasting circulating levels of 
glucose in lean and obese subjects (Figures 7.1, 7.2 and 7.3).
Following the carbohydrate meal, a rise in the circulating concentrations of 
glucose was observed in both sets of subjects with highest mean values compared with 
fasting occurring at 30 minutes in the lean subjects and 45 minutes in the obese 
subjects (Figure 7.1, values given in Appendix 5, Table 5A). The circulating 
concentrations then decreased towards fasting values over the 3 hour post-prandial 
sampling period. The obese subjects showed higher total (p<0.01) and incremental 
(p<0.05) integrated responses for glucose levels following the carbohydrate meal than 
the lean subjects (Figure 7.4).
There were no significant differences in circulating glucose levels from fasting 
value observed at any time point following ingestion of the fat meal in either obese 
or lean subjects (Figure 7.2).
Infusion of octreotide led to a reduction in fasting glucose concentrations prior 
to ingestion of the carbohydrate meal in both obese (p<0.01) and lean (p<0.01) 
subjects (Figure 7.3). Administration of octreotide led to glucose intolerance 
following the carbohydrate meal which was observed as a continual rise in circulating 
glucose concentrations throughout the entire 3 hour post-prandial sampling period in 
both obese and lean subjects. This was demonstrated by higher total and incremental 
integrated glucose responses following the carbohydrate meal during the octreotide 
infusion than the carbohydrate meal alone in both obese and lean subjects (all 
significances p<0.01).
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Figure 7.4 Total and incremental areas under the curve for plasma glucose 
responses to Hycal, fat or Hycal during i.v. octreotide meals in lean 
and obese subjects (values denote mean ± S.E. (n=6)).
Bars with common superscript (uppercase) are significantly different
(p<0.01).
Bars with common superscript (lowercase) are significantly different 
(p<0.05).
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7.3.2 Triglyceride responses
The triglyceride responses are shown in Figures 7.5, 7.6 and 7.7 with the 
values given in Appendix 5, Table 5.B. The total and incremental areas under the 
curve are shown in Figure 7.8.
Obese subjects had higher fasting circulating concentrations of triglycerides 
(p<0.01) than lean subjects (Figures 7.5, 7.6 and 7.7).
Following the carbohydrate meal both with and without the infusion of 
octreotide there were no significant differences observed at any time point in either 
obese or lean subjects from their fasting circulating levels of triglycerides (Figures 7.5 
and 7.7). However, a decrease in triglyceride concentrations was observed following 
the administration of heparin at 120 minutes following the meal. This reached 
statistical significance at 135 minutes (15 minutes after heparin administration) for 
both obese and lean subjects (p<0.01) following the carbohydrate meal alone. For the 
carbohydrate meal ingested during infusion of octreotide this reached statistical 
significance at 135 minutes (15 minutes after heparin adminstration) for obese subjects 
(p<0.01) and 150 minutes (30 minutes after heparin administration) for the lean 
subjects (p<0.01). The total integrated response was higher in obese subjects than in 
lean subjects (p<0.01) but there were no significant differences between the two sets 
of subjects observed when incremental integrated responses were compared for the 
carbohydrate meal alone (Figure 7.8). However, the incremental integrated response 
to the carbohydrate meal during infusion of octreotide was greater in lean subjects 
than in obese subjects (p<0.05).
Following the ingestion of the fat meal there was a gradual rise in circulating 
triglycerides in both obese and lean subjects with the highest mean value occurring 
at 120 minutes. Following administration of the heparin bolus at 120 minutes the 
circulating triglyceride concentrations were observed to decrease (Figure 7.6). This 
reached statistical significance at 135 minutes, 15 minutes after administration of 
heparin, (p<0.01 for lean and p<0.05 for obese subjects) and 150 minutes, 30 minutes 
after administration of heparin, (p<0.01 for obese subjects). There were no significant 
differences in total or incremental integrated responses to the fat meal in obese 
compared with lean subjects.
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Figure 7.8 Total and incremental areas under the curve for serum triglyceride 
responses to Hycal, fat or Hycal during i.v. octreotide meals in lean 
and obese subjects (values denote mean ± S.E. (n=6)).
Bars with common superscript (uppercase) are significantly different
(p<0.01).
Bars with common superscript (lowercase) are significantly different 
(p<0.05).
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7.3.3 Insulin responses
The insulin responses are shown in Figures 7.9, 7.10 and 7.11 with the values 
given in Appendix 5, Table 5.C. The total and incremental areas under the curve are 
shown in Figure 7.12.
The data for the incremental area under the insulin curve were markedly 
heteroscedastic (Bartletts Fmax = 139.9); following logarithmic transformation, Fmax 
reached 21.8, which exceeded the critical Fmax at a  = 0.05. Therefore the non- 
parametric Mann-Whitney test was employed to make comparisons between the 
groups. In view of the risk of cumulative probability error arising as a result of 
repeated comparisons, significance was assumed only when p<0.005.
Obese subjects had higher fasting levels of insulin (p<0.05) than lean subjects 
(Figures 7.9, 7.10 and 7.11).
Following the carbohydrate meal a rise in circulating concentrations of insulin 
was observed in both lean and obese subjects (Figure 7.9) with the highest mean 
values observed at 60 minutes in obese subjects and at 30 minutes in lean subjects. 
The total and incremental integrated response to the carbohydrate meal was higher in 
obese subjects when compared with the response observed in lean subjects (p<0.01) 
(Figure 7.12).
Following ingestion of the fat meal, there was a small but statistically 
significant rise in circulating insulin concentrations in the obese subjects (Figure 7.10) 
peaking at 45 minutes having reached significance at 30 minutes (p<0.05). There was 
no increase in circulating insulin concentrations observed in lean subjects. The total 
integrated response to the fat meal was significantly higher in the obese subjects 
compared with the lean subjects (p<0.01) but the incremental integrated responses 
were not significantly different (Figure 7.12).
Infusion of octreotide led to a decrease in fasting circulating concentrations 
(p<0.05) of insulin in both obese and lean subjects (Figure 7.11). The postprandial 
secretion profile of insulin was almost totally abolished when the carbohydrate meal 
was ingested during infusion of octreotide. This was demonstrated by significantly 
lower total and incremental integrated responses to the carbohydrate meal when 
ingested during the infusion of octreotide in both sets of subjects (all significances
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Figure 7.12 Total and incremental areas under the curve for plasma insulin 
responses to Hycal, fat or Hycal during i.v. octreotide meals in lean 
and obese subjects (values denote mean ± S.E. (n=6)).
Bars with common superscript (uppercase) are significantly different
(p<0.01).
Bars with common superscript (lowercase) are significantly different 
(p<0.05).
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p<0.01) compared to responses to the meal without infusion of octreotide. Total and 
incremental integrated responses to the carbohydrate meal during infusion of octreotide 
were higher in the obese subjects than in lean subjects (p<0.01) (Figure 7.12).
7.3.4 C-peptide responses
The C-peptide responses are shown in Figures 7.13, 7.14 and 7.15 with the 
values given in Appendix 5, Table 5.D. The total and incremental areas under the 
curve are shown in Figure 7.16.
Obese subjects exhibited higher fasting levels of C-peptide (p<0.05) than the 
lean subjects (Figures 7.13, 7.14 and 7.15).
Following the carbohydrate meal a rise in circulating concentrations of C- 
peptide was observed (Figure 7.13) with the highest mean values occurring at 60 
minutes in both obese and lean subjects. Total and incremental integrated responses 
to the meal were both significantly higher in the obese subjects (p<0.05) (Figure 7.16).
Following ingestion of the fat meal there was a smaU rise in circulating 
concentrations of C-peptide peaking at 30 minutes and 45 minutes in the lean and 
obese subjects respectively but reaching statistical significance at 30 minutes (p<0.05) 
in obese and lean subjects (Figure 7.14). The total integrated response to the fat meal 
was higher in obese than lean subjects (p<0.01) but the incremental integrated 
response was not significantly different between the two groups (Figure 7.16).
Infusion of octreotide resulted in decreased fasting circulating C-peptide 
concentrations (p<0.01) in both sets of subjects (Figure 7.15). The postprandial 
secretion profüe was also attenuated when the carbohydrate meal was ingested during 
infusion of octreotide in both obese and lean subjects. This was demonstrated by 
reduced total and incremental integrated responses to the carbohydrate meal during the 
octreotide infusion compared with when ingested without octreotide infusion (all 
significances p<0.01) in both obese and lean subjects (Figure 7.16). The circulating 
concentrations began to rise again after 60 minutes in both sets of subjects. Both total 
and incremental integrated responses to the carbohydrate meal during the infusion of 
octreotide were significantly higher in obese compared with lean subjects (p<0.01).
183
5
t ii
CO
-H
I
B0
1C/5
I
f
iX)0
11
.S1
&
2
(/)
g
B
I
Ù
kJI
g
m
C
Oo
o
§
on
i l
o lNO O
m m r4
I
184
1f
a
ni
CO
+1
I
BI
I
>
o(U
¥
(DX)O
1
cS
c3
2C/3
(30
&
2
I
£
Ô1cS
S
Tf-
I
QO
QO
a
Ooo
r4
I
I
i
I
185
+ 1
(Ue
B
o
c
(L>
" O
c/5<Ü
g
1 3
-J2
o
<L)
1 5 "
ü J
c/5
<U
C/5
(D
X )
O
1
rB
C
(U
T )
*43
O
(U
h
oo
o
c
o
S3
«4-,
_ c
>
• 1-î
W )a
• c
3
T3
c d
(Us
ccJ
O
3
o
c/5
(U
c/5
C
Oex
C/J
<Ü
Vh
<u
' ü
<L)
e u
Ù VOII
c 3 Ge
c/5i2 WfX00
V5
d)k4g
PU
G
13
O
N
O
00
o
?
i l
8 |
Mc
o  ^VO ^
1
QJ-I
o
186
Figure 7.16 Total and incremental areas under the curve for plasma C-Peptide 
responses to Hycal, fat or Hycal during i.v. octreotide meals in lean 
and obese subjects (values denote mean ± S.E. (n=6)).
Bars with common superscript (uppercase) are significantly different
(p<0.01).
Bars with common superscript (lowercase) are significantly different 
(p<0.05).
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7.3.5 GIP responses
The GIF responses are shown in Figures 7.17, 7.18 and 7.19 with the values 
given in Appendix 5, Table 5.E. The total and incremental areas under the curve are 
shown in Figure 7.20.
There was no significant difference in fasting levels of GIF between obese and 
lean subjects (Figures 7.17, 7.18 and 7.19).
Following the carbohydrate meal a rise in circulating concentrations of GIF 
was observed in both obese and lean subjects with the highest mean values occurring 
at 60 minutes in obese subjects and 90 minutes in lean subjects (Figure 7.17). There 
were no significant differences in either total or incremental integrated responses to 
the meal observed between obese and lean subjects (Figure 7.20).
Following ingestion of the fat meal there was a rise in the circulating 
concentrations of GIF observed in obese and lean subjects, with the highest mean 
values occurring at 60 minutes in obese subjects and at 45 minutes in lean subjects 
(Figure 7.18). There were no significant differences in either total or incremental 
integrated responses to the fat meal observed between obese and lean subjects (Figure 
7.20).
Infusion of octreotide led to a decrease in the fasting circulating concentrations 
(p<0.05) of GIF in obese and lean subjects (Figure 7.19).
Infusion of octreotide led to total suppression of the postprandial secretion 
profile of GIF (p<0.01) following the carbohydrate meal in obese and lean subjects. 
This was demonstrated by significantly lower total and incremental responses to the 
carbohydrate meal (p<0.01) in obese and lean subjects during infusion of octreotide 
(Figure 7.20). The incremental integrated response to the carbohydrate meal during 
infusion of octreotide was significantly different in obese compared with lean subjects
(p<0.01).
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Figure 7.20 Total and incremental areas under the curve for plasma GEP responses 
to Hycal, fat or Hycal during i.v. octreotide meals in lean and obese 
subjects (values denote mean ± S.E. (n=6)).
Bars with common superscript significantly different (p<0.01).
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7.3.6 GLP-1 (7-36) amide responses
The GLP-1 (7-36) amide responses are shown in Figures 7.21, 7.22 and 7.23 
with the values given in Appendix 5, Table 5.F. The total and incremental areas 
under the curve are shown in Figure 7.24.
There was no significant difference in fasting circulating concentrations levels 
of GLP-1 (7-36) amide observed between obese and lean subjects (Figures 7.21, 7.22 
and 7.23).
Following the carbohydrate meal a rise was observed in circulating 
concentrations of GLP-1 (7-36) amide in both obese and lean subjects (Figure 7.21). 
The highest mean values occurred at 15 minutes in obese subjects and 90 minutes in 
lean subjects. Obese subjects exhibited a diminished response to the carbohydrate 
meal compared with lean subjects (p<0.01) determined by comparing incremental 
integrated response for the two sets of subjects (Figure 7.24). Due to wide variation 
in fasting concentrations of GLP-1 (7-36) amide Bartletts Fmax test analysis
of variance of the total integrated area under the curve showed the variances were not 
homogeij^us. The situation was not improved by log or square-root transformations 
of the data and so Duncan’s range test could not be reliably used on this set of data.
Following ingestion of the fat meal both obese and lean subjects exhibited a 
small rise in circulating concentrations of GLP-1 (7-36) amide with highest mean 
values occurring at 45 minutes (Figure 7.22). There was no significant difference in 
the response of the two sets of subjects to this meal but incremental integrated 
response of lean subjects was lower than the response they exhibited to the 
carbohydrate meal (p<0.05). A marked reduction in circulating concentrations of 
GLP-1 (7-36) amide was observed in samples following administration of heparin at 
120 minutes (p<0.01 for both sets of subjects when compared with 135 minute 
sample).
The infusion of octreotide did not result in decreased fasting concentrations of 
GLP-1 (7-36) amide in either obese or lean subjects. However, octreotide infusion led 
to suppression of the postprandial response to the carbohydrate meal in both obese and 
lean subjects (Figure 7.23). The incremental integrated response to the carbohydrate 
meal was reduced with octreotide infusion for lean subjects (p<0.01) but no significant
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Figure 7.24 Total and incremental areas under the curve for plasma GLP-1 
responses to Hycal, fat or Hycal during i.v. octreotide meals in lean 
and obese subjects (values denote mean ± S.E. (n=6)).
Bars with common superscript (uppercase) are significantly different 
(p<0.01).
Bars with common superscript (lowercase) are significantly different 
(p<0.05).
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reduction was observed in obese subjects. Again, there was a marked reduction in 
circulating GLP-1 (7-36) amide concentrations following administration of heparin at 
120 minutes following the meal. In obese subjects this reached significance at 135 
minutes (15 minutes after heparin administration) (p<0.01) and in lean subjects at 150 
minutes (30 minutes after administration of heparin (p<0.05).
7.3.7 Lipoprotein lipase responses
The lipoprotein lipase activity measurements are shown in Figures 7.25, 7.26 
and 7.27 with the values given in Appendix 5, Table 5.G.
Following the administration of heparin there was a rise in lipoprotein lipase 
activity measurements in plasma samples which was observed in both sets of subjects 
and following all three meals.
There were no significant differences in post-heparin plasma lipoprotein lipase 
activity between obese and lean subjects following the carbohydrate meal (Figure 
7.25).
The lean subjects appeared to have lower levels of lipoprotein lipase activities 
following the fat meal but this was not found to be statistically significant (Figure 
7JKX
Infusion of octreotide did not suppress post-heparin plasma lipoprotein lipase 
activity in either obese or lean subjects (Figure 7.27).
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7.4 DISCUSSION
7.4.1 Glucose responses
The glucose responses to the carbohydrate meal were in agreement with 
previously published data both in magnitude and time of peak values (Hampton et al., 
1986; Nauck et al., 1986; Shuster et al., 1988; Tillil et al., 1988). The higher 
integrated responses to the carbohydrate meal demonstrated by the obese subjects 
indicates impaired glucose tolerance which is common in obesity (Bjomtorp et al., 
1971).
There was no change in plasma glucose response to ingestion of the fat meal 
in either obese or lean subjects. This would be expected since there are only very 
small amounts of carbohydrate, in the form of lactose, found in double cream.
The reduction of fasting glucose levels during the infusion of octreotide may 
be due to the inhibition of secretion of glucagon by octreotide. Both somatostatin 
(Schusdziarra, 1983) and octreotide (Creutzfeldt et al., 1987) have been shown to 
suppress glucagon secretion. In the fasting state glucagon is responsible for 
maintenance of circulating glucose concentrations by mobihsing glucose from 
glycogen stores. All subjects demonstrated glucose intolerance following the 
carbohydrate meal during infusion of octreotide. This effect is likely to be due to 
inhibition of insulin secretion.
7.4.2 Triglyceride responses
Obese subjects displayed elevated fasting circulating concentrations of 
triglycerides compared with lean subjects which is consistent with other studies 
(Nestel, 1978).
There were no changes in triglyceride concentrations in response to the 
carbohydrate meal in either set of subjects whether during infusion of octreotide or 
alone. This would be expected since the carbohydrate meal contains no fat. However, 
there was a significant reduction in measured concentrations of triglycerides in 
samples removed following the administration of the heparin bolus at 120 minutes
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following ingestion of the meal. Again, this observation would be expected as heparin 
causes elevated circulating concentrations of lipoprotein lipase as it is removed from 
the vascular endothelium. This results in hydrolysis of triglycerides both in vivo and 
in vitro, in the plasma samples. The greater total integrated response by obese 
subjects to the carbohydrate meal in the absence of octreotide would be expected and 
is likely to be due to the much higher basal levels of triglycerides observed in this set 
of subjects. This is reflected in the fact that there was no difference between the two 
sets of subjects in incremental integrated triglyceride responses to the carbohydrate 
meal. The greater incremental integrated triglyceride response observed in lean 
subjects following the carbohydrate meal during infusion of octreotide may be caused 
by the reduction of measured triglyceride levels in samples obtained after heparin 
administration. Therefore this difference is unlikely to be of physiological importance 
since it may have arisen through in vitro or in vivo hydrolysis of triglycerides by the 
action of lipoprotein lipase as a result of heparin administration.
It is interesting to note that there was no difference between the two sets of 
subjects in the total and incremental integrated triglyceride responses to the fat meal 
despite the higher basal circulating concentrations of triglyceride in obese subjects.
7.4.3 Insulin responses
IS
I^  well established that hyperinsulinaemia is common in obesity and the 
observation in the present study that obese subjects had higher fasting concentrations 
of insulin is in agreement with this (Karam, Grodsky and Forsham, 1963; Glass et aL, 
1981).
The insulin response to the ingestion of the carbohydrate meal in lean subjects 
is in agreement with previous reports (Hampton et aL, 1986; Nauck et at., 1986; 
Shuster et ai, 1988; Tillil et al., 1988) as are greater total and incremental integrated 
insuhn responses to the carbohydrate meal in obese subjects (Polonsky et al., 1988). 
The pathophysiological mechanisms of hyperinsulinaemia in obesity remain to be 
elucidated. In the fasting state elevated levels appear to depend on hypersecretion of 
insulin by the pancreatic B-cell, whilst postprandial hyperinsulinaemia following a
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carbohydrate load appears to be related to reduced hepatic insulin extraction in 
addition to hypersecretion (Bonora et aL, 1984).
Ingestion of the carbohydrate meal during infusion of octreotide led to 
suppression of the postprandial insulin profile. This in turn would be responsible for 
the reduction of glucose tolerance observed in both groups of subjects. It is already 
well established that somatostatin (Schusdziarra, 1983) and octreotide (Creutzfeldt et 
aL, 1987) suppress the secretion of insulin. The small rise in insulin levels observed 
towards the end of the postprandial sampling period in obese subjects (Figure 7.11) 
may be due to the fact that glucose levels had become very high (Figure 7.3); giving 
a much stronger stimulus to the pancreatic B-cell to secrete insulin and thus overriding 
the depressive effect of octreotide. This was more pronounced in obese subjects as 
the total and incremental insulin responses to the meal were higher in obese subjects 
than in lean subjects. It is reasonable to speculate that, since there was no significant 
difference in the glucose concentrations at this time, either the pancreatic B-cells are 
more sensitive to glucose stimulation or that the circulating concentrations of 
octreotide reached were lower in obese subjects as a consequence of using the same 
dose of octreotide. A fixed dose of octreotide for all subjects was selected that would 
totally suppress secretion of insulin and GIP as opposed to adjusting the dose for 
bodyweight since obese subjects would not have correspondingly increased blood 
volume. Circulating concentrations of octreotide were not measured in the present 
study and so the explanation for this increase in insulin secretion in obese subjects 
during octreotide infusion is not clear.
Following the fat meal there was a slight elevation of mean circulating insulin 
concentrations between 15 and 60 minutes in obese subjects but not in lean subjects. 
This may relate to the absorption of the small amount of carbohydrate present in 
double cream in the form of lactose, consistent with increased pancreatic B-cell 
sensitivity in obese subjects as suggested above.
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7.4.4 C-peptide responses
The fasting circulating concentrations of C-peptide in this study are consistent 
with similar comparisons in lean and obese subjects (Bonora et aL, 1990) where obese 
subjects also exhibited elevated fasting values implying increased insulin secretion.
The postprandial secretion profile of C-peptide was consistent with previous 
reports (Hampton et aL, 1986; Nauck et aL, 1986; Shuster et aL, 1988). The higher 
total and incremental integrated C-peptide responses to the carbohydrate meal 
observed in obese subjects suggests that these subjects have an exaggerated pancreatic 
B-cell secretory response to a carbohydrate meal compared to lean subjects. This 
secretory profile was suppressed when the carbohydrate meal was ingested during 
infusion of octreotide. As was observed with the insulin response, circulating 
concentrations of C-peptide began to rise again after 60 minutes and this is probably 
due to the stronger stimulus of raised glucose levels overriding the inhibitory effect 
of the octreotide on the pancreatic B-cell. As with the carbohydrate meal ingested 
alone, obese subjects exhibited greater integrated responses than lean subjects to the 
carbohydrate meal ingested during infusion of octreotide, indicating a greater 
pancreatic B-cell response. These results suggest that elevated insulin responses in 
obese subjects result from increased secretion and not from reduced hepatic extraction 
of insulin.
As seen with the insulin responses to the fat meal there was a small but 
significant rise in C-peptide concentrations between 30 and 45 minutes in obese 
subjects. There was also a small rise in C-peptide concentrations at this time in the 
lean subjects which may be due to absorption of a small amount of carbohydrate, in 
the form of lactose, present in double cream. There was no corresponding rise of 
circulating insulin concentrations in lean subjects, which may be due to the longer 
half-life of C-peptide than insulin in plasma. The increased total but not incremental 
integrated C-peptide responses to this meal in obese subjects reflects the difference in 
basal concentrations.
205
7.4.5 GIP responses
The results obtained in the present study support earlier suggestions that GIP 
is not involved in the postprandial hyperinsulinaemia of obesity (Lauritsen, 
Christensen and Stockholm, 1980; Amland et aL, 1984; Morgan et aL, 1992).
There is some discrepancy in reported fasting circulating concentrations of GIP 
but values obtained in the present study are in agreement with several authors (Kuzio 
et aL, 1974; Krarup, Holst and Larsen, 1985; Hampton et aL, 1986). Other authors 
have reported higher fasting values (Cleator and Gourlay, 1975; Nauck et aL, 1986) 
and others lower (Shuster et aL, 1988) in obese subjects. The observation that there 
was no significant difference between fasting concentrations of GIP in obese compared 
to lean subjects is in agreement with previously reported data (Lauritsen, Christensen 
and Stockholm, 1980; Amland et aL, 1984; Morgan et aL, 1992).
The magnitude and profile of GIP responses to the carbohydrate meal was 
consistent with previously reported studies (Kuzio et aL, 1974; Cleator and Gourlay, 
1975; Hampton et aL, 1986; Nauck et aL, 1986) and there were no differences 
observed between obese and lean subjects. Ingestion of the carbohydrate meal during 
the infusion of octreotide led to total suppression of GIP secretion in both obese and 
lean subjects. This was expected as it is already well established that somatostatin 
(Schusdziarra, 1983) and octreotide (Creutzfeldt et aL, 1987) suppress secretion of 
GIP.
The profile of the GIP response to the fat meal was similar to previous studies 
(Cleator and Gourlay, 1975) with peak values occurring around 30-45 minutes and 
concentrations remaining elevated for the duration of the postprandial sampling period. 
Again no differences were found in responses to the fat meal between obese and lean 
subjects.
7.4.6 GLP-1 (7-36) amide responses
The results from this study show a lower GLP-1 (7-36) amide response to the 
ingestion of a carbohydrate meal in obese compared with lean subjects. This suggests
206
that GLP-1 (7-36) amide, like GIP, is not involved in the postprandial 
hyperinsulinaemia of obesity.
There has only been one previous report of GLP-1 concentrations in obesity. 
Obese subjects were reported to exhibit higher circulating concentrations of GLP-1 
than lean controls following a carbohydrate meal (Fukase et aL, 1993). The 
discrepancy between these results and those obtained in the present study may be due 
to the assays used to determine GLP-1 levels. The assay used in the present study 
utilises an antiserum that has been raised against the amidated C-terminal and so 
reacts 100% with GLP-1 (7-36) amide and equally with GLP-1 (1-36) amide via the 
C-terminal amide. The assay used by Fukase et al. (1993) measured GLP-1 (7-36) 
amide and GLP-1 (7-37) by difference in values obtained using antisera directed at the 
N-terminal and C-terminal of GLP-1 (1-37). It is possible that the increase in 
circulating GLP-1 by these authors could be due to an increase in GLP-1 (7-37) since 
their assays are unable to distinguish between this form and GLP-1 (7-36) amide. 
Results from the present study showed a decrease in the GLP-1 (7-36) amide levels.
"This could be as a result of impaired secretion of GLP-1 in the obese state or possibly 
impairment of amidation of GLP-1 which occurs in the intestine and to a lesser extent 
the pancreas (Mojsov, Kopczynski and Habener, 1990). The amidation has been 
demonstrated not to be a mechanism that regulates biological activity since both GLP- 
1 (7-36) amide and GLP-1 (7-37) are equally potent at increasing circulating 
concentrations of insulin and C-peptide in man (0rskov, Wettergren and Holst, 1993) 
and these authors concluded that the C-terminal amidation is not important for its 
effects on the endocrine pancreas. It would therefore be interesting to compare 
circulating levels of GLP-1 (7-36) amide and GLP-1 (7-37) in lean and obese subjects 
in an attempt to explain these discrepancies.
This observation of lower circulating GLP-1 (7-36) amide levels in the plasma 
of obese subjects suggests a possible role of this hormone as a satiety factor in 
humans. Overfeeding is known to cause obesity in man (Danforth, 1985) but the 
study of human eating behaviour is complex (Pudel, 1978). Despite a great deal of 
research in this area the exact mechanisms regulating food intake in animals and in 
man remain to be elucidated. It has been reported that the brain contains GLP-1 (7- 
36) amide in the hypothalamus (Kreymann et aL, 1989) which is known to be
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important in the control of food in t^e (Woods and Gibbs, 1989). The same group 
of workers have also demonstrated the presence of specific receptors for GLP-1 (7-36) 
amide in the central nervous system (Kanse et aL, 1988). The localisation of GLP-1 
(7-36) amide within the hypothalamus has not been ascertained. Therefore, the 
involvement of the ventromedial hypothalamus, which is a centre associated with the 
control of food intake, is not yet confirmed. A recent study in rats has demonstrated 
that intracerebroventricular injection of GLP-1 (7-36) amid^resulted in increased food 
intake compared with animals injected with non-immune serum (Lambert, et aL, 
1993). The results from the present study support a role for GLP-1 (7-36) amide in 
the control of voluntary food intake in man.
A recent report found that infusion of GLP-1 (7-36) amide into normal and 
diabetic subjects resulted in improved glucose tolerance through increased glucose 
transport (Gutniak et aL, 1992). The lower circulating concentrations of GLP-1 (7-36) 
amide observed in the present study may be important in the impaired glucose 
tolerance and the insulin resistance of obesity. Therefore, lower circulating 
concentrations of GLP-1 (7-36) amide in obese subjects may contribute to the 
hyperinsulinaemia of obesity by perpetuating insulin resistance.
The possibility that decreased concentrations of circulating GLP-1 (7-36) amide 
result from increased catabolism of the peptide in the body in obese subjects cannot 
be ruled out. A recent study showed that in healthy subjects the rates of metabolism 
of GLP-1 (7-36) amide and GLP-1 (7-37) were identical (0rskov, Wettergren and 
Holst, 1993). Whether the rates of catabolism are affected in the obese state remains 
unknown. The kidney has been shown to be an important site in catabolism of GLP-1 
(Ruiz-Grande et aL, 1990) and it is possible that in the obese state the rate of 
catabolism of the peptide could be elevated, resulting in lower circulating 
concentrations.
The small reduction in circulating GLP-1 (7-36) amide levels following the 
administration of heparin may be due to a physiological effect of heparin by directly 
inhibiting GLP-1 (7-36) amide secretion or via the resulting elevated levels of free 
fatty acids in the plasma. Free fatty acid concentrations were not measured in the 
present study but presence of lipoprotein lipase in the circulation as a result of heparin 
administration is known to result in increased concentrations of fatty acids (Eckel,
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1989). Circulating concentrations of fatty acids are known to be elevated in obesity 
(Bjomtorp, Bergman and Vamauskas, 1969) but the effect on GLP-1 (7-36) amide 
secretion has not been investigated. In the light of the observation of decreased 
circulating concentrations of GLP-1 (7-36) amide in response to heparin 
administration, investigation of the possible effects of free fatty acids on GLP-1 (7-36) 
amide secretion may shed light on the mechanism by which concentrations are 
reduced in obesity. A recent study has reported that infusion of GLP-1 (7-36) amide 
in healthy subjects resulted in decreased circulating concentrations of free fatty acids 
(0rskov, Wettergren and Holst, 1993). This effect may be linked to the hormone’s 
ability to improve glucose tolerance (Gutniak et aL, 1992).
The possibility that heparin present in the plasma samples interferes in the 
assay for GLP-1 (7-36) amide, by affecting the antibody binding, also requires further 
investigation. This is however less likely to be the explanation for the observed 
reduction in GLP-1 (7-36) amide concentrations since highest amounts of heparin 
would be observed in samples taken 5 minutes following heparin administration at 120 
minutes. In fact, lowest concentrations of GLP-1 (7-36) amide were seen at 15 or 30 
minutes following heparin administration.
7.4.7 Lipoprotein lipase responses
In the present study no difference in post-heparin lipoprotein lipase activity 
was detected either between obese and lean subjects or in response to ingestion of 
different meals. Neither did the attenuation of gastrointestinal hormone and insulin 
secretion by octreotide affect the post-heparin plasma lipoprotein lipase activity. A 
previous study has shown fasting post-heparin lipoprotein lipase activity to be similar 
in obese and lean subjects (Taskinen and Nikkila, 1977).
Previous studies have reported higher levels of lipoprotein lipase activity in 
obese subjects when measured in adipocytes or adipose tissue pieces. This has led to 
some confusion over the expression of the results. Studies using isolated adipocytes 
where results are expressed per cell have shown increased lipoprotein lipase activity 
in obese subjects (Pykalistd, Smith and Brunzell, 1975; Taskinen and Nikkila, 1977; 
Schwartz and Brunzell, 1978). When lipoprotein lipase activity is expressed per unit
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mass of adipose tissue then it was found to decrease with increasing obesity (Persson, 
1973) or to be similar in obese and lean subjects (Taskinen and Nikkila, 1977). This 
discrepancy could be explained by the fact that fat cells are larger in obese subjects 
and so there would be fewer per unit mass of adipose tissue in the obese subjects 
which could then mask any changes in lipoprotein lipase production by adipocytes 
from obese subjects. This has also been shown in studies where the activity was 
expressed in both terms (Pykalistd, Smith and Brunzell, 1975; Taskinen and Nikkila, 
1977; Bjomtorp et aL, 1975). A positive correlation between fat cell size and 
lipoprotein lipase activity per adipocyte has been demonstrated (Taskinen and Nikkila, 
1977; Bjomtorp et aL, 1975). By estimating total body fat in conjunction with 
lipoprotein lipase activity measurements per adipocyte and per weight of adipose 
tissue, it has been shown that obese subjects have higher amounts of lipoprotein lipase 
and therefore a higher capacity to store triglyceride (Taskinen and Nikkila, 1977).
Determination of lipoprotein lipase in isolated adipocytes does not include the 
lipoprotein lipase that is bound to the vascular endothelium. The determination of 
lipoprotein lipase in post-heparin plasma obviously indicates the amount of enzyme 
bound to the vascular endothelium but this measurement may include lipoprotein 
lipase derived from muscle. It is possible that the lipoprotein lipase activity in muscle 
is decreased in obese subjects therefore resulting in inappropriately low measurements 
of post-heparin lipoprotein lipase activity. It is therefore necessary to assess the 
functional importance of the various techniques available to measure lipoprotein lipase 
activity in order to determine which represents the pool of enzyme responsible for the 
accumulation of triglyceride in adipose tissue.
Post-heparin plasma lipoprotein lipase activity was measured two hours 
postprandially in the present study, approximately 1.5 hours after peak responses of 
insulin, GIP and GLP-1 (7-36) amide to a meal. If these hormones are involved in 
the post-prandial control of lipoprotein lipase activity, any post-translational changes 
in lipoprotein lipase would be expected to have occurred at this time. A previous 
investigation showed adipose tissue lipoprotein lipase activity to reach a maximum 
two hours following a carbohydrate meal (Nilsson-Ehle, Carlstrom and Belfrage, 
1975). However, this increase may not necessarily be reflected in post-heparin plasma
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lipoprotein lipase and there has been some recent evidence suggesting that pre-heparin 
lipoprotein lipase activity peaks six hours following a fat meal (Karpe et aL, 1992).
GIP has been shown to stimulate the activity of lipoprotein lipase in rat 
adipocytes in culture (Eckel, Fujimoto and Brunzell, 1979), in extracts of rat adipose 
tissue (Oben et aL, 1991c) and to stimulate heparin-releasable lipoprotein lipase 
activity in explants of rat adipose tissue (Knapper et aL, 1993).
In the present study, infusion of octreotide which largely abolished postprandial 
hormone secretory profiles did not lead to suppression of post-heparin plasma 
lipoprotein lipase activity.
There is continuing uncertainty about which measurement of lipoprotein lipase 
should be taken as representing the functional enzyme. This probably reflects the 
uncertainty surrounding the regulation of the activity of this enzyme and in particular 
its transport from the adipocyte to the vascular endothelium. Once the mechanisms 
and significance of the regulation of this process has been identified and assessed it 
may be possible to assess which approach or combination of approaches to the 
measurement of the activity of the enzyme are most appropriate for determining the 
deposition of triglycerides in adipose tissue.
In summary, the results from this study confirm the hyperlipidaemia, 
hyperinsulinaemia and increased C-peptide levels associated with obesity. GIP was 
not shown to be involved in hyperinsulinaemia of obesity. The carbohydrate- 
stimulated postprandial GLP-1 (7-36) amide responses were attenuated in obese 
compared with lean subjects suggesting that this hormone is also not responsible for 
the hyperinsulinaemia of obesity. There were no differences observed in post-heparin 
plasma lipoprotein lipase activity between obese and lean subjects, nor were there 
differences observed in response to different meal types. Octreotide suppressed the 
secretion of insulin, C-peptide GIP and GLP-1 (7-36) amide but was again without 
effect on postprandial post-heparin plasma lipoprotein lipase activity. This may reflect 
lipoprotein lipase activity in adipose tissue and its lack of response to hormonal 
influences over the time scales measured, but other factors may be involved. The 
negative findings may be related to the contribution of lipoprotein lipase from muscle 
masking differences between the two groups of subjects. Decreased concentrations 
of GLP-1 (7-36) amide may perpetuate insulin resistance and glucose intolerance. The
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lower concentrations of GLP-1 (7-36) amide observed in obese subjects have been 
adduced in evidence to support the suggestion that this hormone may have a role in 
the control of satiety in humans.
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CHAPTER 8
GENERAL DISCUSSION
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The principal objective of these studies, outlined in Chapter 1, was to examine 
whether gastrointestinal hormones have a role to play in deposition and mobilisation 
of lipids in adipose tissue. Various gastrointestinal hormones were tested in vitro to 
examine control of fatty acid synthesis and lipolysis in rat adipose tissue, and 
lipoprotein lipase activity in both rat adipose tissue and human adipose tissue obtained 
from needle biopsies. The hormonal effects on fatty acid synthesis were assessed in 
vitro after in vivo dietary manipulation of circulating hormone concentrations by 
altering the composition of dietary oil and dietary fibre in rats. Finally the in vivo 
role of gastrointestinal hormones in the control of heparin-releasable lipoprotein lipase 
in lean and obese human volunteers was compared by blocking hormonal secretion by 
administering the long lasting somatostatin analogue. Octreotide. Circulating 
concentrations of GIP and GLP-1 (7-36) amide in lean and obese subjects were also 
compared in this study in order to assess whether these hormones are involved in the 
hyperinsulinaemia of obesity.
The role of gastrointestinal and pancreatic hormones in fatty acid synthesis and 
lipolysis was evaluated in vitro using explants of rat epididymal adipose tissue. Prior 
reports of stimulatory effects of GIP on fatty acid synthesis and lipoprotein lipase 
activity in rats were not supported by these data. The reasons for this are not clear 
in spite of considerable investigation. Possible explanations are that there were batch 
differences in the source of GIP used, or degradation of GIP in the medium. It is 
possible that the lipogenic effect of GIP resulted from a ‘permissive’ effect, maybe 
on glucose transport into adipocytes. It has already been established that GIP can 
stimulate transport of glucose into rat adipocytes (Stanch, Bar and Mazzaferri, 1985; 
Hauner et at., 1988) and GLP-1 (7-36) amide also can stimulate glucose transport 
(Gutniak et aL, 1992), and conceivably this mechanism has contributed to the 
observed lipogenic effect of GIP in previous studies. GLP-1 (7-36) amide and 
somatostatin-14 were also found to be without effect on either fatty acid synthesis or 
lipolysis.
However, some gastrointestinal hormones were shown to modulate metabolic 
activity in adipose tissue. Secretin displayed the most pronounced effects on lipolysis 
especially in combination with insulin, suggesting a role for secretin in the 
mobilisation of lipids. Postprandial secretion of secretin would therefore appear to
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have no physiological role in lipid deposition. Elevated concentrations of secretin 
have been reported in response to prolonged fasting (Henry, Flanagan and Buchanan, 
1975) and strenuous exercise (Oktedalen, Opstad and Schaffalitzky de Muckadell, 
1983) when the body requires mobilisation of energy stores. The action of secretin 
is unlikely to be mediated via the glucagon receptor since in the present study insulin 
was found to inhibit glucagon-stimulated lipolysis but to enhance secretin-stimulated 
lipolysis. This is supported by reports that secretin does not displace glucagon from 
adipocyte membrane receptors (Bataille, Freychet and Rosselin, 1974). Further 
investigation to ascertain whether this effect is of physiological importance is required. 
Additionally, the activation of hormone-sensitive lipase by secretin needs to be 
demonstrated using secretin concentrations within the physiological range observed 
during fasting or after strenuous exercise.
Other results indicate a role for neurotensin and GLP-2 in stimulation of fatty 
acid synthesis although observed effects were small compared to those of insulin, and 
further investigations into the actual concentrations in the incubation medium should 
confirm whether the effects are of physiological importance. The demonstration of 
control of fatty acid synthesis by GLP-2 is of particular interest since no biological 
effects of this peptide have previously been demonstrated outside the brain and yet it 
is secreted in significant quantities together with GLP-1. This synergistic effect could 
be of physiological importance since GLP-2 would be secreted concomitantly with 
insuhn. The precise mechanism of action is not clear but future studies should assess 
the effect of GLP-2 on glucose transport by adipocytes, on binding of insulin to 
adipocyte membrane receptors and on activation of acetyl CoA carboxylase.
Peptide YY was shown to exert weak lipolytic effects. When administered 
alone or in conjunction with insulin, the peptide enhanced the rate of lipolysis whereas 
it significantly reduced glucagon-stimulated lipolysis. These conflicting observations 
suggest that peptide YY has more than one site of action in control of lipolysis. It 
would therefore be valuable to assess the action of peptide YY on hormone-sensitive 
lipase activity in adipocytes.
Effects of other hormones were small and occurred at high concentrations and 
therefore are unlikely to be of physiological importance. However, this should be 
verified by monitoring actual concentration of peptides in the culture medium.
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However, as these hormones are secreted simultaneously in response to a meal 
investigation of the additive effects would be valuable.
For a more complete assessment of the role of these peptides in fat deposition 
it would be useful to assess whether these hormones control lipoprotein lipase activity 
in vitro, A limited study to confirm GIF stimulation of heparin-releasable lipoprotein 
lipase activity in rat adipose tissue was unsuccessful and this could, as with the 
absence of an effect on fatty acid synthesis, result from degradation of the hormone 
in the medium or from a ‘permissive’ effect of the hormone. A preliminary 
investigation into the effect of secretin on heparin-releasable lipoprotein lipase 
suggested that the hormone decreases the activity of this enzyme in rat adipose tissue, 
consistent with the proposed action of secretin in mobilising lipids for energy. 
Possible actions of other gastrointestinal hormones on lipoprotein lipase activity could 
be investigated by measuring heparin-releasable lipoprotein lipase from explants of rat 
adipose tissue. In vivo investigation of control of lipoprotein lipase activity could be 
performed by monitoring incorporation of labelled dietary lipids into adipose depots 
to assess functional lipoprotein lipase activity.
Catecholamines are known to reduce lipogenesis (Halestrap and Denton, 1974) 
and to stimulate lipolysis (Hales, Luzio, and Siddle, 1978). Insulin is the only 
hormone with an antilipolytic effect of any quantitative significance in mammals and 
has been shown to inhibit catecholamine- and hormone-stimulated lipolysis (Denton, 
Brownsey and Belsham, 1981). It was unexpected, therefore, that insulin appeared to 
potentiate the lipolytic effect of isoproterenol in explants of rat adipose tissue. The 
reason for this effect is not clear but recent reports suggest that exposure of adipocytes 
to insulin can result in an increase in receptor numbers for catecholamines (Maynard 
et al.y 1992). Chronic exposure of adipose tissue to insulin alone can result in 
elevated rates of lipolysis and higher activity of hormone-sensitive lipase (Kang et al., 
1993). Results obtained from this study are consistent with these reports.
Investigations into the effects of manipulation of dietary composition showed 
significant effects on hormonal sensitivity of adipose tissue. Ingestion of a diet 
containing 5% fish oil (w/w) by rats resulted in lower rates of hepatic cholesterol 
synthesis and in reduced circulating triglycerides accompanied by a reduced rate of 
hepatic triglyceride production; rats fed a mixed oil diet (replicating UK fatty acid
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intake) exhibited elevated circulating concentrations of insulin (Zampelas, 1993). 
Rates of basal and insulin-stimulated fatty acid synthesis in rat adipose tissue were 
however found to be higher in the fish oil-fed group than the other two groups. This 
was suggested to be due to incorporation of co-3 polyunsaturated fatty acids from the 
dietary fish oil into the membrane phospholipids with possible consequent changes in 
membrane fluidity, resulting in changes in insulin sensitivity of the adipocytes. This 
is supported by reports that alterations in fatty acid composition of cell membranes of 
hepatocytes reflect dietary fatty acid composition (Strum-Odin et al., 1987), that the 
proportion of polyunsaturated fatty acids in cell membranes leads to changes in 
fluidity of plasma membranes (Wahle, 1983), and that insulin receptor function is 
affected by changes in membrane fluidity (Tepperman and Tepperman, 1985). These 
observed changes in hormone sensitivity in response to ingestion of co-3 fatty acids 
have implications for patterns of body fat distribution in populations eating large 
amounts of fish oil, such as Eskimos.
The results of these dietary studies demonstrate a role for modification of 
dietary fatty acid composition in control of deposition and mobihsation of lipids in 
adipose tissue. The increase in insulin sensitivity of the adipose tissue may be 
mediated by alterations in the phospholipid composition of cell membranes consequent 
to the incorporation of co-3 polyunsaturated fatty acids from dietary fish oil.
Having established that dietary inclusion of fish oil influences fatty acid 
synthesis in adipose tissue, it would be useful to investigate whether lipolysis and 
lipoprotein lipase activity are also affected. A similar dietary study should be utilised 
to assess basal and glucagon-stimulated rates of lipolysis and heparin-releasable 
lipoprotein lipase activity in explants of rat adipose tissue. This would lead to a more 
complete assessment of the effect of dietary co-3 polyunsaturated fatty acids on lipid 
deposition and mobilisation in adipose tissue. In order to confirm the mechanism for 
the action of dietary 0)-3 polyunsaturated fatty acids, the fatty acid composition of 
adipocyte cell membranes should be compared together with assessment of insulin 
receptor binding by adipocyte plasma membranes.
An in vivo study using human volunteers investigated postprandial hormone 
secretion and lipoprotein lipase activity in lean and obese subjects in response to 
carbohydrate and fat meals. Hyperinsulinaemia was demonstrated in obese subjects
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but no alteration was seen in their postprandial GIF responses and GLP-1 (7-36) amide 
responses were unaltered or attenuated compared to lean subjects. These studies show 
that neither GIF nofGLF-1 (7-36) amide can contribute to the hyperinsulinaemia of 
obesity. These results support the hypothesis that GIF does not contribute to the 
hyperinsulinaemia of obesity (Lauritsen, Christensen and Stockholm, 1980; Amland 
et al., 1984; Morgan et a l, 1992) In addition the results contradict a previous report 
of elevated GLF-1 (7-36) amide in obesity (Fukase et al., 1993). There were also no 
differences found in post-heparin plasma lipoprotein lipase activity between obese and 
lean subjects, in response to either a carbohydrate or fat meal. Ingestion of the 
carbohydrate meal during administration of octreotide resulted in total suppression of 
insulin and GIF secretion but this was not associated with changes in post-heparin 
plasma lipoprotein lipase activity. These results suggest that elevated concentrations 
of insulin in obese subjects do not lead to increased lipoprotein lipase activity in these 
subjects within the time scale measured and that attenuation of insulin, GIF and GLF- 
1 (7-36) amide secretion by octreotide does not affect lipoprotein lipase activity. 
However, the functional importance of this particular measurement of lipoprotein 
lipase needs to be assessed as the regulation of activity of this enzyme is not fully 
elucidated.
The lower circulating concentrations of GLF-1 (7-36) amide found in obese 
subjects suggest the involvement of this hormone in the regulation of food intake, as 
a satiety factor. Further investigations into the control of food intake and development 
of satiety in humans are required in order to establish whether this effect is of 
physiological importance in the development of obesity in humans. In addition, future 
work should include comparison of circulating concentrations of GLF-1 (7-37) in 
obese and lean subjects to ascertain whether this peptide has a role in the 
hyperinsulinaemia of obesity.
In summary, these studies have shown that with the exceptions of insulin, 
glucagon and secretin, gastrointestinal and pancreatic hormones exert small effects on 
the control of lipid deposition and mobilisation in adipose tissue in vitro. 
Hyperinsulinaemia in obesity has been shown not to affect post-heparin plasma 
lipoprotein lipase in humans and the suppression of secretion of insulin, GIF and GLF- 
1 (7-36) amide by octreotide was similarly without effect on lipoprotein lipase activity.
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These studies taken together, suggest only a minor role for gastrointestinal hormones 
in adipose tissue metabolism. However, the overall effect of the postprandial co­
secretion of the vast array of gastrointestinal and pancreatic hormones is difficult to 
assess and there are undoubtedly additive effects which warrant further investigation. 
Dietary alterations have however been shown to result in changes in hormonal 
sensitivity of adipose tissue. In particular, inclusion of co-3 polyunsaturated fatty 
acids, in the form of fish oil, enhance the insulin sensitivity of adipose tissue in rats. 
GIF and GLF-1 (7-36) amide were shown not to contribute to the hyperinsulinaemia 
of obesity. However, the reduced circulating concentrations of GLF-1 (7-36) amide 
found in obese subjects following a carbohydrate load suggest that this hormone may 
have a role to play in postprandial satiety in humans.
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APPENDIX 1 Results from chapter 3: Effect of alterations in the fatty acid 
composition of dietary lipid on fatty acid synthesis in 
adipose tissue of rats.
Table l.A Circulating concentrations of cholesterol, triglycerides and insulin in 
rats fed diets containing fish, com or mixed oil (values denote mean 
with S.D. in parentheses (n=9)).
FISH OIL CORN OIL MIXED OIL
CHOLESTEROL
(mM)
1.11 (0.20) 1.20 (0.23) 1.18 (0.36)
TRIGLYCERIDES
(mM)
0.58 (0.19) 0.89 (0.36) 1.31 (0.74)
INSULIN
(nM)
0.33 (0.16) 0.45 (0.33) 2.11 (1.45)
Table l.B Basal and insulin-stimulated rates of incorporation of acetate into 
saponifiable fatty acids by explants of epididymal adipose tissue of rats 
fed diets containing fish, corn or mixed oil (values are given in nmol 
acetate incorporated per mg tissue per 2 hour incubation and denote 
mean with ± S.D. in parentheses (n=6)).
FISH OIL CORN OIL MIXED OIL
BASAL 2.23 (0.12) 1.34 (0.21) 1.49 (0.20)
INSULIN (2nM) 6.75 (1.00) 3.38 (0.49) 3.45 (0.46)
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APPENDIX 2 Results from chapter 4: Effect of dietary non-starch 
polysaccharide composition on fatty acid synthesis in rat 
adipose tissue.
Table 2.A Circulating concentrations of cholesterol and triglycerides in rats fed
diets containing cellulose, bran, guar or sugar beet fibre (values denote 
mean with ± S.D. in parentheses (n=10)).
CELLULOSE BRAN GUAR SBF
DIET DIET DIET DIET
CHOLESTEROL 1.48 1.47 1.10 1.26
(mM) (0.34) (0.15) (0.34) (0.21)
TRIGLYCERIDES 2.79 3.07 2.06 2.39
(mM) (0.41) (0.35) (0.17) (0.30)
Table 2.B Rates of basal and insulin-stimulated (2nM) incorporation of acetate 
into saponifiable fatty acids by explants of epididymal adipose tissue 
of rats fed diets containing cellulose, bran, guar or sugar beet fibre 
(values are given in nmol acetate incorporated/mg tissue per 2 hour 
incubation and denote mean with ± S.D. in parentheses (n=8)).
CELLULOSE
DIET
BRAN
DIET
GUAR
DIET
SBF
DIET
BASAL 0.28 (0.09) 0.45 (0.10) 0.58 (0.13) 0.40 (0.10)
INSULIN
(2nM)
0.50 (0.13) 0.68 (0.17) 0.90 (0.20) 0.67 (0.18)
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APPENDIX 3 Results from chapter 5: The effect of gastrointestinal
hormones on fatty acid synthesis and lipolysis in rat adipose 
tissue.
Table 3. A Effect of insulin, isoproterenol and glucagon on glycerol production by 
explants of rat epididymal adipose tissue (values denote mean with 
S.D. in parentheses (n=4) per 2 hour incubation).
HORMONE TREATMENT GLYCEROL PRODUCED 
(nmol/mg per incubation)
BASAL 3.82 (0.86)
ISOPROTERENOL (5pM) 16.90 (0.89)
ISOPROTERENOL (5pM) 
+
INSULIN (2nM)
28.67 (3.49)
GLUCAGON (2nM) 15.54 (2.50)
GLUCAGON (2nM) 
+
INSULIN (2nM)
10.12 (2.31)
INSULIN (2nM) 6.93 (0.89)
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Table 3.B Effect of insulin and glucagon on incorporation of acetate into 
saponifiable fats by explants of rat epididymal adipose tissue (values 
denote mean with S.D. in parentheses (n=13) per 2 hour incubation).
HORMONE TREATMENT ^^ C ACETATE INCORPORATION 
(nmol/mg per 2 hours)
BASAL 3.30 (2.33)
INSULIN (2nM) 14.75 (5.32)
GLUCAGON (4nM) 1.74 (1.12)
Table 3.C Effect of insulin and glucagon on glycerol production by explants of 
rat epididymal adipose tissue (values denote mean with S.D. in 
parentheses (n=13) per 2 hour incubation).
HORMONE TREATMENT ^^ C ACETATE INCORPORATION 
(nmol/mg per 2 hours)
BASAL 3.76 (1.77)
INSULIN (2nM) 5.00 (1.74)
GLUCAGON (4nM) 16.51 (4.47)
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Table 3.D Effect of GIP on incorporation of acetate into saponifiable fatty acids 
and on glycerol production by explants of rat epididymal adipose tissue 
(values denote mean with S.D. in parentheses (n=4) per 2 hour 
incubation).
CONDITIONS [GIP]
ACETATE
INCORP^
(nmol/mg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 3.40 (0.20) 3.37 (0.69)
4nM 2.88 (0.47) 3.93 (1.17)
40nM 3.50 (0.45) 3.31 (0.97)
400nM 3.52 (0.74) 3.39 (0.57)
INSULIN
(2nM)
OnM 14.10 (0.92) 5.01 (0.38)
4nM 15.22 (2.73) 4.82 (1.63)
40nM 15.01 (1.93) 4.18 (0.70)
400nM 16.53 (2.30) 4.33 (1.20)
GLUCAGON
(4nM)
OnM 1.60 (0.39) 17.72 (1.87)
4nM 1.46 (0.08) 19.14 (2.13)
40nM 1.47 (0.18) 17.46 (1.35)
400nM 1.48 (0.19) 19.22 (1.98)
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Table 3.E Effect of secretin on incorporation of acetate into fatty acids and 
glycerol production by explants of rat epididymal adipose tissue (values 
denote mean with S.D. in parentheses (n=4) per 2 hour incubation).
CONDITIONS [SECRETIN]
ACETATE
INCORF
(nmol/mg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 2.07 (0.19) 0.78 (0.63)
4nM 0.88 (0.06) 13.09 (1.74)
40nM 1.02 (0.10) 15.47 (2.67)
400nM 1.29 (0.19) 21.61 (2.13)
INSULIN
(2nM)
OnM 8.81 (1.08) 2.15 (0.70)
4nM 7.92 (0.42) 17.66 (0.85)
40nM 4.33 (0.28) 32.14 (5.29)
400nM 3.32 (0.29) 36.06 (3.84)
GLUCAGON
(4nM)
OnM 0.95 (0.24) 8.15 (1.97)
4nM 1.05 (0.09) 17.51 (1.93)
40nM 1.39 (0.19) 24.34 (1.29)
400nM 1.41 (0.14) 25.54 (3.47)
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Table 3.F Effect of GLP-1 (7-36) amide on incorporation of acetate into 
saponifiable fatty acids and glycerol production by explants of rat 
epididymal adipose tissue (values denote mean with S.D. in parentheses 
(n=4) per 2 hour incubation).
CONDITIONS [GLP-l(7-36) AMIDE]
ACETATE
INCORP^
(nmol/mg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 3.03 (0.44) 2.90 (1.32)
4nM 3.37 (0.75) 1.76 (1.76)
40nM 3.39 (0.16) 1.40 (0.95)
40nM 3.72 (0.80) 6.17 (1.44)
INSULIN 
. (2nM)
OnM 17.01 (3.98) 5.57 (3.43)
4nM 15.36 (2.28) 2.76 (0.35)
40nM 15.50 (2.77) 2.65 (1.08)
400nM 15.81 (2.36) 4.24 (4.19)
GLUCAGON
(4nM)
OnM 1.14 (0.19) 17.30 (1.63)
4nM 1.10 (0.09) 19.36 (4.44)
40nM 1.25 (0.23) 18.80 (0.43)
400nM 0.94 (0.08) 17.75 (5.13)
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Table 3.G Effect of GLP-1 (7-37) on incorporation of acetate into saponifiable 
fatty acids and glycerol production by explants of rat epididymal 
adipose tissue (values denote mean with S.D. in parentheses (n=4) per 
2 hour incubation).
CONDITIONS [GLP-1 (7-37)]
ACETATE
INCORP^
(nmol/mg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 1.17 (0.17) 3.15 (1.85)
4nM 1.17 (0.12) 3.59 (1.92)
40nM 1.11 (0.12) 4.92 (3.26)
400nM 1.31 (0.23) 3.79 (0.68)
INSULIN
(2nM)
OnM 9.45 (0.80) 2.83 (0;56)
4nM 10.47 (2.17) 6.23 (3.22)
40nM 10.31 (1.23) 6.83 (2.44)
400nM 11.17 (0.55) 8.89 (1.65)
GLUCAGON
(4nM)
OnM 0.89 (0.17) 22.00 (2.22)
4nM 1.20 (0.24) 25.88 (4.12)
40nM 0.96 (0.13) 25.59 (1.49)
400nM 0.96 (0.22) 23.85 (2.22)
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Table 3.H Effect of GLP-1 (1-37) on incorporation of acetate into saponifiable 
fatty acids and glycerol production by explants of rat epididymal 
adipose tissue (values denote mean with S.D. in parentheses (n=4) per 
2 hour incubation).
CONDITIONS [GLP-1 (1-37)]
ACETATE
INCORP^
(nmol/mg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 2.35 (0.33) 3.87 (0.69)
4nM 3.02 (0.33) 5.73 (1.96)
40nM 2.28 (0.23) 6.34 (0.93)
400nM 2.84 (0.39) 5.35 (1.12)
INSULIN
(2nM)
OnM 13.82 (1.28) 5.49 (1.87)
4nM 13.43 (0.65) 7.09 (0.86)
40nM 13.19 (2.28) 6.75 (1.19)
400nM 13.22 (1.54) 6.83 (1.81)
GLUCAGON
(4nM)
OnM 1.50 (0.06) 15.31 (1.82)
4nM 1.33 (0.15) 17.26 (1.64)
40nM 1.33 (0.15) 14.23 (3.05)
400nM 1.47 (0.33) 22.28 (2.62)
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Table 3.1 Effect of GLP-2 on incorporation of acetate into saponifiable fatty 
acids and glycerol production by explants of rat epididymal adipose 
tissue (values denote mean with S.D. in parentheses (n=4) per 2 hour 
incubation).
CONDITIONS [GLP-2]
ACETATE
INCORP^
(nmol/mg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 3.49 (0.37) 4.51 (1.57)
4nM 3.67 (0.35) 5.80 (1.15)
40nM 3.54 (0.41) 5.84 (1.73)
400nM 4.06 (0.53) 5.22 (0.54)
INSULIN
(2nM)
OnM 10.70 (0.71) 7.49 (1.33)
4nM 12.80 (1.88) 7.80 (1.66)
40nM 14.34 (1.27) 9.27 (1.69)
400nM 13.90 (2.40) 8.87 (1.06)
GLUCAGON
(4nM)
OnM 1.98 (0.31) 19.55 (2.65)
4nM 2.14 (0.31) 19.32 (1.89)
40nM 2.44 (0.06) 17.61 (3.22)
400nM 2.47 (0.30) 23.37 (3.12)
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Table 3 J Effect of oxyntomodulin on incorporation of acetate into saponifiable 
fatty acids and glycerol production by explants of rat epididymal 
adipose tissue (values denote mean with S.D. in parentheses (n=4) per 
2 hour incubation).
CONDITIONS [OXYNTOMODULIN]
ACETATE
INCORP^
(nmol/mg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 1.99 (0.24) 5.14 (0.87)
4nM 2.47 (0.31) 7.78 (3.84)
40nM 2.54 (0.37) 7.29 (4.20)
400nM 2.36 (0.12) 5.27 (0.19)
INSULIN
(2nM)
OnM 15.79 (2.89) 5.25 (1.33)
4nM 17.14 (1.64) 8.75 (2.22)
40nM 17.78 (2.79) 10.09 (4.12)
400nM 16.93 (1.83) 8.74 (1.71)
GLUCAGON
(4nM)
OnM 1.46 (0.17) 16.83 (1.57)
4nM 1.61 (0.13) 24.83 (2.34)
40nM 1.51 (0.05) 22.60 (2.02)
400nM 1.36 (0.12) 27.15 (9.66)
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Table 3.K Effect of somatostatin-14 on incorporation of acetate into saponifiable 
fatty acids and glycerol production by explants of rat epididymal 
adipose tissue (values denote mean with S.D. in parentheses (n=4) per 
2 hour incubation).
CONDITIONS [SOMATOSTATIN-14]
ACETATE
INCORP^
(nmol/mg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 2.05 (0.14) 3.68 (1.34)
4nM 2.07 (0.15) 3.56 (0.99)
40nM 2.16 (0.26) 3.39 (0.29)
400nM 1.96 (0.25) 4.78 (1.22)
INSULIN
(2nM)
OnM 12.52 (0.61) 5.04 (1.13)
4nM 11.14 (2.74) 4.61 (0.83)
40nM 10.33 (3.17) 3.94 (1.28)
400nM 12.45 (0.99) 4.84 (0.34)
GLUCAGON
(4nM)
OnM 1.42 (0.35) 20.95 (2.28)
4nM 1.53 (0.14) 21.20 (2.49)
40nM 1.66 (0.21) 19.96 (3.16)
400nM 1.63 (0.18) 19.30 (1.14)
264
Table 3.L Effect of somatostatin-28 on incorporation of acetate into saponifiable 
fatty acids and glycerol production by explants of rat epididymal 
adipose tissue (values denote mean with S.D. in parentheses (n=4) per 
2 hour incubation).
CONDITIONS [SOMATOSTATIN-28]
ACETATE
INCORP^
(nmol/mg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 1.41 (0.13) 4.13 (1.62)
4nM 1.37 (0.30) 4.42 (1.57)
40nM 1.51 (0.10) 4.68 (1.52)
400nM 1.54(0.17) 5.65 (2.59)
INSULIN
(2nM)
OnM 12.17 (0.67) 6.36 (0.68)
4nM 13.14 (2.89) 8.24 (1.42)
40nM 13.08 (2.14) 6.30 (3.31)
400nM 13.78 (0.32) 5.74 (2.08)
GLUCAGON
(4nM)
OnM 1.18 (0.31) 19.49 (2.58)
4nM 1.26 (0.07) 20.96 (4.30)
40nM 1.24 (0.29) 21.66 (2.81)
400nM 1.26 (0.20) 26.04 (2.70)
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Table 3.M Effect of octreotide on incorporation of acetate into saponifiable fatty 
acids and glycerol production by explants of rat epididymal adipose 
tissue (values denote mean with S.D. in parentheses (n=4) per 2 hour 
incubation).
CONDITIONS [OCTREOTIDE]
ACETATE
INCORP^
(nmol/mg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 0.77 (0.09) 8.10 (2.09)
4nM 0.82 (0.12) 4.49 (2.99)
40nM 0.91 (0.06) 4.88 (2.36)
400nM 0.88 (0.17) 4.81 (2.24)
INSULIN
(2nM)
OnM 8.87 (1.25) 7.33 (2.49)
4nM 11.72(0.81) 4.58 (2.05)
40nM 9.85 (0.93) 4.22 (2.19)
400nM 9.33 (1.05) 7.65 (1.49)
GLUCAGON
(4nM)
OnM 0.61 (0.11) 18.81 (3.90)
4nM 0.68 (0.08) 22.80 (3.49)
40nM 0.65 (0.04) 26.03 (1.55)
400nM 0.66 (0.07) 24.86 (2.75)
266
Table 3.N Effect of pancreatic polypeptide on incorporation of acetate into 
saponifiable fatty acids and glycerol production by explants of rat 
epididymal adipose tissue (values denote mean with S.D. in parentheses 
(n=4) per 2 hour incubation).
CONDITIONS [PANCREATIC
POLYPEPTIDE]
ACETATE
INCORP^
(nmol/mg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 7.11 (1.28) 2.65 (1.63)
4nM 7.04 (0.60) 1.91 (1.03)
40nM 7.78 (0.53) 1.46 (1.27)
400nM 7.59 (1.11) 2.00 (1.30)
INSULIN
(2nM)
OnM 24.99 (3.00) 2.34 (0.64)
4nM 24.11 (1.35) 2.70 (0.40)
40nM 23.27 (2.72) 2.73 (0.87)
400nM 26.16 (3.33) 2.16 (1.02)
GLUCAGON
(4nM)
OnM 3.00 (0.34) 8.99 (1.53)
4nM 2.80 (0.40) 6.43 (0.43)
40nM 2.49 (0.57) 6.20 (2.75)
400nM 2.75 (0.30) 8.33 (2.16)
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Table 3.0 Effect of peptide Y Y on incorporation of acetate into saponifiable fatty
acids and glycerol production by explants of rat epididymal adipose 
tissue (values denote mean with S.D. in parentheses (n=4) per 2 hour 
incubation).
CONDITIONS [PEPTIDE YY]
ACETATE
INCORP^
(nmol/mg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 8.07 (0.64) 1.82 (0.44)
4nM 6.98 (1.30) 1.46 (0.61)
40nM 7.69 (1.48) 1.71 (0.43)
400nM 7.77 (0.77) 5.05 (0.98)
INSULIN
(2nM)
OnM 22.95 (2.10) 3.98 (0.29)
4nM 19.34 (2.70) 5.38 (1.45)
40nM 19.08 (0.39) 6.63 (1.33)
400nM 18.51 (1.95) 6.57 (1.32)
GLUCAGON
(4nM)
OnM 4.87 (0.72) 10.90 (1.16)
4nM 5.33 (0.66) 6.46 (0.48)
40nM 6.29 (0.61) 8.44 (0.68)
400nM 6.28 (0.63) 8.60 (0.27)
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Table 3.P Effect of neurotensin on incorporation of acetate into saponifiable fatty 
acids and glycerol production by explants of rat epididymal adipose 
tissue (values denote mean with S.D. in parentheses (n=4) per 2 hour 
incubation).
CONDITIONS [NEUROTENSIN]
ACETATE
INCORP^
(nmoVmg)
GLYCEROL
PRODUCED
(nmol/mg)
BASAL
OnM 6.01 (0.36) 4.81 (0.53)
4nM 5.76 (0.24) 6.12 (1.64)
40nM 5.97 (0.57) 4.90 (0.79)
400nM 7.61 (0.78) 5.91 (0.84)
INSULIN
(2nM)
OnM 20.57 (2.17) 6.19 (1.14)
4nM 22.37 (0.96) 5.84 (0.82)
40nM 20.27 (2.19) 6.16 (0.86)
400nM 20.17 (2.63) 6.06 (1.19)
GLUCAGON
(4nM)
OnM 2.02 (0.12) 18.63 (1.44)
4nM 2.09 (0.17) 19.00 (2.26)
40nM 2.02 (0.20) 18.55 (1.45)
400nM 2.13 (0.29) 19.83 (1.35)
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APPENDIX 4 Results from chapter 6: Hormonal control of adipose tissue
lipoprotein lipase in rats and human volunteers.
Table 4.A Effects of insulin, GIF, octreotide and secretin on heparin-releasable
lipoprotein lipase activity from rat epididymal adipose tissue (values 
denote mean ± S.D. (n=6) per incubation).
HORMONE
TREATMENT
LIFOFROTEIN LIFASE ACTIVITY 
(nmol oleate/min per mg)
BASAL 16.25 ± 2.55
INSULIN (2nM) 23.61 ± 2.20
GIF (8nM) 12.15 ± 1.17
OCTREOTIDE (8nM) 13.29 ± 1.40
SECRETIN (lOnM) 12.32 ± 1.29
INSULIN (2nM) + 
GIF (8nM)
21.04 ± 3.38
INSULIN (2nM) + 
OCTREOTIDE (8nM)
20.37 ± 5.17
GIF (8nM) + 
OCTREOTIDE (8nM)
12.15 ± 1.72
INSULIN (2nM) + 
GIF (8nM) + 
OCTREOTIDE (8nM)
22.56 ± 5.29
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Table 4.B Effect of insulin and GIF on heparin-releasable lipoprotein lipase 
activity from explants of human adipose tissue (values denote mean ± 
S.D. (n=7) per incubation).
HORMONE
TREATMENT
LIFOFROTEIN LIFASE ACTIVITY 
(nmol oleate released/min per mg)
BASAL 4.8 ± 2.3
INSULIN (2nM) 6.4 ±5.1
GIF (8nM) 5.5 ± 3.8
INSULIN (2nM) + 
GIF (8nM) 6.5 ±2.4
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APPENDIX 5 Results from chapter 7: I n  v iv o  investigation of the 
functional interrelationships between the gastrointestinal 
peptides GIP and GLP-1 (7-36) amide and heparin- 
releasable lipoprotein lipase activity in obese and lean 
subjects.
Table 5.A Glucose responses to test meals in lean and obese subjects (values are 
given in mM and denote mean with ± S.E. in parentheses (n=6)).
TIME
AFTER
MEAL
(MIN)
HYCAL FAT HYCAL + 
OCTREOTIDE
LEAN OBESE LEAN OBESE LEAN OBESE
-30 5.2 5.4 5.1 5.4 5.1 5.4
(0.1) (0.2) (0.2) (0.2) (0.2) Oil)
0 5.0 5.4 5.0 5.4 4.4 4.8
(0.1) (0.2) Oil) (0.2) (0.2) (0.2)
15 7.0 6.8 4.8 5.3 4.3 5.1
(0.5) 013) Oil) (0.1) (0.2) (0.2)
30 7.6 8.3 4.7 5.6 5.3 6.4
(0.6) 015) (0.1) 017) (0.4) (0.4)
45 7.2 8.4 4.7 5.2 6.7 8.0
016) 018) (0.1) (0.2) (0.5) (0.6)
60 6.6 8.4 4.6 4.8 8.3 9.6
(0 7) (1.0) (0.1) Oil) (0.4) (0 7)
90 5.5 7.0 4.6 5.0 11.4 11.9
(0 3) 018) (0.2) (0.1) 019) 019)
120 4.9 7.4 4.9 5.0 13.2 13.0
(0.4) (0.4) Oil) (0.1) (1.0) (1.0)
135 5.2 7.0 4.8 5.1 13.9 13.4
013) (0.4) (0.1) Oil) (0.9) (1.1)
150 5.6 6.8 4.9 5.1 14.6 13.5
(0 3) 017) (0.2) Oil) 018) (1.0)
180 5.5 5.9 4.9 5.0 15.4 13.1
(0.4) (0.9) Oil) (0.1) (0 7) (1.0)
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Table 5.B Triglyceride responses to test meals in lean and obese subjects (values
are given in mM and denote mean with ± S.E. in parentheses (n=6)).
TIME
AFTER
MEAL
(MIN)
HYCAL FAT HYCAL + 
OCTREOTIDE
LEAN OBESE LEAN OBESE LEAN OBESE
-30 0.87
(0.12)
1.70
(0.24)
0.93
(0.10)
1.20
(0.25)
0.74
(0.07)
1.57
(0.28)
0 0.84
(0.10)
1.65
(0.24)
0.82
(0.10)
1.34
C121)
0.79
(0.07)
1.70
(0.23)
15 0.86
(0.10)
1.64
(0.23)
0.88
(0.13)
1.36
(0.19)
0.79
(0.08)
1.76
(0.23)
30 0.92
(0.14)
1.69
(0.22)
0.91
(0.12)
1.40
0.21)
0.80
(0.08)
1.77
(0.22)
45 0.89
(0.10)
1.75
(0.21)
0.95
(0.13)
1.47
(0.26)
0.78
(0.09)
1.73
(0.20)
60 0.83
(0.10)
1.78
(0.21)
1.05
(0.14)
1.67
(0.18)
0.75
(0.09)
1.64
(0.20)
90 0.78
(0.09)
1.73
0123)
1.33
(0.16)
1.80
(0.20)
0.68
(0.08)
1.50
(0.15)
120 0.74
(0.09)
1.69
(0.29)
1.59
(0.18)
1.94
(0.24)
0.63
(0.07)
1.43
(0.18)
135 0.55
(0.06)
1.40
(0.22)
1.21
(0.17)
1.69
0.23)
0.50
(0.04)
1.20
(0.16)
150 0.45
(0.03)
1.09
(0.19)
1.00
(0.12)
1.29
0126)
0.40
(0.03)
0.77
(0.10)
180 0.37
(0.02)
0.73
(0.11)
0.74
(0.09)
0.95
0.21)
0.33
(0.04)
0.62
(0.10)
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Table 5.C Insulin responses to test meals in lean and obese subjects (values are
given in pM and denote mean, with ± S.E. in parentheses (n=6)).
TIME
AFTER
MEAL
(MIN)
HYCAL FAT HYCAL + 
OCTREOTIDE
LEAN OBESE LEAN OBESE LEAN OBESE
-30 2&2
(9.0)
81.7
(19.21)
29.2
(8.1)
94.7
(30.3)
31.2
(10.4)
120.3
(36.5)
0 28.8
(7.2)
87.5
(26.4)
29.5
(9.0)
83.7
(21.1)
12.7
(3.2)
21.5
047)
15 190.3
(40.7)
429.8
(126.7)
2&8
dO)
111.0
(28.0)
16.5
(5.5)
16.8
(20)
30 375.7
(80.5)
725.5
(151.3)
48.5 
(5 9)
129.0
(44.8)
16.0
(4.7)
25.2
(23)
45 371.3
(55.9)
846.0
(169.60
42.7
(&1)
166.5
(52.1)
16.3
(3.4)
27.7
(20)
60 326.8
(31.S0
868.2
(153.7)
27.2
(23)
123.8
(36.9)
18.3
(3.8)
41.0
(145)
90 282.3
(47.1)
619.3
(155.1)
26.7
(16)
103.3
(28.7)
35.2
(11.6)
75.3
(27.4)
120 180.3
(22.9)
699.6
(119.9)
24.3
(3.5)
99.7
(29.2)
40.5
(23.0)
145.0
(52.7)
135 169.5
(15.7)
633.5
(122.1)
31.2
04.9)
103.5
(30.2)
37.8
(16.5)
180.0
(60.4)
150 201.3
(55.21)
528.7
(142.1)
33.7
0L8)
94.8
(25.5)
42.5
(16.3)
162.0
(53.4)
180 127.5
(27.9)
373.8
(217.2)
33.3
(&7)
81.3
(21.3)
37.8
(11.1)
196.5
(67.0)
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Table 5.D C-Peptide responses to test meals in lean and obese subjects (values are
given in nM and denote mean with ± S.E. in parentheses (n=6)).
TIME
AFTER
MEAL
(MIN)
HYCAL FAT HYCAL + 
OCTREOTIDE
LEAN OBESE LEAN OBESE LEAN OBESE
-30 0.41
(0.07)
0.73
(0.08)
0.44
(0.02)
0.70
(0.10)
0.39
(0.05)
0.85
0113)
0 0.38
(0.06)
0.75
(0.09)
0.37
(0.01)
0.72
(0.10)
0.14
(0.03)
0.33
(0.03)
15 1.11
(0.17)
1.58
(0.20)
0.43
(0.03)
0.80
(0.12)
0.09
(0.02)
0.24
(0.03)
30 1.83
0133)
2.30
(0.15)
0.49
(0.05)
0.85
(0.15)
0.08
(0.03)
0.28
(0.04)
45 1.92
(0.35)
2.65
(0.16)
0.48
(0.05)
0.99
(0.18)
0.09
(0.03)
0.31
(0.05)
60 2.12
(0.24)
:283
(0.14)
0.46
(0.03)
0.87
0113)
0.11
(0.02)
0.35
(0.07)
90 1.88
(0.29)
2.57
(0.17)
0.43
(0.03)
0.81
(0.11)
0.19
(0.04)
0.51
(0.11)
120 1.61
(0.22)
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(0.18)
0.39
(0.02)
0.73
(0.08)
0.33
(0.10)
0.85
(0.18)
135 1.55
(0.16)
2.60
(0.19)
0.41
(0.03)
0.85
(0.11)
0.36
(0.09)
0.96
(0.17)
150 1.67
(0.14)
2.43
(0.16)
0.44
(0.02)
0.82
(0.08)
0.40
(0.08)
0.98
(0.17)
180 1.43
(0.22)
1.93
0133)
0.45
(0.04)
0.74
(0.07)
0.48
(0.09)
1.11
0119)
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Table 5.E GIP responses to test meals in lean and obese subjects (values are
given in pM and denote mean with ± S.E. in parentheses (n=6)).
TIME
AFTER
MEAL
(MIN)
HYCAL FAT HYCAL + 
OCTREOTIDE
LEAN OBESE LEAN OBESE LEAN OBESE
-30 19.4 31.6 11.3 38.7 37.7 44.8
(860 (13.60 (66) (9.5) (9.5) (21.0)
0 15.5 21.2 14.2 19.0 10.3 16.0
(5J) (13.20 (8.1) (9.3) (6.1) (9.9)
15 173.5 187.0 82.5 54.3 5.0 10.7
(48.1) (26.6) (26.8) (12.7) (3.3) (9 j)
30 184.8 225.8 211.4 150.5 5.8 7.7
(47.7) (26.9) (55.9) (39.6) (5.8) C^7)
45 193.3 240.7 280.5 236.7 5.5 7.0
(42.1) (23.4) (55.4) (40.9) (5.1) C7.0)
60 217.9 248.5 274.4 308.8 7.3 7.2
(31.3) (24.3) (44.9) (40.8) (6.S0 (7.2)
90 240.1 218.3 278.9 280.0 6.5 5.5
(22.8) (29.7) (37.1) (34.0) (4.3) C%5)
120 216.9 216.6 242.2 273.5 5.7 4.8
(20.0) (40.2) (47.1) (26.5) (3.1) 018)
135 235.0 217.0 238.2 252.2 4.5 3.0
(26.8) (26.1) (58.3) (19.6) (3.20 (3.0)
150 231.5 201.5 271.0 241.7 3.0 2.8
(21.5) (16.1) (40.3) (19.6) (3.0) C28)
180 213.2 142.5 262.3 204.8 6.8 3.7
(16.9) (10.8) (35.3) (28.0) (4.4) (3.7)
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Table 5.F GLP-1 (7-36) amide responses to test meals in lean and obese subjects
(values are given in pM and denote mean with ± S.E. in parentheses
(n=6)).
TIME
AFTER
MEAL
(MIN)
HYCAL FAT HYCAL + 
OCTREOTIDE
LEAN OBESE LEAN OBESE LEAN OBESE
-30 20.2 15.3 18.8 13.7 14.2 17.2
(1.5) C23) (25) (1.8) (1.7) (16)
0 16.9 13.6 11.2 13.5 7.2 12.5
(2.3) (29) (23) (17) (3.2) (4.9)
15 39.8 27.1 11.7 16.1 9.3 13.3
(8.8) (10.6) (28) (3.4) (1.3) 017)
30 47.8 22.5 21.6 27.4 6.9 13.4
(10.2) (17) (2.4) (8.1) (2.7) (4.9)
45 48.7 18.3 29.5 32.1 10.4 16.1
(12.40 0L3) (14) (9.3) (1.6) 0L8)
60 50.1 19.0 27.8 24.0 10.1 15.6
(11.20 (3.7) 01.9) 0L5) (1.8) (4.9)
90 55.1 13.9 27.7 19.4 10.6 16.8
(17.0) (3.20 (18) (4.0) (2 0) 0L7)
120 33.5 18.2 28.3 17.7 14.9 17.0
(5.(0 (6.20 OLO) 01.7) (20) 0L8)
135 32.4 9.3 15.9 4.7 8.3 7.7
0L8) (13) (2.9) (2.5) (21) (2.9)
150 29.4 5.0 16.2 4.0 5.2 8.3
(6.7) (1.7) (2.4) (23) (25) (3.3)
180 34.3 13.1 21.9 12.5 10.5 16.6
(3.0) (3.3) (4.1) (3.2) (23) (3.3)
277
Table 5.G Post-heparin plasma lipoprotein lipase responses to test meals in lean
and obese subjects (values are given as nmol oleate released /minute
per ml plasma and denote mean with ± S.E. in parentheses (n=6)).
TIME
AFTER
HEPARIN
(MIN)
HYCAL FAT HYCAL + 
OCTREOTIDE
LEAN OBESE LEAN OBESE LEAN OBESE
0 0.0 0.0 0.5 0.2 0.0 0.4
(0.0) (0.0) (0.2) (0.2) ODO) 0)3)
5 118.1 96.3 165.9 162.8 158.0 136.1
(29.4) (20.4) (29.1) (15.0) (23.4) (22.0)
10 150.6 127.3 110.1 188.2 204.2 177.9
(39J0 (26.6) (32.2) (16.3) (32.1) (14.6)
15 182.8 162.4 140.0 192.5 211.6 208.0
(38.20 (28.0) (51.2) (15.4) (38.5) (17.3)
30 224.5 195.1 123.6 191.5 256.1 221.0
(31.1) (27.5) (22.5) (29.7) (39.80 (14.9)
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Basal and hormone-stimulated rates of lipogenesis in liver and adipose tissue of rats fed on 
corn oil and fish oil diets. By C. M. W il l ia m s , J. M . B e e t y , A. Z a m p e l a s , N. 
F u r l o n GER, and L. M o r g a n , The Nutritional Metabolism Research Group, 
School o f  Biological Sciences, University o f Surrey, Guildford GU2 5X H  
Although feeding fish oil reduces circulating triacylglycerol levels, the mechanism of this 
effect has not been fully established. In the present investigation we have studied the 
effects o f feeding fish oil on basal and hormone-stimulated rates of lipogenesis in adipose 
tissue and liver in the rat. Two groups of eight Wistar albino rats were pair-fed diets 
containing 10% fat (as energy) either as corn oil or fish oil for a period of 2 weeks. 
Animals were killed in the fed state after overnight meal feeding, and blood was 
collected by cardiac puncture. In the liver slices the rates of basal, insulin (4 nM)-, gastric 
inhibitory polypeptide (GIP) (6 nM)- and GlP-finsulin (6 nM+4 nM)-stimulated “^^ C- 
glucose incorporation, and in adipose tissue explants the rates of basal and insulin (2 
nM)-stimulated ^'^C-acetate incorporation, were measured.
Basal Insulin GIP Insulin-f-GIP
Additions Mean SE Mean SE Mean SE Mean SE
A dipose tissue 
(nmol acetate incorporated/mg): 
Corn oil 1 34 0 21 3 38 0 05
Fish oil 2 23* 0-12 6 75* 1 00 — --- -
Liver
(nmol glucose incorporated/mg): 
Corn oil 0 83 0 08 1-25 1 4 6 0 92 0 14 l-65 t 0 2 4
Fish oil 0 62 0 0 9 0 9 6 0 21 0 81 0 10 1-351 0 18
* Significantly different from corn oil-fed rats; *P <0 01. 
t  Significantly different from basal-fed rats: tP < 0  05.
Rates of basal and insulin-stimulated acetate incorporation were significantly higher in 
adipose tissue of fish oil-fed animals (P < 0  01, both cases). In the liver, GIP or insulin 
alone had no effect on glucose incorporation into lipids, but GIP in the presence of  
insulin resulted in a significantly increased incorporation of glucose into lipids (corn oil 
P < 0  01; fish oil P<0-05).
It is concluded that in fish oil-fed animals there is increased sensitivity to the effects of 
insulin in adipose tissue. This effect may be mediated through enhanced receptor 
sensitivity resulting from changes in membrane phospholipid fatty acid composition.
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